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1.1 Transition Metal-Catalyzed C–H Functionalization 
Organic synthesis is the transformative science that enables selective molecular 
engineering with notable applications towards biochemistry and material sciences as 
well as agrochemical and pharmaceutical industries, among others. Thus far, 
molecular syntheses have largely involved the generation of a huge number of 
undesired by-products, the depletion of limited natural resources and overall high 
energy consumption.[1] In order to obviate or at least reduce these drawbacks, the 
development of transition metal-catalyzed C─H functionalization has attracted 
significant attention, resulting in both environmentally-benign and economically-
attractive processes compared with traditional organic synthetic routes. Among them 
are the use of catalytic transformations, the avoidance of unnecessary 
prefunctionalization and auxiliaries to increase the atom economy,[2] and the use of 
mild reaction conditions[3] towards full resource economy.[4] 
 
1.1.1 Transition Metal-Catalyzed Cross-Couplings vs. C–H Activation 
The beginning of transition metal-catalyzed coupling chemistry can be traced back to 
inter alia the early copper-catalyzed reactions by Glaser[5] and Ullmann.[6] In the past 
several decades, transition metal-catalyzed cross-coupling reactions have been well 
developed and widely applied in organic synthesis, and provide useful methods to 
construct complex scaffolds.[7] For example, Suzuki–Miyaura,[8] Stille,[9] Corriu–
Kumada,[10] Hiyama,[11] and Negishi cross-coupling reactions,[12] have been well 
studied and are nowadays established as powerful methods in the toolbox of organic 
chemists (Scheme 1.1). These important contributions were recognized with the 




Scheme 1.1. Transition metal-catalyzed cross-coupling reactions. 
It is well known that traditional cross-coupling requires two fully pre-functionalized 
starting materials, namely organic (pseudo)halides and organometallic reagents.[13] 
Therefore, the direct functionalization of C–H bonds is extremely desirable in terms of 
the step- and atom-economy of organic syntheses (Scheme 1.2). 
 
Scheme 1.2. C–H activation versus cross-couplings. 
 
1.1.2 Mechanistic Manifolds 
For transition metal-catalyzed C–H functionalizations, the catalytic cycle can often be 
divided into three main steps (Scheme 1.3): (i) the C─H activation, (ii) the 
functionalization of the organometallic intermediate, and finally (iii) the regeneration 





Scheme 1.3. Generalized catalytic cycle for transition metal-catalyzed C─H activation. 
 
In general terms, the C─H cleavage event is the key step of the mechanism. 
Computational chemistry has made a particularly strong contribution to the 
understanding of the range of possible mechanisms for the C─H scission.[14] The C─H 





Scheme 1.4. Modes of action for various C–H cleavage mechanisms by transition 
metals. 
 
Oxidative addition to cleave C–H bonds was mostly observed with electron-rich 
complexes of late transition metals.[15] For early transition metals with d0-configuration, 
this mode of action is obviously not feasible. In contrast, σ-bond metathesis and 
1,2- addition are possible ways to achieve C–H activation with early transition 
metals,[14a] while electrophilic substitution was proposed for cationic complexes of late 
transition metals.[16] In recent years, the base-assisted C–H activation has gained major 
attraction as a model for C–H cleavage in C–H functionalizations by an isohypsic 
pathway.[15] 
Further investigations indicated that several distinct transition states could be involved 






Scheme 1.5. Transition state models for base-assisted C–H metalation. 
 
Intramolecular electrophilic substitution (IES)[17] is the mechanism for alkoxide bases 
and relies on a highly strained, thus high-energy, four-membered transition state. 
Concerted metalation-deprotonation (CMD)[18] and ambiphilic metal-ligand activation 
(AMLA)[19] were independently disclosed and describe the interaction of metal, 
carboxylate-ligand and C–H bond, especially for electron-deficient substrates, such as 
perfluoroarenes or pyridine-N-oxides. In sharp contrast, base-assisted internal 
electrophilic substitution (BIES)[20] was proposed to explain the preferred reactivity of 
electron-rich substrates in the majority of such transformations. 
Thus far, the vast majority of C–H functionalizations was accomplished by cost-
intensive and toxic 4d and 5d transition metal catalysts, such as palladium,[21] 
iridium,[22] rhodium,[23] and ruthenium.[24] Here, new opportunities are represented by 
the development of 3d transition metal-catalyzed C–H activation, with possible 
benefits due to the significantly lower toxicity, high natural abundance and cost-
effective nature of the employed metal catalysts.[25]  
 
1.2 Cobalt(III)-Catalyzed C─H Activation 
Cobalt is one of the more abundant elements in the Earth crust, with a concentration 
of approximately 25 ppm, compared to 1 ppb for noble metals, such as iridium and 
rhodium.[26] As a result, significant attention has recently been directed towards the 
use of less expensive, more abundant, and cost-efficient cobalt catalysts.[27] The 
identification of cobalt complexes as a suitable catalysts for promoting C–H 
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functionalisations relates to the relatively well-developed field of rhodium-catalyzed 
C–H functionalisation.[23e, 28] Yet, a notable challenge is constituted by the fact that the 
electronic properties of the 3d transition metal cobalt significantly differ from those of 
the 4d or 5d homologues in terms of electronegativity and spin orbit couplings, among 
others.[25, 29] The reduced electronegativity of cobalt as compared to the homologous 
group 9 elements translates into more nucleophilic organometallic cobalt 
intermediates, which allow for unprecedented reaction pathways in transition metal-
catalyzed C–H activations as well as significantly improved positional and chemo-
selectivities.[30] 
1.2.1 Early Examples of Cobalt-Catalyzed C─H Activation 
Cobalt-catalyzed C–C bond formation has been known since 1941 by Kharasch and 
Fields.[31] An early example of cobalt-catalyzed C–H functionalization was developed 
by Murahashi,[32] providing a low-valent cobalt-catalyzed carbonylation protocol. This 
protocol provided access to phthalimidine 2 or indazolone 4 through an annulation 
reaction of carbon monoxide with Schiff-bases using Co2(CO)8 as the catalyst (Scheme 
1.6). 
 
Scheme 1.6. Cobalt-catalyzed carbonalytion of benzaldimine 1 and azobenzene 3. 
 
Despite these early advances, the most significant applications of cobalt in catalysis 
have been noted in the field of hydroformylation[33] and the development of the 
Pauson–Khand reaction.[34] Further advances in cobalt-catalyzed C–H functionalization 





cobalt(III)-mediated trifluoroacetylation of aromatic compounds operating via a 
proposed single electron transfer (SET) mechanism and stoichiometric in cobalt 
complex (Scheme 1.7). 
 
Scheme 1.7. Stoichiometric cobalt(III)-mediated trifluoroacetylation of arene 5. 
 
1.2.2 C–H Activation with Well-Defined Cobalt Complexes 
As to the elementary step of C–H cobaltation, Klein and co-workers showed that the 
cyclometalated cobalt complex 9 can be prepared by treating azobenzene 7 with 
[Co(CH3)(PMe3)4] (8) (Scheme 1.8).[36] 
 
Scheme 1.8. Stoichiometric C–H metalation using complex 8. 
 
In subsequent studies, Klein found that various substrates containing different donor 
groups, featuring oxygen,[37] nitrogen,[38] sulfur,[39] and phosphorus,[40] also formed 
cyclocobaltated complexes (Scheme 1.9). The cyclometalation was not restricted to 
the formation of five-membered cobaltacycles, but also the formation of six-
membered complex 11 and even less favorable four-membered cobaltacycle 13[41] 




Scheme 1.9. Cyclocobaltated complexes prepared by C─H and C─F activation using 
stoichiometric complex 8. 
 
In an early example, the low-valent catalytic approach was developed by Kisch and co-
workers in 1994, reporting the ortho-alkenylation of aromatic azo compounds.[42] 
Thereafter, low-valent cobalt-catalyzed C─H functionalizations have been rapidly 
developed over the last 10 years by the groups of Yoshikai,[43] Nakamura,[44] and 
Ackermann,[45] among others.[46] It is noteworthy that, in most of these studies, the 
active catalyst is ill-defined, being generated in situ from a cobalt salt, a (pre-)ligand 
and an organometallic species, resulting in a somewhat limited functional group 
tolerance. The development of catalytic protocols using well-defined high-valent 





1.2.2 High-Valent Cobalt(III)-Catalyzed C─H Activations 
A significant advance in the field of cobalt(III) catalysis was made by Matsunaga/Kanai 
and co-workers in 2013 (Scheme 1.10).[47] This work used the Cp*CoIII-type catalyst,[48] 
whereby the [Cp*Co(C6H6)](PF6)2 complex was shown to catalyze the coupling of 2-
arylpyridine 24 with N-sulfonyl imines 25 and α,β-unsaturated ketones 26. The same 
group also extended this protocol to indole-based substrates.[49] 
 
Scheme 1.10. Cp*Co(III)-catalyzed hydroarylation of electrophiles. 
 
Subsequently, the Matsunaga group showed the C2-selective alkenylation of indoles 
29 bearing a carbamoyl directing group, which was realized with a Cp*CoIII catalyst and 
KOAc as the additive (Scheme 1.11a).[50] Remarkably, while the judicious choice of the 
carbamate directing group and the use of a different cationic complexes allowed for 
either the formation of the thermodynamically more stable cyclized product 33 
(Scheme 1.11b)[30] or the tetrasubstituted alkenes 34 (Scheme 1.11c).[51] Interestingly, 
Cp*Rh(III) catalysts were found to be inefficient in this transformations. The unique 
reactivity of cobalt(III) catalysts highlighted the different electronegativity of cobalt as 




Scheme 1.11. Cp*Co(III)-catalyzed addition onto alkynes. 
More recently, Matsunaga/Kanai and co-workers further demonstrated that the air- 
stable [Cp*Co(CO)I2] complex, in combination with a silver salt (AgSbF6), displayed 
superior activity for a C–N forming protocol when compared to the [Cp*Co(C6H6)](PF6)2 
catalyst.[27a] 
1.2.2.1 Cp*Co(III)-Catalyzed Allylations 
Recently, C─H allylations have been reported with different allylating reagents 
(Scheme 1.12). The Ackermann and Glorius groups independently described the 
allylation of pyrimidylindoles with allylic electrophiles via a β-O elimination pathway 
(Scheme 1.12a).[53] Moreover, Matsunaga reported the dehydrative allylation of 
indoles with allylic alcohols through a β-hydroxide elimination pathway (Scheme 






Scheme 1.12. Cp*Co(III)-catalyzed C─H allylations. 
 
Meanwhile, the Ackermann group reported the unique Z-selective allylation via 
C─H/C─C activation by cobalt(III) catalysis under mild conditions (Scheme 1.13). 
Remarkably, this reaction showed a broad substrate scope and delivered the 
thermodynamically less stable (Z)-alkenes with excellent levels of diastereoselectivity. 
This conversion was found to be more efficient and selective with the [Cp*Co(CO)I2] 
catalyst as compared with the analogous [Cp*RhCl2]2 catalyst. 
 




A plausible catalytic cycle is based on an initial C–H cobaltation by the cationic cobalt 
species 45, resulting in the formation of complex 46. Subsequently intermediate 46 is 
coordinated by the allyl alcohol derivative. Thereafter, migratory insertion of the 
allylic double bond into the Co–C bond yields the key intermediate 47. Finally, the 
product is released via β-oxygen elimination, which is about 2.4 kcal/mol more 
favorable than a β-hydride elimination (Scheme 1.14). 
 
Scheme 1.14. Plausible catalytic cycle for Cp*Co(III)-catalyzed C─H/C─C allylations. 
 
1.2.2.2 Cp*Co(III)-Catalyzed Allenylation 
Ma developed a rhodium-catalyzed C─H bond allenylation with activated propargyl 
carbonates.[56] Inspired by the Ma group’s work, the Sundararaju group recently 
reported a dehydrative C–H allenylation from propargyl alcohols with phenylpyrazoles 
49 via β-hydroxyl elimination (Scheme 1.15).[57] 
 





1.2.2.3 Cp*Co(III)-Catalyzed C(sp3)─H activation 
Significant achievements have been made in Cp*Co(III)-catalyzed C(sp2)─H 
functionalization. Recently, Sundararaju and coworkers reported a 
carboxylate- assisted Cp*Co(III)-catalyzed C(sp3)─H alkenylation[58] (Scheme 1.16a) and 
amidation[59] (Scheme 1.16b) of activated 8-methylquinoline 52. 
 
Scheme 1.16. Cp*Co(III)-catalyzed C(sp3)─H alkenylation and amidation. 
 
1.2.2.4 Asymmetric Cp*Co(III)-Catalyzed C─H Activation 
The full control of selectivity is of paramount importance to achieve synthetically 
meaningful C−H activations. The Ackermann group developed the first asymmetric 
Cp*Co(III)- catalyzed C−H activation.[60] Moreover, the design of a novel chiral acid 
enabled cobalt(III)-catalyzed C−H alkylations on indoles with high regio- and enantio-
selectivities (Scheme 1.17). 
 
Scheme 1.17. First example of Cp*Co(III)-catalyzed asymmetric C─H activations. 
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1.3 Manganese-Catalyzed C─H Activation 
Precious transition metals, such as palladium, rhodium, and iridium, play a 
predominant role in the field of C–H activation, which has met with great success in 
the last 20 years. Unfortunately, the high costs,[53a] low abundance,[61] and toxicities[62] 
of these metals limit their further applications in pharmaceutical industries. Thus, 
manganese is an attractive, efficient, and the third most naturaly abundant transition 
metal. Moreover, the valence electron configuration of elemental manganese and the 
wide range of possible oxidation states of manganese (−3 to +7) holds great potential 
in organometallic chemistry and catalysis. 
 
1.3.1 Early Examples of Manganese-Catalyzed C─H Functionalization 
The inspiration for developing metal-catalyzed C–H functionalizations is largely based 
on the studies of stoichiometric C–H activations with metal complexes. The first 
example of a manganese-mediated C–H activation was arguably reported by Stone and 
Bruce in 1970, who achieved the synthesis of the manganese complex 62 from 
azobenzene 7 and [MnMe(CO)5] (61) through a stoichiometric C–H activation event 
(Scheme 1.18).[63] 
 
Scheme 1.18. Pioneering example of stoichiometric C–H activation by manganese(I). 
 
Thereafter, a large number of reactions of well-defined manganacycles via 
stoichiometric C–H activation have been disclosed by the groups of Nicholson/Main,[64] 
Woodgate,[65] and Liebeskind,[66] among others. So far, a variety of directing groups,[67] 
which contain nitrogen,[68] oxygen,[69] and phosphorous,[70] have been utilized and 





activations (Scheme 1.19). 
 
Scheme 1.19. Selected complexes synthesized by C─H activation with [MnR(CO)5]. 
 
40 years have passed until the first directed manganese(I)-catalyzed C–H activation 
was reported by Kuninobu and Takai in 2007. They initially investigated stoichiometric 
C─H activation and insertion of aldehydes with the manganese complex [MnBr(CO)5] 
(Scheme 1.20a). Only trace amounts of product 76 were obtained with catalytic 
amounts of the manganese complex. At the outset of their optimization studies, 






Scheme 1.20. Stoichiometric manganese(I)-mediated and manganese(I)-catalyzed 
hydroarylation of aldehydes. 
 
A plausible catalytic cycle was proposed based on mechanistic studies as presented in 
Scheme 1.21. The catalytically active manganese(I) species 72 was proposed to 
facilitate C–H activation by oxidative addition, thereby delivering a putative 
manganese(III) hydride species 77. Subsequently, migratory insertion of the polar 
carbonyl bond into the nucleophilic carbon−manganese bond takes place. Finally, the 
the silyl-protected benzylic alcohol 79 is formed through reductive elimination 
facilitated by triethylsilane. Thereafter, C–H activation regenerates the active 






Scheme 1.21. Proposed catalytic cycle for the manganese(I)-catalyzed C–H addition 
to aldehydes. 
 
In contrast, Wang and co-workers developed a silane-free manganese(I)-catalyzed C–
H addition to aldehydes 75, albeit with stoichiometric amounts of ZnBr2 and Me2Zn 
(Scheme 1.22a). Moreover, the authors were able to extend the substrate scope to 
electrophilic nitriles 82 (Scheme 1.22b).[72] 
 




1.3.2 Manganese(I)-Catalyzed C─H Functionalization 
1.3.2.1 Manganese(I)-Catalyzed C─H Allylations 
Ackermann and co-workers developed the first manganese-catalyzed C−H allylation 
of arenes by employing allyl carbonates 39 as the allylating reagent. The corresponding 
allylated ketones 84 were obtained with excellent diastereoselectivities, upon acidic 
workup (Scheme 1.23a). By analogy to the above described allylation method, the 
group of Ackermann devised another manganese(I)-catalyzed decarboxylative 
allylation via C–H/C–O functionalization, using dioxolanones 86 as the allylating 
reagents. Moreover, the high robustness of the manganese(I) catalytic system was 
reflected by using H2O as the optimal reaction medium and the reaction was fully 
tolerant of air (Scheme 1.23b). 
 
Scheme 1.23. Manganese(I)-catalyzed C–H allylations. 
 
1.3.2.2 Manganese(I)-Catalyzed C─H Activations with Propargylic Carbonates 
Glorius described a manganese-catalyzed regioselective C–H allenylation of indoles 37 
with propargylic carbonates 88 through a β-oxygen elimination pathway (Scheme 
1.24a).[73] Importantly, Ackermann achieved the full control of chemoselectivity in 





90.[74] By the judicious choice of the additive, alkenylated products 91 and allenylated 
products 92 can be selectively furnished. Notably, for the first time in base metal-
catalyzed C–H functionalizations, a continuous flow system was exploited, thereby 
shortening the reaction time to 20 min and leading to improved mass and heat transfer 
control (Scheme 1.24b). 
 
Scheme 1.24. Manganese(I)-catalyzed C–H allenylation and alkenylation. 
 
Likewise, Glorius and co-workers reported on a manganese(I)-catalyzed annulation of 
propargyl carbonates 88 with imines 93 to generate isoquinolines 94. Notably, the use 
of alkynes with a leaving group in β-position led to high levels of regioselectivity in the 
annulation reaction. Based on their mechanistic studies, the authors proposed that a 
β-oxygen elimination occurs to deliver an allenylated intermediate, which 





Scheme 1.25. Manganese(I)-catalyzed C–H annulation via β-oxygen elimination. 
 
1.3.2.3 Manganese(I)-Catalyzed C─H/Het─H Annulations 
Annulation reactions are among the most fundamental and useful transformation in 
organic synthesis.[15] They provide a straightforward and step-economical method for 
the synthesis of heterocycles, which are important motifs in pharmaceuticals, natural 
products and agrochemicals.[76] In 2015, Ackermann and coworkers developed the 
first manganese-catalyzed C─H annulation of acrylates 96 by ketimines 95, thus 
providing access to valuable β-amino acid esters (Scheme 1.26). Mechanistically, a key 
feature of this annulation process is an intramolecular attack of the 
carbon−manganese bond to the ketimine, thereby delivering intermediate 99. 
Subsequently, proto-demetallization delivers the desired product 97. 
 
Scheme 1.26. Manganese(I)-catalyzed synthesis of cis-β-amino acid derivatives 97. 
 
Afterwards, the Ackermann group reported on the first manganese(I)-catalyzed C–H 
annulation with methylenecyclopropanes (MCPs) 100, delivering a variety of densely 





manganese-carbon bond, the key C─C cleavage step takes place to deliver 
intermediate 102, which then undergoes an intramolecular nucleophilic attrack to 
form the 103. Thereafter, a proto-demetalation releases the desired product 101 
(Scheme 1.27).[77] 
 
Scheme 1.27. Manganese(I)-catalyzed annulation via C–H/C−C functionalization. 
 
Thereafter, Rueping and Wang independently reported on manganese(I)-catalyzed C–
H hydroarylations of allenes with indoles 35. Notably, a unique cascade reaction 
consisting of a C–H hydroarylation and subsequent Smiles rearrangement was 
observed (Scheme 1.28).[78]  
 
Scheme 1.28. Manganese(I)-catalyzed 1,2-diheteroarylation of allenes. 
 
Furthermore, Ackermann developed the first manganese(I)-catalyzed carbonylative 
annulation for the synthesis of pyrido[1,2-a]pyrimidin-4-ones 108. Detailed 
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mechanistic studies proposed a facile insertion of CO into the manganese complex. 
Then, a migratory insertion of the alkyne deliveres an eight-membered metallacycle. 
Finally, the desired product is formed by imine extrusion. Moreover, the outstanding 
synthetic utility of the manganese catalysis was reflected by the versatile late-stage 
diversification of numerous marketed drugs and natural products (Scheme 1.29).[79] 
 
Scheme 1.29. Manganese(I)-catalyzed carbonylative annulation. 
 
1.3.3 Low-Valent Manganese(II)-Catalyzed C─H Functionalizations 
Despite considerable advances in manganese(I)-catalyzed C─H functionalization, this 
approach is limited to multiple bond migratory insertions. Recently, the Ackermann 
group reported the first low-valent MnCl2-catalyzed C─H alkylation with alkyl halides. 
The unprecedented low-valent manganese-catalyzed C─H activation occurred under 
zinc-free reaction conditions in the absence of any expensive phosphine ligands, 
providing versatile access to C─H alkylated benzamides through assistance of the 
removable TAM[80] (triazolyl-methyl) group (Scheme 1.30).[81] 
 
Scheme 1.30. Low-valent MnCl2-catalyzed C─H alkylation. 
 
Taking inspiration from this elegant work, Nakamura reported a similar MnCl2-
catalyzed C─H methylation of amides.[82] By contrast, Ackermann developed MnCl2-
catalyzed C─H alkylation with primary as well as challenging secondary halides and 







Scheme 1.31. Low-valent MnCl2-catalyzed secondary alkylation on heterocycles 112. 
 
1.4 Electrochemical Transition Metal-Catalyzed C–H Activation 
Electroorganic synthesis have become an established, useful, and environmentally- 
benign alternative to classic organic synthesis for the oxidation or reduction of organic 
compounds.[84] Since dangerous and toxic redox reagents are replaced by electric 
current and the overall energy consumption is reduced.[85]  
 
1.4.1 Electrocatalytic Palladium-Catalyzed Transformations 
In an early contribution, a palladium(II/0)-catalyzed Fujiwara-Moritani-type C–H 
alkenylation reaction was devised by Amatore and Jutand in 2007. The main challenge 
for the palladium(II)-catalyzed Heck-type reaction is the recycling of palladium(0) back 
to a catalytically active palladium(II) species. Thus, various drastic oxidants have been 
used in stoichiometric amounts, such as silver(I), copper(II), t-BuOOH, and 
benzoquinone. In contrast, by applying electricity, a catalytic amount of hydroquinone 
will be oxidized to benzoquinone at the anode in each catalytic cycle albeit in a divided 




Scheme 1.32. Electrocatalytic palladium-catalyzed Fujiwara-Moritani reaction. 
 
In 2009, Kakiuchi disclosed a palladium-catalyzed halogenation using electrochemical 
C–H functionalization by palladium catalysis. Electricity was here required for the 
generation of an electrophilic Cl+ cation from HCl(aq) (Scheme 1.33).[87] Later, they 
extended the palladium-catalysis to the homodimerization of phenylpyridines 24 in 
the presence of stoichiometric or co-catalytic amounts of iodine.[88] 
 
Scheme 1.33. Electrochemical halogenation of phenylpyridines. 
 
Thus far, electrochemical C–H activation was severely limited to transformations of 
C(sp2)–H bonds. More recently, Mei reported the C(sp3)–H oxygenation by 






Scheme 1.34. Palladium-catalyzed oxygenation of C(sp3)–H bonds. 
 
The catalytic cycle is initiated by a base-assisted[15] type C–H activation with palladium 
complex 121 to furnish intermediate 122. Complex 121 is directly oxidized at the anode 
to form a palladium(III) or palladium(IV) species 123. Finally, reductive elimination 
from the high-valent palladium center gives palladium(II)−product complex 124, which 
can undergo ligand exchange to furnish the product 120 (Scheme 1.35). Based on the 
same strategy, Mei and co-workers demonstrated the electrocatalytic palladium-




Scheme 1.35. Plausible mechanism for the palladium-catalyzed C–H oxygenation. 
 
1.4.2 Electrocatalytic Cobalt-Catalyzed Transformations 
Cobalt-catalyzed electrochemical cross-couplings are known for over a decade through 
the pioneering work from Périchon and Gosmini.[91] However, cobalt-catalyzed 
electrochemical C–H activation remained elusive. Recently, a breakthrough was 
realized by the merger of electrochemical cobalt-catalyzed C–H activation, which was 
first viable for the C–H oxygenation of benzamides 125.[92] Later, this approach was 
extended to electrochemical C–H/N–H alkyne annulations.[93] Thereafter, Ackermann 
established the cobalt-catalyzed C–H amination of benzamides employing a N,O-
bidentate directing group.[94] Afterwards, Lei disclosed a less-effective transformation 
using 8-aminoquinoline (AQ) as the directing group.[95] Furthermore, Ackermann could 
achieve the unprecedented removal of the hydrazide directing group by a simple 





recently, Ackermann devised the first electrocatalytic C–H activation with allenes 135 
which was characterized by excellent levels of chemo-, position-, and regio-
selectivity.[97] (Scheme 1.36) 
 
 
Scheme 1.36. Versatile C–H activation by cobaltaelectrocatalysis. 
 
Based on mechanistic observations, the cobalt(II) precatalyst is oxidized at the anode 
to yield the active cobalt(III) catalyst, which is then coordinated by the substrate. 
Subsequently, insertion and reductive elimination form the desired products and a 
cobalt(I) species, which can undergo anodic oxidation to re-generate the cobalt(II) 




Scheme 1.37. Representative plausible mechanism for the cobalt-catalyzed 
electrochemical C–H activation. 
 
1.4.3 Electrocatalyzed Transformations by Other Transition Metals 
Ackermann recently reported on the first electrochemical C–H activation under 
rhodium catalysis to realize cross-dehydrogenative alkenylations with weakly 
coordinating benzoic acids 137 and the procedure also proved applicable to amides 
138 and indoles 35 (Scheme 1.38a).[98] Subsequently, the same group demonstrated 
rhodaelectro-catalyzed C–H activations, for [2+2+2] cycloadditions, which set the stage 
for the synthesis of novel non-planar polycyclic aromatic hydrocarbons (PAHs) from 
simple arylboronic acids 142 and alkynes 30 (Scheme 1.38b).[99] Based on detailed 
mechanistic studies, they proposed a rhodium(III) to rhodium(I) pathway for 






Scheme 1.38. Rhodaelectro-catalyzed C–H functionalization. 
 
Xu group developed the ruthenium-catalyzed electrochemical [3+2] annulation of 
aniline to access indoles (Scheme 1.39a).[100] Concurrently, Ackermann developed a 
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ruthenium-catalyzed synthesis of isocoumarines by C–H/O–H annulation. 
Noteworthily, it showed for the first time weakly coordinating benzoic acids as 
substrates for ruthenium-catalyzed electrochemical C–H activation (Scheme 1.39b).[101] 
 
Scheme 1.39. Electrooxidative ruthenium-catalyzed C–H functionalization. 
 
Recently, Ackermann reported on the first electrochemical nickel-catalyzed C–H 
aminations.[102] It is noteworthy that the studies highlight a distinct working mode by 
fast C–H scission, involving a scarce nickel(IV) intermediate (Scheme 1.40). 
 
Scheme 1.40. Electrooxidative nickel-catalyzed C–H aminations. 
 
1.5 Low-Valent Iron-Catalyzed C─H Activation 





various iron compounds are present in biological systems and are an essential part of 
important metabolic processes, such as in cytochrome P450. These unique properties 
prompted the use of iron catalysts in pharmaceutical and agrochemical industries or 
for the synthesis of cosmetics, among others.[104] Inspired by early contributions in the 
field of catalytic cross-coupling[105] C–C bond forming, the researchers explored the 
use of iron catalysts for developing C−H activation strategies. Indeed, low-valent iron 
species were found to be instrumental for the activation of thermodynamically stable 
C(sp2)–H as well as C(sp3)–H bonds under mild reaction conditions, providing a step- 
and atom-economical approach for the formation of new C−C and C−Het bonds.[25, 
106] 
1.5.1 Iron-Catalyzed C─H arylation 
Inspired by early studies on iron-catalyzed cross-coupling reactions,[107] Nakamura, 
Yoshikai, and coworkers discovered an unusual C–H activation within an attempted 
cross-coupling of 2-bromopyridine with an in situ generated diphenylzinc reagent. 
Thus, product 8b was also observed, which was suggested to be formed by an iron-
catalyzed C–H arylation of the initially formed 2-phenylpyridine 24.[108] This 
observation and the subsequent detailed optimization studies of the key reaction 
parameters led to the development of an efficient low-valent iron-catalyzed C–H 
arylation. Interestingly, additional a broad of scope, such as 2-arypyrimidine 150,[108] 
2-arylpyrazole 49,[108] ketimines 83[109] and benzamide 138[110], were found to be 




Scheme 1.41. iron-catalyzed C–H arylation. 
 
The use of 8-aminoquinoline 148 as a powerful directing group was originally 
established by Daugulis for palladium-catalyzed functionalizations of unactivated 
C(sp3)–H bonds.[111] In sharp contrast, Nakamura reported on iron catalysts in 
combination with the diphosphine ligand dppz for the arylation of unactivated C(sp3)–
H bonds by 8-aminoquinoline-assistance.[112] 
 
Scheme 1.42. iron-catalyzed C(sp3)–H arylation. 
 
The 8-aminoquinoline auxiliary is difficult to removal usually requires harsh reaction 
conditions. Thus, a major advance developed by Ackermann group in iron-catalyzed 
C–H activation was accomplished by introducing a modular family of easily accessible 
triazole-based TAM groups.[113] In 2014, Ackermann group identified the easily 
accessible 1,2,3-triazole as an enabling motif in bidentate directing groups for the iron-





revealed the TAM group to display an improved directing group compared with 8-
aminoquinoline auxiliary.  
 
Scheme 1.43. iron-catalyzed C(sp2)–H and C(sp3)–H arylation by TAM groups. 
 
1.5.2 Iron-Catalyzed C─H Activation through Triazole Assistance 
The modular nature of the triazole group set the stage for the versatile C–H activation 
under iron catalysis. In 2016, Ackermann group reported iron-catalyzed C−H allylation 
by less expensive and readily available allyl chlorides 164 which were found to be 
suitable electrophiles (Scheme 1.44a).[114] Later, The Ackermann group successfully 
employed the triazole directing group to enable the first iron-catalyzed C–H 
alkynylation with alkynyl bromides 166 proceeding with excellent levels of chemo- and 
siteselectivities (Scheme 1.44b).[115] Ackermann group devised an iron-catalyzed 
synthesis of isoquinolones 169 via the C−H/N−H annulation of alkynes 30 by the 
proper choice of the triazole group (Scheme 1.44c).[116] Very recently Ackermann group 
reported on the first use of allenes 104 for iron-catalyzed C−H annulations under 
external oxidant-free conditions (Scheme 1.44d). The use of allenyl acetates 104 hence 
allowed for the synthesis of isoquinolones 171 with high yields and functional group 
tolerance. Importantly, a strong influence of the directing group was observed for the 
synthesis of exo-methylene isoquinolines 170 with gem-disubstituted triazolyl amides 
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159 under the same reaction conditions. 
 









Transition metal-catalyzed C─H activations have emerged as increasingly powerful 
tools for sustainable organic syntheses.[117] Remarkable advances in this area have 
been achieved by Prof. Dr. Lutz Ackermann and coworkers, which are mainly focused 
on the development of chemo- and site-selective syntheses of valuable organic 
molecules, with applications to pharmaceutical chemistry, materials sciences and 
peptide assembly.[25] In this context, the development of novel base metal-catalyzed 
and electrocatalytic C─H activation reactions by environmentally-benign, less 
expensive and earth-abundant cobalt, manganese and iron catalysts should be 
investigated. 
Inspired by the success of cobalt(III) complexes as catalysts for a cascade alkyne 
annulation via the release of the carbamate directing group,[30] we decided to probe 
the newly chemoselectivity in cobalt(III)-catalyzed cascade C–H activation/directing 
group migration/alkyne annulation of 2-pyridylpyridones 172 with propargylic 
carbonates 88. Interestingly, the completely unprecedented products 173 could be 
obtained. 
 
Scheme 2.1. Base metal-catalyzed C─H/C─N/C─C Annulation of pyridones 172. 
 
With previous achievements on sustainable 3d transition metal-catalyzed C–H 
activation,[106a, 118] it was demonstrated that cobalt(III) catalysis[27a, 29] and manganese(I) 
catalysis[71, 74-75, 77-79, 119] feature similar reactivity and selectivities.[120] In stark contrast, 
we initiated the development of the first manganese-catalyzed dehydrocyanative 




Particularly, arene C–H arylations have been identified as powerful alternatives to 
traditional cross-couplings, avoiding the use and multi-step preparation of 
prefunctionalized arenes.[123] While the majority of arene C–H arylations was thus far 
accomplished with precious, toxic transition metals,[123] recent focus has shifted 
towards the use of more sustainable 3d transition metals.[25] Despite of tremendous 
advances in redox-neutral manganese(I)[124] catalysis, arene C–H arylations with earth-
abundant, less toxic manganese complexes have as of yet proven elusive. Here, the 
first manganese(II/III/I)-catalyzed organometallic versatile azine C–H arylations should 
be developed. (Scheme 2.2). What’s more, it is of great significance to develop a new 
tool using continuous flow for the safe handling of reactive reagents on scale by 
improved control of heat and mass transfer (Scheme 2.2). 
 
Scheme 2.2. Continuous flow and electrocatalytic manganese- or iron-catalyzed C–H 
arylations. 
 
In recent years, a tremendous progress has been achieved in utilizing low valent iron 
catalysts for C–H functionalizations. All documented iron-catalyzed C–H arylations 





vicinal-dichloride dichloroisobutane (DCIB) as the sacrificial oxidant.[118d] 
Unfortunately, DCIB is elusive on commercial scale, features considerable safety 
hazards, generates overstoichiometric amounts of corrosive byproducts, and is toxic, 
which overall significantly deteriorates the environmental footprint of oxidative iron 
catalysis. Importantly, DCIB is also characterized by costs that are comparable to those 
of the typical noble transition metal catalyst Pd(OAc)2, hence jeopardizing the inherent 
green nature of the iron-catalyzed C–H activation approach. Thus, a strategy for the 
unprecedented DCIB-free, iron-catalyzed C–H arylation through the action of user-





3. Results and Discussion 
3.1 Domino C–H Activation/Directing Group Migration/Alkyne 
Annulation: Unique Selectivity by d6-Cobalt(III) Catalysts 
Indolizinones are versatile heterocycles that are widely founded as the key structural 
motifs present in molecules with medicinal benefits, natural products and diverse 
bioactivities, such as the antitumor agent camptothecin and A58365A. (Scheme 
3.1).[126] A novel rhodium-catalyzed C–H allenylation of amides with propargyl 
carbonates was developed.[56] Additionally, Glorius[73] and Sundararaju[57] reported the 
Earth-abundant manganese(I)[118b]- and cobalt(III)-catalyzed[25, 29] C–H allenylation of 
indoles and pyrazoles. Furthermore, our group recently reported an unprecedented 
manganese-catalyzed dehydrocyanative Domino-C–H annulation.[127]  
With advances in transition metal-catalyzed C–H activation,[106a, 118] there are indeed 
aspects in C–H functionalizations, such as reactivity and stereoselectivity that can be 
controlled not only by the judicious choice of ligands, but also by the distinctive 
features of the metal. In this regard, there are several reports on the distinct 
chemoselectivities for cobalt(III) complexes as compared to the corresponding 
rhodium(III) catalysis. However, there is still no example to explore the distinct 
selectivity features between cobalt(III) and manganese(I) catalysis. We hence decided 
to explore the feasibility of cobalt(III)-catalyzed cascade C–H annulation of 2-
pyridinepyridone 172a with propargylic carbonate 88a. 
 





3.1.1 Optimization Studies for Cobalt-Catalyzed Domino Annulation 
We probed the effect exerted by representative transition-metal complexes, additives 
and solvents on the envisioned C–H annulation of pyridone 172a with propargylic 
carbonate 88a (Table 3.1). Sodium acetate as additive delivered the desired product 
173aa in moderate yields, whereas sodium pivalate was the least effective additive 
(entries 1–3). Lower reaction temperatures were detrimental to the reaction outcome 
(entry 4). Furthermore, no reaction was observed when omitting the cobalt(III) catalyst, 
which is a clear hint for cobalt catalysis to be operative in this reaction. In contrast, 
rhodium(III) catalysis led to a significant drop in reactivity (entry 6). Furthermore, 
ruthenium(II) catalysis and cationic sandwich complex [Cp*Co(MeCN)3](SbF6)2)] were 
not competent catalysts for the C–H annulation (entries 7 and 8). Interestingly, solvent 
TFE by far outcompeted DCE and PhCF3 (entries 9–11), delivering the desired product 
173aa in 52%. Thereafter, a series of additives were tested, and HOAc led to a 
significant increase in reactivity (entries 12–14). Remarkably, the catalytic 
performance was only moderately affected by the absence of the silver additive (entry 
15).  
Table 3.1. Optimization of the cobalt-catalyzed annulation.[a] 
 
Entry [TM] Additive Solvent Yield (%) 
1 [Cp*Co(CO)I2] --- HFIP 20 
2 [Cp*Co(CO)I2] NaOPiv HFIP 14 
3 [Cp*Co(CO)I2] NaOAc HFIP 46 
4 [Cp*Co(CO)I2] NaOAc HFIP ---[b] 
5 --- NaOAc HFIP --- 
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6 [Cp*RhCl2]2 NaOAc HFIP 17 
7 [RuCl2(p-cymene)]2 NaOAc HFIP --- 
8 [Cp*Co(MeCN)3](SbF6)2 HOAc TFE 6[c] 
9 [Cp*Co(CO)I2] NaOAc DCE --- 
10 [Cp*Co(CO)I2] NaOAc PhCF3 --- 
11 [Cp*Co(CO)I2] NaOAc TFE 52 
12 [Cp*Co(CO)I2] AgOAc TFE 56 
13 [Cp*Co(CO)I2] HOAc TFE 81 
14 [Cp*Co(CO)I2] --- TFE 42 
15 [Cp*Co(CO)I2] HOAc TFE 55[c] 
[a] Reaction conditions: 172a (0.50 mmol), 88a (1.50 mmol), [TM] (10 mol %), AgSbF6 
(20 mol %), additive (50 mol %), solvent (2.0 mL), 90 °C, 20 h. Yields of isolated products. 
[b] At 50 °C. [c] Without AgSbF6. 
 
3.1.2 Scope of Cobalt(III)-Catalyzed C–H/C–N Functionalization 
3.1.2.1 Cobalt(III)-Catalyzed C–H/N–O Functionalization with Substituted Pyridones 
172 
With the optimized C–H activation/pyridine migration manifold in hand, we explored 
the versatility of the C–H Domino annulation employing a representative set of various 
substituted pyridones 172 (Scheme 3.2). First, various substituents in the C4-position 
of the pyridine 172b, 172d, 172e, 172f and 172g were tested, such as bromo, chloro, 
carboxylate, trifluoromethyl and methyl groups. Notably, all functional groups were 
fully tolerated, delivering the desired annulation products in good yields ranging from 
52% to 75% and high chemoselectivities. Furthermore, the substitution pattern on the 
pyridyl-directing group did not influence the reactivity, with overall very good yields. 









Scheme 3.2. Cobalt(III)-catalyzed C–H/N–O functionalization with substituted 
pyridones 172. 
the desired products 173la in good yield. Finally, a wealth of valuable electrophilic 
functional groups in C3-position, including sulphonamide, bromo, chloro, and even 
sensitive cyano were fully tolerated, serving as a handle for future late-stage 
modifications. The cobalt(III) catalyst was characterized by high levels of chemo- and 
position-selectivity. The connectivity of the indolizinones 173aa, 173ca, and 173ga was 
unambiguously confirmed by X-ray crystallographic analysis. 
3.1.2.2 Cobalt(III)-Catalyzed C–H/N–O Functionalization with Substituted Propargylic 
Carbonates 88 
Furthermore, a comprehensive study as to the scope of the alkyne 88 was performed 
(Scheme 3.3). A variety of alkynes 88 featuring various electron-donating or electron-
withdrawing groups, and even heteroarenes, such as thiophene 88g, delivered the 
desired product 173ag with high catalytic efficacy. It is noteworthy that valuable 
functional groups were fully tolerated by the chemo-selective cobalt catalyst likewise.  
However, additional sterically substituents adjacent to the oxygen atom of the 
carbonate group were not well tolerated, with methyl (1-(phenylethynyl)cyclopropyl) 
carbonate 88l, methyl (1-(phenylethynyl)cyclopentyl) carbonate 88m and methyl (1-
(phenylethynyl)cyclohexyl) carbonate 88n remaining untouched when submitted to 
the reaction conditions. This outcome is likely explained by an excessive steric 
hindrance near the catalyst-coordinating oxygen atom of the alkyne group. Indeed, the 







Scheme 3.3. Cobalt(III)-catalyzed C–H/N–O functionalization with substituted 




3.1.3 Mechanistic Studies 
3.1.3.1 Effect of Leaving and Directing Groups 
The key importance of the leaving and the directing groups for the cobalt-catalyzed C–
H activation/pyridine migration Domino annulation transformation is evident through 
a set of control experiments (Scheme 3.4). The regioselectivity of the alkyne insertion 
can be controllable by a chelating moiety and the steric hindrance of propargylic 
compounds 88. Further experiments showed that the nature of the substrate and the 
directing group played a crucial role in the transformation. Indoles 35, 2-
phenylpyridine 24 as well as 2-pyrrolpyridine 172aa unfortunately delivered no or only 
traces of the desired products under identical reaction condition. Moreover, the use 
of the directing groups like pyrimidine 172ab, aryl 172ac and isoquinoline 172ad 
turned out to be unsuccessful. 
 





3.1.3.2 Competition Experiments 
Given the unique selectivity features of the cobalt(III) catalyst, we conducted 
mechanistic studies to delineate its mode of action. To this end, competition 
experiments between electron-rich and electron-deficient pyridones 172g/172f as 
well as electron-rich and electron-deficient alkynes 88i/88k were conducted. For 
pyridones 172, a competition experiment of 4-methyl pyridones 172g with 4-
trifluoromethyl pyridones 172f displayed a clear preference for the more electron-rich 
pyridones 172 in favor of the 4-methyl substituted arene 172g (Scheme 3.5a). This 
observation is in good agreement with a base-assisted intramolecular electrophilic-
type substitution (BIES)[20c, 20d, 20f] mechanism by a cationic cobalt catalyst. For the 
alkynes 88, a similar competition experiment was conducted, showing a clear 
preference for electron-rich alkyne 88i over trifluoro alkyne 88k (scheme 3.5b). 
 
Scheme 3.5. Competition experiments. 
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3.1.3.3 H/D-Exchange Experiments 
Furthermore, deuteration studies using [D]3-TFE as the co-solvent showed significant 
H/D-corporation in the reisolated starting material. A deuterium incorporation of 90% 
in C2-position suggested a facile and reversible C–H activation event, highlighting an 
organometallic C–H activation mechanism (Scheme 3.6). 
 
Scheme 3.6. H/D exchange experiments. 
 
3.1.3.4 Kinetic Isotope Effect 
The kinetic isotope effect (KIE) of the cobalt(III)-catalyzed C–H activation was 
determined by independent experiments of substrates 172a and [D]1-172a, resulting 
in a minor value of kH/kD ≈ 1.3 (Scheme 3.7). The minor kinetic isotope effect illustrated 
that the C–H cobaltation is not rate-determining step, providing an additional support 
for the fast C–H scission.  
 
 Scheme 3.7. Kinetic isotope effect experiment.  
 
3.1.4 Late-Stage Modifications 
The synthetic utility of our regioselective annulation reaction was reflected by the 







Scheme 3.8. Late-stage modifications. 
 
3.1.5 Proposed Catalytic Cycle 
Based on our mechanistic studies and precedent literature reports,[78, 128] we propose 
that the cobalt(III)-catalyzed Domino C–H activation commences by a reversible C–H 
activation, followed by a migratory alkyne insertion, providing key intermediate 178 
(Scheme 3.9). Thereafter, the nucleophilicity of Co–C bond could leads to the migration 
of the pyridine group rather than a β-oxygen elimination.[54, 129] Finally, an 
intramolecular nucleophilic substitution for the displacement of the carbonate 




Scheme 3.9. Plausible catalytic cycle for cobalt-catalyzed Domino C–H activation. 
 
3.2 Manganese(I)-Catalyzed C–H Activation/Diels-Alder/retro-Diels-
Alder Domino Alkyne Annulation 
The use of inexpensive MnBr(CO)5 for C–H functionalization reaction has been 
intensively studied in the last few years.[25, 118b, 124d] In this regard, not only the cost-
efficiency of these metals is of prime importance, but also a systematic study of their 
unique reactivity profile is essential for making considerable advances in transition 
metal-catalysis.  
Domino reactions have the potential to simplify reactions by forming several bonds in 
a one-pot fashion, which allows for the minimization of waste compared to stepwise 
reactions.[130] Drawing inspiration from the work of our program on sustainable C–H 
activation,[131] a manganese(I)-catalyzed Domino-C–H activation/Diels-Alder/retro-





3.2.1 Optimization of Domino C–H Activation/Diels-Alder/retro-Diels-Alder 
 
The optimization studies for the Domino C–H annulation/Diels-Alder/retro-Diels-Alder 
reaction were initiated by testing representative bases, additives and solvents with the 
pyridone 172a with propargylic carbonate 88a (Table 3.2). In order to understand the 
requirements of the transformation, different bases and additives were tested. Indeed, 
the desired C–H transformation was effective with NaOAc as the base, and BPh3 as the 
additive (entries 1–7). Subsequently, several different manganese(I) catalysts were 
tested for this Domino reaction (entries 8–9), and it turned out that the MnBr(CO)5 as 
the catalyst of choice (entries 8). In addition, simple dirhenium(0) decacarbonyl and 
cationic sandwich complex [Cp*Co(MeCN)3](SbF6)2)] were not competent catalysts for 
the C–H annulation (entries 10 and 11). To our delight, the reaction efficacy could be 
improved by DME as the optimal solvent (entries 12–16). A control experiment 
revealed that the C─H functionalization did not occur without the MnBr(CO)5 catalyst 
(entry 17). Finally, control experiments under ambient air or catalytic water additive 
confirmed the sensitivity of this catalytic system (entries 18–19).  
 
Table 3.2. Optimization of Domino C–H activation/Diels-Alder/retro-Diels-Alder.[a] 
 
 
Entry [TM] Base Additive Solvent Yield (%) 
1 MnBr(CO)5 NaOAc --- PhMe 17 
2 MnBr(CO)5 Cy2NH --- PhMe --- 
3 MnBr(CO)5 NaOAc ZnCl2 PhMe --- 
50 
 
4 MnBr(CO)5 NaOAc ZnBr2 PhMe --- 
5 MnBr(CO)5 NaOAc AgOTf PhMe --- 
6 MnBr(CO)5 NaOAc FeCl3 PhMe --- 
7 MnBr(CO)5 NaOAc BPh3 PhMe 35 
8 MnBr(CO)5 NaOAc BPh3 PhMe 60[b] 
9 Mn2(CO)10 NaOAc BPh3 PhMe --- 
10 Re2(CO)10 NaOAc BPh3 PhMe --- 
11 [Cp*Co(MeCN)3](SbF6)2 NaOAc BPh3 PhMe --- 
12 MnBr(CO)5 NaOAc BPh3 Et2O --- 
13 MnBr(CO)5 NaOAc BPh3 1,4-dioxane 28 
14 MnBr(CO)5 NaOAc BPh3 CH2Cl2 46 
15 MnBr(CO)5 NaOAc BPh3 THF 50 
16 MnBr(CO)5 NaOAc BPh3 DME 71 
17 --- NaOAc BPh3 DME --- 
18 MnBr(CO)5 NaOAc BPh3 DME --- [c] 
19 MnBr(CO)5 NaOAc BPh3 DME --- [d] 
[a] Reaction conditions: 172a (0.25 mmol), 88a (0.38 mmol), [TM] (10 mol %), base (50 
mol %), additive (0.25 mmol), solvent (1.0 mL), 100 °C, 24 h. Yields of isolated products. 
[b] MnBr(CO)5 (20 mol %) was used. [c] Under air. [d] H2O (10 mol %) was added. 
 
3.2.2 Scope of Manganese(I)-Catalyzed C–H Activation/Diels-Alder/retro-Diels-Alder 
Domino Alkyne Annulation 
3.2.2.1 Manganese-catalyzed Domino C–H activation/Diels-Alder/retro-Diels-Alder 
with Pyridones 172 
 
Under the optimized reaction conditions for the manganese(I)-catalyzed C–H 
functionalization / Diels-Alder/retro-Diels-Alder Domino reaction, we explored its 





substituents of C3, C4, C5- substituted pyridines 172b, 172c, 172d, 172e, 172f were 
tested, without a trend concerning the electronic properties and overall moderate to 
good yields. Interestingly, the sterically congested naphthalene-derived pyridone 172g 
afforded the corresponding product 180ga with good yield. Notably, different 
substituents in the C4 and C5-position to the directing group delivered the 
corresponding product with high yield. In contrast, when sterically shieldly 
substituents in the C3 and C6-position of pyridine directing group were employed, 
unfortunately only traces of the desired products were obtained, probably due to 
steric effects in the Diels-Alder and retro-Diels-Alder reaction. Furthermore, the 
connectivity of the indolones 180aa, 180da, 180ea, and 180ga was unambiguously 




Scheme 3.10. Manganese-catalyzed Domino C–H activation/Diels-Alder/retro-Diels-





3.2.2.2 Manganese-catalyzed Domino C–H activation/Diels-Alder/retro-Diels-Alder 
with propargylic carbonates 88 
Thereafter, the effect of the substitution pattern of the propargylic carbonates 88 were 
studied (Scheme 3.11). First, terminal alkyne 88b and alkyl alkyne 88c were employed, 
furnishing the desired products 180ac and 180ad in good to excellent yield. 
Additionally, the functionalization via a five-, six- and even seven-membered cycle with 
substrate 88f, 88g and 88h turned out to be favourable, delivering excellent yield of 
the desired products under otherwise identical reaction condition. Remarkably, a 
cyclohexene substituents of 88i was tolerated, with a minor drop in the activity, 
probably due to a competing coordination to manganese catalysis. Furthermore, a 
variety of alkynes 88 featuring heteroarenes, such as thiophene 88j and indole 88k, 
delivered the desired products 180aj and 180ak with high catalytic efficacy. It is 
noteworthy that a valuable alkene functional group was fully tolerated by the chemo-





Scheme 3.11. Manganese-catalyzed Domino C–H activation/Diels-Alder/retro-Diels-
Alder with propargylic carbonates 88. 
 
3.2.3 Mechanistic Studies 
Given the unique selectivity features of the manganese(I) catalyst, we conducted 
mechanistic studies to delineate its mode of action. Hence, experimental and 
computational[127a] (performed by Dr. R. Kuniyil) mechanistic studies were performed 
in order to gain insights into the reaction’s mechanism. 
3.2.3.1 H/D-Exchange Experiments 
To rationalize the C–H activation mechanism, a catalytic reaction in the presence of 





88a. Starting material 172a could be reisolated and deuterium incorporation was 
observed in the C-6 position with 90% deuteration. This finding is indicative of a 
reversible C–H metalation. Furthermore, a catalytic reaction in the presence of 
deuterated co-solvent CD3OD was carried out under otherwise unchanged reaction 
conditions. In the starting material 172a and the product 180aa significant amounts of 
H/D-exchange in the C6- and C3-positions of the pyridone were detected. The H/D-
scrambling in the C3-position of the product can be explained by a reversible 
electrophilic activation (Scheme 3.12). 
 
Scheme 3.12. H/D exchange experiments. 
 
3.2.3.2 Kinetic Isotope Effect 
To gain a deeper mechanistic understanding of the C–H activation elementary step, a 
KIE-experiment by comparison of independent reaction rates of 2-pyridylpyridone 
(172a) and [D]1-172a was performed. In this reaction, a KIE of kH/kD  1.2 was obtained 
(Scheme 3.13), indicating that the C–H manganesation is not the rate-determining step 






Scheme 3.13. Kinetic isotope effect experiment. 
 
3.2.3.3 Late-stage modifications 
To highlight the synthetic potential of the devised manganese-catalyzed C–H 
annulation, several modifications of the isolated products 180 were performed. The 
generated alkyl indolones 181 were generated via hydrogenation by a palladium on 
chacoal catalytic system. (Scheme 3.14). 
 
Scheme 3.14. late-stage modifications. 
 
y = 0,7207x - 1,6707
R² = 0,998






















3.2.3.4 Domino C–H activation/Diels-Alder/retro-Diels-Alder with Cyclometalated 
Complex 
Subsequently, we further investigate the mechanism of the manganese(I)-catalyzed C–
H annulation. The novel five-membered manganacycle 146, which is proposed to be 
an intermediate in the catalytic cycle, was synthesized according to a modified 
literature procedure[129] (Scheme 3.15a). Furthermore, it was studied whether the 
desired product 180aa could be obtained by the reaction of the pyridone 172a with 
propargylic carbonate 88a. Notably, the well-defined complex 182 was found to be 
competent both in catalytic as well as stoichiometric C–H activations (Scheme 3.15b 
and c), thus providing support for organomanganese 182 being a key intermediate in 
the C–H activation manifold. 
 




3.2.3.5 Domino C–H activation/Diels-Alder/retro-Diels-Alder with allene 
In addition, the importance of the allene intermediate for subsequent Diels-Alder as 
well as a retro-Diels-Alder step after the C–H activation was studied (scheme 3.16). To 
substantiate the plausibility of an allene intermediate, the C4-substituted pyridone 
172e and 88a was performed by the same reaction for a shortened reaction time. The 
allene intermediate 183 was isolated in 20% yield. Afterwards, it was studied whether 
the desired product 180aa can be provided by the reaction of the key allene 
intermediate 183 without manganese catalysis. The reaction proved viable in 64% 
yield with the same chemoselectivity as for the catalytic transformation. This 
observation indicates that the allene 183, which proved to be a key intermediate of 
the catalytic reaction. 
 
Scheme 3.16. Domino C–H activation/Diels-Alder/retro-Diels-Alder with allene. 
 
3.2.3 Proposed Catalytic Cycle 
The manganese(I)-catalyzed C–H activation/Diels-Alder/retro-Diels-Alder Domino 
alkyne annulation of pyridones 172 most likely proceeds via a reversible and facile 
BIES-type C–H activation, which is supported by the results obtained from the H/D-





mechanistic studies and literature precedents, we propose a plausible catalytic cycle 
to be initiated by an acetate-assisted organometallic C–H activation through chelation 
assistance (Scheme 3.17). Thereafter, alkyne insertion occurs to deliver the 
intermediate 185, which subsequently undergoes β-oxygen elimination,[129] thus 
forming the allene intermediate 186. Finally, a BPh3-mediated [4+2] Diels-Alder 
reaction, followed by base-induced elimination of HCN through retro-Diels-Alder 
reaction, provides the desired product 180aa. 
 
Scheme 3.17. Plausible catalytic cycle for Domino C–H activation
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3.3 Manganese(II/III/I)-Catalyzed C–H Arylations in Continuous Flow 
C–H activation has emerged as a transformative platform in molecular synthesis.[117c, 
132] Particularly, arene C–H arylations have been identified as powerful alternatives to 
traditional cross-couplings, avoiding the use and multi-step preparation of 
prefunctionalized arenes.[123] Despite the significant progress in arene C–H arylations 
in recent years, most methodologies either required harsh reaction conditions or were 
restricted to precious, toxic noble transition metal catalysts.[123] Recently, the focus has 
shifted towards the use of more sustainable 3d transition metals.[29, 106a, 118e, 133] 
Thereby, the development of the first manganese-catalyzed arene C–H arylations use 
of continuous flow technology[134] on the privileged pyridine motif represented a 
promising objective.  
3.3.1 Optimization of C–H Arylation in Continuous Flow 
The optimization studies were commenced by exploring several reaction conditions 
for the desired manganese-catalyzed C–H arylation in continuous flow (Table 3.3). A 
preliminary oxidant optimization identified DCIB as the optimal oxidant (entries 1, 2 
and 6). Both flow rate and pressure had a minor effect on the overall efficacy (entries 
1-5). Control experiments highlighted the essential role of TMEDA and the 
neocuproine ligand (entries 8-13). Lower reaction temperatures were detrimental to 
the reaction outcome (entries 14-15). Finally, the unique performance of the 
manganese catalysis regime was reflected by iron, copper, nickel, ruthenium, and even 












Table 3.3. Optimization of C–H arylation in continuous flow.[a] 
 
Entry [TM] Oxidant Rate / (µL/min) T / °C yield (%) 
1 MnCl2 DCIB 200 80 53 
2 MnCl2 DCB 100 80 61 
3 MnCl2 DCB 100 80 70[b] 
4 MnCl2 DCIB 100 80 74 
5 MnCl2 DCIB 100 80 72[c] 
6 MnCl2 --- 100 80 ˂ 5 
7 --- DCIB 100 80 13 
8 MnCl2 DCIB 100 80 59[d] 
9 MnCl2 DCIB 100 80 65[e] 
10 MnCl2 DCIB 100 80 59[f] 
11 MnCl2 DCIB 100 80 44[g] 
12 MnCl2 DCIB 100 80 43[h] 
13 MnCl2 DCIB 100 80 62[i] 
14 MnCl2 DCIB 100 60 18 
15 MnCl2 DCIB 100 100 72 
16 Fe(acac)3 DCIB 100 80 --- 
17 Cu(OAc)2 DCIB 100 80 --- 
18 (DME)NiCl2 DCIB 100 80 --- 
19 RuCl3·nH2O DCIB 100 80 --- 
20 PdCl2 DCIB 100 80 --- 
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[a] Reaction conditions: 112a (0.25 mmol), 151a (1.00 mmol), [TM] (10 mol %), 
neocuproine (20 mol %), TMEDA (0.50 mmol), oxidant (0.75 mmol), THF (0.5 M). Yield 
of isolated products. [b] 2 bar back pressure. [c] 6 bar back pressure. [d] Without 
neocuproine. [e] Neocuproine (10 mol %). [f] Neocuproine (40 mol %). [g] Without 
TMEDA. [h] 2,2’-dipyridyl (20 mol %) as the ligand. [i] 1,10-phenanthroline (20 mol %) 
as the ligand.  
 
3.3.2 Scope of Manganese-Catalyzed C–H Arylation 
3.3.2.1 Scope of Manganese-Catalyzed C–H Arylation in Flow 
With the optimized manganese-catalyzed C–H arylation identified, the robustness in 
the modification of diversely decorated amides 112 in continuous flow was probed 
(Scheme 3.18). Thus, a variety of pyridines 112 were smoothly converted by weak 
amide-chelation assistance. The manganese-catalyzed C–H arylation occurred without 
racemization of chiral amide 112j and proved tolerant of inter alia reactive conjugated 
styrene 112i. To our delight, the low-valent manganese catalysis regime was not 
limited to the 2-pyridyl pattern but proved amenable to the direct diversification of 
structural isomers 112l-o as well as diazine 112p likewise. The flow manganese-
catalyzed C–H arylation was conveniently performed in only 100 minutes, avoiding 
special high-pressure equipment. This feature on an exothermic C–H functionalization 
illustrates the beneficial asset of improved mass transfer and heat dissipation in flow 






Scheme 3.18. Scope of manganese-catalyzed C–H arylation with amides 112 in flow. 
 
Thereafter, we tested the versatility of the manganese catalysis manifold with respect 
to the arylating component (Scheme 3.19). Thus, different substitution patterns as well 
as valuable functional groups on the aryl magnesium bromide 151 were extensively 
tested. Furthermore, a variation of substituents in the para-position of the aryl 




Scheme 3.19. Scope of manganese-catalyzed C–H arylation in flow. [a] 112j (0.25 
mmol), MesMgBr (1.00 mmol), MnCl2 (20 mol %), TMEDA (0.50 mmol), nBuBr (0.75 
mmol), THF (1.0 M). 
Furthermore, substituents in the meta-position were well tolerated and afforded the 
desired arylated products 188ah, 188ai. Thereby, the heteroaromatic thiophene was 
introduced. Finally, the sterically congested mesityl group did not influence the 





connectivity of the thus obtained products 188 was unambiguously established by X-
ray diffraction analysis. 
3.3.2.1 Scope of Manganese-Catalyzed C–H Arylation in Batch 
The manganese-catalyzed C–H arylation regime was not limited to continuous flow 
technology, but could also be conducted in batch, thereby delivering the desired 






Scheme 3.20. Scope of manganese-catalyzed C–H arylation in batch. 
 
3.3.3 Mechanistic Studies 
Given the unique versatility of the novel manganese-catalyzed low-valent C–H 
arylation, we became attracted to delineating its mode of action. Hence, experimental 
and computational[135] (performed by Dr. J. C. A. Oliveira) mechanistic studies were 
performed in order to gain insights into the reaction’s mechanism. 
3.3.3.1 Competition Experiments 
In addition, competition experiments between electron-rich and electron-deficient 
arylating component 151 as well as intramolecular competition with substrates 112 
were carried out by comparing the reaction rates. Intermolecular competition 
experiment indicated that electron-rich arylating components were preferentially 
transferred (Scheme 3.21). For the amides 117, a competition experiment of C(2)–H 
amide 112a and C(3)–H amide 112l displayed a fast C(3)–H functionalization occurred 






Scheme 3.21. competition experiments. 
 
3.3.3.2 Kinetic Isotope Effect 
The kinetic isotope effect (KIE) of the manganese(II/III/I)-catalyzed C–H arylations 
reaction was measured by comparison of independent reaction rates for substrate 
112a and its isotopically labeled analogue [D]1- 112a, resulting in a minor value of 
kH/kD ≈ 1.4, which suggests a facile and not turnover-limiting C−H activation to be 
operative (Scheme 3.22). The observed KIE is in good agreement with the results 
obtained from the DFT studies by Dr. J. C. A. Oliveira, suggesting a ligand-to-ligand 
hydrogen transfer (LLHT), which enabled the proto-demetalation by delivering the 







Scheme 3.22. Kinetic isotope effect experiment. 
 
3.3.3.3 Manganese-Catalyzed C–H Arylations with Well-Defined Catalyst 
 
Furthermore, it was studied whether the desired product 188aa could be obtained 
with the single-component manganese-neocuproine complex 189 (Scheme 3.23).[136] 
The reaction displayed a comparable catalytic efficacy as the in-situ generated system. 
These findings indicate the neocuproine being coordinated to manganese, while the 




Scheme 3.23. Manganese-catalyzed C–H arylations with cyclometalated complex. 
 
 
y = 12,1x + 1,35
R² = 0,9992






















3.3.3 Synthetic Utility of Manganese-Catalyzed C–H Arylation 
The synthetic utility of our manganese-catalyzed C–H arylation in continuous flow was 
illustrated by the gram-scale synthesis of product 188aa in only 100 minutes (Scheme 
3.24a). Moreover, the selective methylation of the aryl group was achieved using FeCl3, 
dppen as an in-site generated catalyst. Furthermore, the annulation product 191 was 
obtained by using POCl3 in a microwave reactor at 150 °C.[137] (Scheme 3.24b). 
Scheme 3.24. Synthetic utility of manganese-catalyzed C–H arylation. Reaction 
conditions: a FeCl3 (15 mol %), dppen, MeMgBr, ZnCl2·TMEDA, DCB, THF, 60 °C, 16 h. b 





3.4 Metallaelectrocatalyses: Electricity for Resource-Economic Iron-
Catalyzed C–H Activation 
 
Major achievements in the research area of iron-catalyzed C–H arylations continue to 
be strongly limited by the need for superstoichiometric quantities of the vicinal-
dichloride dichloroisobutane (DCIB) as the sacrificial oxidant.[118d] Unfortunately, DCIB 
is elusive on commercial scale, features considerable safety hazards, generates 
overstoichiometric amounts of corrosive byproducts, and is toxic, which overall 
significantly deteriorates the environmental footprint of oxidative iron catalysis. 
Therefore, a significantly more sustainable approach would be the iron-catalyzed C–H 
activations through the action of user-friendly electricity.  
 
3.4.1 Optimization of the Ferraelectro-catalyzed C–H Arylation 
 
The optimization studies were set out to identify reaction conditions for the elusive 
electrooxidative iron-catalyzed C–H arylation of TAM-benzamide 159 bearing a 
peptide-isosteric click-triazole[20e, 138] in a user-friendly undivided cell setup (Table 3.4). 
After considerable preliminary experimentation, we observed that the desired 
electrochemical C–H arylation product 192 was obtained at an exceedingly mild 
reaction temperature of 40 °C, when using a RVC anode, along with a platinum 
cathode (entries 1-3). Notably, the electrochemical C–H activation was even operative 
at room temperature, reflecting the outstanding performance of the 
metallaelectrocalysis manifold (entry 4). Among a representative set of iron sources, 
Fe(acac)3 was found to be optimal (entries 5-6).[42] Control experiments confirmed the 
essential role of the electricity, the iron catalyst and the additive (entries 7-14). The 
iron-catalyzed electrooxidative C–H arylation proved likewise viable in the biomass-





metallaelectrocatalysis (entry 15).  
Table 3.4. Optimization of the ferraelectrocatalyzed C–H arylation. [a] 
 
Entry [Fe] T [°C] Yield [%] 
1 Fe(acac)3 60 75[b] 
2 Fe(acac)3 60 90 
3 Fe(acac)3 40 95 
4 Fe(acac)3 23 74 
5 FeCl3 40 80 
6 FeCl2 40 72 
7 Fe(acac)3 40 10[c] 
8 Fe(acac)3 40 86[d] 
9 Fe(acac)3 40 28[e] 
10 --- 40 --- 
11 Fe(acac)3 40 ---[f] 
12 Fe(acac)3 40 76[g] 
13 Fe(acac)3 40 ---[h] 
14 Fe(acac)3 40 ---[i] 
15 Fe(acac)3 40 73[j] 
16 Fe(acac)3 40 ---[k] 
17 Fe(acac)3 40 56[l] 
18 Fe(acac)3 40 87[m] 
19 Fe(acac)3 40 ---[n] 
20 Fe(acac)3 40 73%[o] 
21 Fe(acac)3 40 ---[p] 
22 Fe(acac)3 40 66[q] 
23 Fe(acac)3 40 60[r] 
24 Fe(acac)3 23 75[s] 
[a] Reaction conditions: 159a (0.25 mmol), 151a (1.75 mmol), [Fe] (10 mol %), dppe 
(10 mol %), ZnCl2·TMEDA (0.75 mmol), THF (5.0 mL), 6 h, constant current electrolysis 
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(CCE) at 5 mA, undivided cell, RVC as anode (10 mm × 15 mm × 6 mm), Pt-plate as 
cathode (10 mm × 15 mm × 0.25 mm), isolated yield. [b] RVC as cathode. [c] Without 
electricity, under N2. [d] under N2. [e] Without electricity, under air. [f] TMEDA instead of 
ZnCl2·TMEDA. [g] ZnBr2·TMEDA instead of ZnCl2·TMEDA. [h] MnCl2·TMEDA instead of 
ZnCl2·TMEDA. [i] Cp2Fe instead of ZnCl2·TMEDA. [j] 2-MeTHF instead of THF. [k] 2 (0.50 
mmol). [l] 2 (1.0 mmol). [m] 5 h. [n] divided cell. [o] Ni foam as cathode. [p] Mg-plate as 
anode and cathode. [q] Fe(acac)3 (5 mol %). [r] constant potential electrolysis at 2 V. [s] 
With IKA ElectraSyn. 
 
However, decreasing the amount of the arylating component 151a gave a remarkably 
poor yield, presumably due to the homocoupling of 151a and lower basicity of 151a 
(entries 16-17). Interestingly, the divided cell in contrast fell short in the desired 
catalytic transformation (entry 19). The ferraelectrocatalysis was also conveniently 
conducted with commercially available equipment, mirroring its user-friendly nature 
(entry 24). 
 
3.4.2 Scope of Ferraelectrocatalytic C–H Arylation 
 
With the optimized conditions for the metallaelectrooxidative iron-catalyzed C–H 
arylation being identified, we next probed its robustness with a representative set of 
benzamides 159 (Scheme 3.25). Various benzamides 159 were efficiently converted 
to the arylation products with high efficacy. Differently N-substituted triazoles 159 
were selectively converted into the desired products 192-194. Among others, a wealth 
of alkyl, aryl and halogenated substituents were fully tolerated in the transformation, 
affording products 195-204 in moderate to good yield. Moreover, heteroarene 
thiophene and ferrocene delivered the desired arylated products 205 and 206 with 
high catalytic efficacy. Moreover, the electrochemical C–H activation approach was 





derivative[140] 207 and 208 also proved to be amenable to the C–H activation likewise.  
 
Scheme 3.25. Robustness of the ferraelectrochemical C–H arylation of amides 159. 
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Thereafter, the effect of the substitution pattern was studied in the iron-catalyzed 
metallaelectrochemical C–H arylation (Scheme 3.26). Diversely functionalized 
arylation motifs were efficiently converted to the desired products 209-214 in good to 
excellent yield. Moreover, the heteroaromatic thiophene was well tolerated with 
moderate yield. 
 
Scheme 3.26. Robustness of the metallaelectrochemical C–H arylation. 
 
3.4.3 Comparison of Electrochemical Oxidation versus Chemical Oxidation 
To gain further advantage regarding the Ferraelectrocatalytic C–H arylation, the 
competition experiment between DCIB-free electrochemical and the DCIB-mediated 
transformation was conducted. The results revealed a preferential reactivity in favor 
of the ferraelectrocatalysis. Thus, both the isolated yields (Scheme 3.27a) and the 








Scheme 3.27. Ferraelectrocatalysis: mechanistic insights. 
 
3.4.4 Mechanistic Studies 
After evaluating the robustness of the electrochemical iron-catalyzed C–H arylation in 
terms of functional group tolerance on both coupling partners, detailed mechanistic 
studies were conducted. Thus, the Faradaic efficacy of the reaction was calculated. 
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In the equation, n is the amount of starting material in mol, y is the yield observed for 
a given reaction, z the number of electrons needed to achieve turnover, F is the 
Faraday constant, t is the reaction time in seconds and I the applied current in ampere 
(coulomb per second). Based on this equation, the electron efficacy was calculated for 
the C–H arylation of benzamide 159a: 
0.00025 𝑚𝑜𝑙 ∗ 0.95 ∗ 2 ∗ 96485 𝐶/𝑚𝑜𝑙
21600𝑠 ∗ 0.005 𝐶/𝑠
= 0.424 
The Faradaic efficacy for the given reaction was thus calculated to be 42%, which is 
corresponding to a charge of 4.48 F passed through the solution per each mole of the 
substrate 159a. 
 
3.4.4.1 Competition Experiments 
To gain further insights into the C–H activation mechanism, a competition experiment 
between electron-rich and electron-deficient amides 159 was preformed. It revealed 
a preferential reactivity in favor of the more electron-rich substrate (Scheme 3.28). 
This is however not in line with an C–H oxidative addition or a concerted-metalation-
deprotonation (CMD) pathway.[140] Instead, it can be explained in terms of a ligand-to-
ligand hydrogen transfer(LLHT)[14a] pathway or base-assisted internal electrophilic-







Scheme 3.28. Competition experiments. 
3.4.4.2 Kinetic Isotope Effect 
Subsequently, a KIE experiment by comparison of the initial rates of independent 
reactions with substrate 159a and its deuterated analogue [D5]-159a was conducted. 
The experiments revealed a KIE of kH/kD ≈ 1.2 (Scheme 3.29). A KIE of this magnitude 
suggests that the C–H cleavage step is not turnover-limiting and provides evidence for 







Scheme 3.29. Kinetic profile with substrates 159a or [D5]-159a. 
 
3.4.4.3 Cyclic Voltammetry 
 
Detailed mechanistic studies by cyclic voltammetry (performed by M. Stangier) 
showed a reversible FeII/FeIII oxidation event of the iron catalyst (red) at E1/2= -1.3 V vs. 
Fc0/+, which disappeared upon addition of the arylating reagent 2 (Scheme 3.30, green). 
This finding is in good agreement with a previous report by Jutand on the formation of 
a [PhFeI(acac)]− species,[142] which was shown to be reversibly oxidized to the 
corresponding iron(II) and iron(III) species at oxidation potentials of E1/2 = -0.6 V and 
E1/ 2 = -0.1 V vs. Fc0/+, respectively. These cyclic voltammetry studies on the iron-
catalyzed C–H arylation provide experimental mechanistic insights into an iron(II/III/I) 
manifold by oxidation-induced reductive elimination, with more general implications 
to low-valent iron-catalyzed C–H activation. 
y = 0,4648x + 3,6
R² = 0,9936



























Scheme 3.30. Cyclic voltammetry recorded at 100 mV/s with nBu4NPF6 (0.1 M in 




3.4.4.4 SEM Analysis 
While we thus rationalized the anodic oxidation elementary steps, we next 
interrogated the nature of the cathodic event. Here, detailed analyses of the electrode 
material by means of Scanning Electron Microscopy-Energy-Dispersive X-ray 
Spectroscopy (SEM-EDS) (performed by P. Liu) clearly highlighted the crucial role of 
the zinc additive at the surface of the electrode. Thus, the zinc additive serves multiple 







Scheme 3.31. SEM studies on the post-catalysis cathode material. i) SEM image of 
deposition. ii) SEM-EDS mapping with location of zinc. iii) Elemental distribution. 
 
3.4.4.5 Plausible Catalytic Cycle 
Based on these mechanistic studies, a proposed catalytic cycle for the iron-
electrocatalytic C–H functionalization commences by a facile organometallic C–H 
cleavage, which is supported by the results obtained from the the KIE study (Scheme 
3.29) and the DFT calculations by Dr. J. C. A. Oliveira. Thereafter, the key anodic single-
electron-transfer (SET) oxidation and subsequent transmetalation occur to furnish a 
five-membered ferra(III)cycle 218. As shown in Scheme 3.30, also one electron 
oxidation of intermediate 217 seems possible based on our CV data. Subsequently, 





intermediate 220. Finally, the catalytically active iron(II) intermediate 215 is 
regenerated by anodic oxidation (Scheme 3.32). 
 
 




3.4.5 Gram-Scale of Ferraelectro-Catalyzed C–H Arylation 
Importantly, the robustness of our strategy for electrochemical DCIB-free C–H 
arylations was further illustrated by the gram-scale synthesis of product 192 with 
comparable levels of efficacy (Scheme 3.33). It is noteworthy that 1.40 gram of the 
isolated desired product 192 were obtained in 11 hours under mild reaction condition. 
 
Scheme 3.33. Gram-scale synthesis of 192. 
 
3.4.5 Manganaelectro-Catalyzed C–H Activation 
Given the overall excellent performance of the iron catalyst, the generality of the 
metallaelectrocatalysis strategy was reflected by the merger of electrosynthesis with 
further benign transition metals. Indeed, unprecedented electrochemical manganese-
catalyzed C–H arylation was also realized under otherwise identical reaction 
conditions. In summary, all tested manganaelectro-catalyzed C–H arylations occured 
efficiently to yield the desired products, indicating the broad nature of our approach 











4. Summary and Outlook 
The sustainable and cost-efficient synthesis of key structural motifs for the preparation 
of pharmaceuticals, crop-protection agents, and functional materials remains one of 
the biggest challenges in terms of declining resources and a heightened awareness of 
the ecological costs associated with many processes. Recently, the direct 
functionalization of C–H bonds has emerged as an environmentally-benign platform 
avoids lengthy syntheses and has attracted substantial interest from both academia 
and the chemical industries. While major progress was initially achieved with noble 
transition metal catalysts, the use of inexpensive and earth-abundant 3d metals has 
gained significant momentum within the last decade. 
In the first project, the first example of a complexity-increasing cascade reaction to 
access various indolizinone alkaloid derivatives in a step-economical manner was 
developed (Scheme 4.1). Thus, a versatile cobalt(III) catalyst displayed a unique 
chemo- and regio-selectivity for an efficient protocol comprised C–H activation, C–N 
cleavage, pyridine migration and twofold C–C formation, which notably could not be 
achieved with rhodium(III) and manganese(I) catalysts. The mechanistic findings, 
including H/D exchange, competition experiments and KIE studies, revealed a 
reversible and facile BIES-type C─H metalation pathway to be involved. 
 
Scheme 4.1. Cp*Co(III)-catalyzed cascade annulation C─H/C─N functionalization for 






Thereafter, significant development of a complexity-increasing Domino reaction 
consisting of C–H activation, Diels-Alder reaction and retro-Diels-Alder reaction were 
realized using MnBr(CO)5 catalysis (Scheme 4.2). The dehydrocyanative alkyne 
annulation was achieved by a versatile manganese(I) catalyst through fast 
organometallic C–H activation. Our findings feature pyridine as a transformable 
directing group towards indolone alkaloid derivatives in a step-economical manner. 
Mechanistic studies provided strong support for an acetate-assisted organometallic C–
H activation through chelation assistance. In striking contrast to the analogous 
chemoselective cobalt(III) catalyses, this reaction appeared to be complementary, 
which bears great potential for new uniquely selective synthetic methods based on 
MnBr(CO)5 catalysis. 
 
Scheme 4.2. Manganese(I)-catalyzed C–H activation/Diels-Alder/retro-Diels-Alder 
Domino alkyne annulation. 
In the third project, the first manganese(II/III/I)-catalyzed C–H arylations in continuous 
flow technology were achieved (Scheme 4.3).[134] Within this reaction, an expedient 
substrate scope for C–H functionalizations on synthetically useful pyridines was 
highlighted with high levels of positional selectivity, notably using a most user-friendly 
MnCl2-based catalyst. Extensive mechanistic studies, including detailed experimental 
mechanistic studies, provided support for a facile LLHT C–H activation regime. Our 
findings highlight the practical importance of low-valent transition metal-catalyzed C–
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H functionalizations in user-friendly continuous flow. 
 
Scheme 4.3. Manganese-catalyzed C–H arylation in continuous flow. 
 
In the last two projects, toxic and cost-intensive dihalide oxidants were for the first 
time replaced by electricity as a green and sustainable oxidant, allowing for versatile 
iron- and manganese-catalyzed C–H activations (Scheme 4.4 and 4.5). The 
unprecedented ferraelectrocatalytic C–H arylation enabled direct arylations with 
ample scope, even efficiently occurring at room temperature. The strategy set the 
stage for avoiding chemical oxidants in low-valent metal-catalyzed C–H activation, 
featuring non-toxic, Earth-abundant iron Fe(acac)3 catalysts. Detailed analyses by 
experiment, spectroscopy and computation unravelled key insights into the role of 
additives within an iron(II/III/I) manifold, which should prove invaluable for the future 
design of iron-catalyzed electrochemical strong bond activations. 
 










5. Experimental Section 
5.1 General Remarks 
The catalysis in water or under an atmosphere of air were conducted in the sealed 
tubes or Schlenk tubes. Unless otherwise noted, other reactions were performed 
under N2 atmosphere using pre-dried glassware and standard Schlenk techniques. 
If not otherwise noted, yields refer to isolated compounds, estimated to be >95% pure 
as determined by 1H-NMR.  
 
Vacuum 
The following pressures were measured on the used vacuum pump and were not 
corrected: membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 
mbar. 
 
Melting Points (M.p.) 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC. The reported values are uncorrected. 
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-
plates (MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates 
were visualized under UV-light or developed by treatment with a KMnO4 solution 
followed by careful applying a heat gun. Chromatographic purification of products was 
accomplished by flash column chromatography on MERCK silica gel, grade 60 (0.040–
0.063 mm and 0.063–0.200 mm). 
 
Gas Chromatograpgy (GC)  





chromatography/mass spectrometry using G1760C GCDplus with mass detector HP 
5971, 5890 Series II with mass detector HP 5972 from HEWLETT-PACKARD and 7890A 
GC-System with mass detector 5975C (Triplex-Axis-Detector) from AGILENT 
TECHNOLOGIES equipped with HP-5MS columns (30 m × 0.25 mm × 0.25 m) were used. 
 
Gel permeation chromatography (GPC)  
GPC purifications were performed on a JAI system (JAI-LC-9260 II NEXT) equipped with 
two sequential columns (JAIGEL-2HR, gradient rate: 5.000; JAIGEL-2.5HR, gradient rate: 
20.000; internal diameter = 20 mm; length = 600 mm; Flush rate = 10.0 mL/min and 
chloroform (HPLC-quality with 0.6% ethanol as stabilizer) was used as the eluent. 
 
Infrared Spectroscopy  
Infrared spectra were recorded with a BRUKER Alpha-P ATR FT-IR spectrometer. Liquid 
samples were measured as a film, solid samples neat. The analysis of the spectra was 
carried out using the software from BRUKER OPUS 6. The absorption is given in wave 
numbers (cm−1) and the spectra were recorded in the range of 4000–400 cm‒1. In situ-
IR studies were performed on METTLER TOLEDO ReactIR™ 15 with an iC IR 4.3 software. 
 
Mass Spectrometry  
Electron-ionization (EI) mass spectra were recorded on a Jeol AccuTOF instrument at 
70 eV. Electrospray-ionization (ESI) mass spectra were obtained on Bruker micrOTOF 
and maXis instruments. All systems are equipped with time-of-flight (TOF) analyzers. 
The ratios of mass to charge (m/z) are reported and the intensity relative to the base 
peak (I = 100) is given in parenthesis.  
Nuclear Magnetic Resonance Spectroscopy (NMR)  
Nuclear magnetic resonance (NMR) spectra were recorded on VARIAN Inova 500, 600, 
VARIAN Mercury 300, VX 300, VARIAN Avance 300, VARIAN VNMRS 300 and BRUKER 
Avance III 300, 400 and HD 500 spectrometers. All chemical shifts are given as δ-values 
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in ppm relative to the residual proton peak of the deuterated solvent or its carbon 
atom, respectively. 1H and 13C NMR spectra were referenced using the residual proton 
or solvent carbon peak (see table), respectively. 13C and 19F NMR were measured as 
proton-decoupled spectra. 
 1H-NMR 13C-NMR 
CDCl3 7.26 77.16 
[D]6-DMSO 2.50 39.52 
The observed resonance-multiplicities were described by the following abbreviations: 
s (singlet), d (doublet), t (triplet), q (quartet), hept (heptet), m (multiplet) or analogous 
representations. The coupling constants J are reported in Hertz (Hz). Analysis of the 
recorded spectra was carried out with MestReNova 10 software. 
 
Electrochemistry 
Platinum electrodes (10 mm×15 mm× 0.25 mm, 99.9%; obtained from ChemPur® 
Karlsruhe, Germany) and RVC electrodes (10 mm×15 mm×6 mm, SIGRACELL®GFA 6 
EA, obtained from SGL Carbon, Wiesbaden, Germany) were connected using stainless 
steel adapters. Electrolysis was conducted using an AXIOMET AX-3003P potentiostat 
in constant current mode, CV studies were performed using a Metrohm Autolab 
PGSTAT204 workstation and Nova 2.0 software. Divided cells separated by a P4-




Solvents for column chromatography or reactions not sensitive to air and moisture 
were distilled under reduced pressure prior to use. All solvents for reactions involving 
air- or moisture sensitive compounds were dried, distilled and stored under inert 
atmosphere according to the following procedures:  





tetrahydrofuran, dimethylformamide, diethylether. 
1,2-Dichloroethane (DCE) was dried over CaH2 for 8 h, degassed and distilled under 
reduced pressure.  
1,2-Dimethoxyethane (DME) was dried over sodium and freshly distilled under N2 
1,1,1,3,3,3-Hexafluoropropan-2-ol (HFIP) was distilled from 3 Å molecular sieves. 
Toluene (PhMe), Tetrahydrofuran (THF), Dichloromethane (DCM) and ethyl ether 
(Et2O) were purified using a solvent purification system (SPS-800) from M. BRAUN. 
2,2,2-Trifluoroethanol (TFE) was stirred over CaSO4 and distilled under reduced 
pressure. 
Water (H2O) was degassed by repeated Freeze-Pump-Thaw degassing procedure. 
1,4-Dioxane and Di-(n-butyl)-ether (nBu2O) were distilled from sodium 
benzophenone ketyl. 
Chemicals  
Chemicals obtained from commercial sources with purity above 95% were used 
without further purification. ArMgBr were prepared from aromatic bromo and 
magnesium turnings in anhydrous THF under nitrogen atmosphere and titrated before 
use with I2/LiCl.[143]  
The following compounds are known and were synthesized according to previously 
described methods: 
Cp*CoI2(CO),[47] pyridones 172,[144] propargylic carbonates 88,[145] heterocycles azine 
112,[146] TAM-benzamide 159.[80] 
The following compounds were kindly synthesized and provided by the persons listed 
below:  
Karsten Rauch: [RuCl2(p-cymene)]2, [Cp*RhCl2]2, dry and/or degassed solvents (DCE, 
1,4-dioxane, PhMe, DME). 
Dr. Hui Wang: Cp*CoI2(CO), [Cp*Co(MeCN)3](SbF6)2, 88a. 
M. Sc. Nikolaos Kaplaneris: indole 35, 172a. 
M. Sc. Uttam Dhawa: 172aa. 
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M. Sc. Korkit Korvorapun: 172a. 
M. Sc. Zhigao Shen: amides 112. TAM-benzamide 159. 
5.2 General Procedures 
General Procedure A: Domino C–H Activation/Directing Group Migration/Alkyne 
Annulation: Unique Selectivity by d6-Cobalt(III) Catalysts  
Pyridones 172 (0.50 mmol, 1.0 equiv), propargylic carbonates 88 (1.50 mmol, 3.0 
equiv), Cp*Co(CO)I2 (24.0 mg, 10 mol %), AgSbF6 (34.4 mg, 20 mol %), HOAc (15.0 mg, 
50 mol %), and TFE (2.0 mL) were placed in a 25 mL Schlenk pressure tube under N2 
atmosphere, and stirred at 90 °C for 20 h. After cooling to ambient temperature, the 
mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and 
concentrated in vacuo. Purification by column chromatography on silica gel (n-
hexane/EtOAc: 3/1 → 1/1) afforded the desired products 173. 
 
General Procedure B: Manganese(I)-Catalyzed C–H Activation Domino Alkyne 
Annulation by Transformable Pyridines 
Pyridones 172 (0.25 mmol, 1.0 equiv), propargylic carbonates 88 (0.38 mmol, 1.5 
equiv), MnBr(CO)5 (6.9 mg, 10 mol %), NaOAc (10 mg, 50 mol %), BPh3 (60 mg, 1.0 
equiv), and DME (1.0 mL) were placed in a 25 mL Schlenk pressure tube under N2 
atmosphere, and stirred at 100 °C for 24 h. After cooling to ambient temperature, the 
mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and 
concentrated in vacuo. Purification by column chromatography on silica gel afforded 
the desired products 180. 
 
General procedure C: Manganese(II/III/I)-catalyzed C–H arylation in flow 
A 5 mL oven-dried round-bottom Schlenk flask was charged with amides 112 (0.25 
mmol, 1.0 equiv), MnCl2 (3.1 mg, 10 mol %), neocuproine (10.4 mg, 20 mol %) and 
TMEDA (74 μL, 2.0 equiv) in THF (0.10 mL) and ArMgBr (0.4 mL, 4.0 equiv, 2.5 m in 





3.0 equiv) in THF (0.40 mL) was prepared. The solutions were charged in separate 
syringes pumps (Vapourtec V-3) operating at a flow rate of 100 µL/min. The two 
solutions were mixed with a T-joint connection. Subsequently, the solution was 
pumped into the inlet of the 10 mL standard heated reactor with 100 min residence 
time. The back pressure was set to 4.0 bar and the temperature of the reactor was set 
at 80 °C. Using the Flow Wizard system, the solution was collected automatically. Next, 
a saturated aqueous NH4Cl (15 mL) was added and the reaction mixture was extracted 
with EtOAc (3 × 15 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by column 
chromatography on silica gel. 
 
General procedure D: Manganese(II/III/I)-catalyzed C–H arylation in batch 
To a stirred solution of amides 112 (0.25 mmol, 1.0 equiv), MnCl2 (3.1 mg, 10 mol %), 
neocuproine (10.4 mg, 20 mol %) and TMEDA (74 μL, 2.0 equiv) in THF (0.40 mL), 
ArMgBr (0.40 mL, 4.0 equiv, 2.5 m in THF) was added dropwise over 30 s. Then, the 
mixture was stirred for 1 min at ambient temperature, and a solution of 1,2-dichloro-
2-methylpropane (DCIB) (88 µL, 3.0 equiv) in THF (0.10 mL) was added to the reaction 
mixture. Then, the mixture was placed in a pre-heated oil bath at 60 °C. After stirring 
for 16 h, a saturated aqueous NH4Cl (15 mL) was added and the reaction mixture was 
extracted with EtOAc (3 × 15 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by column 
chromatography on silica gel. 
 
General Procedure E: Ferraelectrocatalyzed C–H Arylation 
The electrocatalysis was carried out in an undivided cell with a RVC anode (10 mm × 
15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). A solution of 
ArMgBr (0.88 mL, 7.0 equiv, 2.0 M in THF) was slowly added to a mixture of amide 159 
(0.25 mmol, 1.00 equiv), Fe(acac)3 (8.8 mg, 10 mol %), dppe (10.0 mg, 10 mol %) and 
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ZnCl2·TMEDA (189 mg, 3.00 equiv) were placed in a 10 mL cell and dissolved in THF 
(5 mL). Electrolysis was performed at 40 °C with a constant current of 5 mA 
maintained for 6 h (4.50 F/mol). At ambient temperature, a saturated aqueous NH4Cl 
solution (10 mL) was added and the RVC anode was washed with EtOAc (3 × 2 mL) in 
an ultrasonic bath. The combined phases were extracted with EtOAc (3 × 10 mL) and 
then dried over Na2SO4. Evaporation of the solvents and purification by column 
chromatography on silica gel (n-hexane/EtOAc) yielded the desired products 192-214. 
General procedure F: Manganaelectrocatalyzed C–H Arylation 
The electrocatalysis was carried out in an undivided cell with a RVC anode (10 mm × 
15 mm × 6 mm) and a platinum cathode (10 mm × 15 mm × 0.25 mm). A solution of 
ArMgBr (0.5 mL, 4.0 equiv, 2.0 m in THF) was slowly added to a mixture of amide 112 
(0.25 mmol, 1.00 equiv), MnCl2 (3.1 mg, 10 mol %), neocuproine (10.4 mg, 20 mol %) 
and TMEDA (74 μL, 2.0 equiv) were placed in a 10 mL cell and dissolved in THF (5 mL). 
Electrolysis was performed at 60 °C with a constant current of 3 mA maintained for 
18 h. At ambient temperature, a saturated aqueous NH4Cl solution (10 mL) was added 
and the RVC anode was washed with EtOAc (3 × 2 mL) in an ultrasonic bath. The 
combined phases were extracted with EtOAc (3 × 10 mL) and then dried over Na2SO4. 
Evaporation of the solvents and purification by column chromatography on silica gel 





5.3 Domino C–H Activation/Directing Group Migration/Alkyne 
Annulation: Unique Selectivity by d6-Cobalt(III) Catalysts 
5.3.1 Characterization Data  
 
3,3-Dimethyl-1-phenyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173aa): The general 
procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 0.50 mmol) 
and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (328 mg, 1.50 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 
173aa (127 mg, 81%) as a white solid. M.p.: 123–124 °C. 1H-NMR (400 MHz, CDCl3) δ 
= 8.61 (dd, J = 4.8, 1.8 Hz, 1H), 7.39–7.27 (m, 4H), 7.27–7.19 (m, 3H), 7.08 (ddd, J = 7.6, 
4.8, 1.2 Hz, 1H), 6.83 (ddd, J = 8.0, 1.2, 1.2 Hz, 1H), 6.33 (dd, J = 9.0, 1.2 Hz, 1H), 6.04 
(dd, J = 6.9, 1.2 Hz, 1H), 2.03 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 162.2 (Cq), 152.5 
(Cq), 150.7 (Cq), 150.4 (Cq), 149.3 (CH), 138.9 (CH), 135.6 (CH), 133.2 (Cq), 131.8 (Cq), 
129.3 (CH), 128.9 (CH), 128.6 (CH), 125.7 (CH), 122.5 (CH), 118.9 (CH), 100.0 (CH), 75.1 
(Cq), 21.1 (CH3). IR (ATR): 1654, 1577, 1529, 1462, 1443, 1154, 793, 701, 617, 498 cm- 
1. MS (ESI) m/z (relative intensity): 651 (7) [2M+Na]+, 315 (100) [M+H]+. HR-MS (ESI) 
m/z calcd for C21H19N2O [M+H]+ 315.1492, found 315.1495. The compound 173aa was 






7-Bromo-3,3-dimethyl-1-phenyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173ba): The 
general procedure A was followed using 4-bromo-2H-[1,2'-bipyridin]-2-one (172b) 
(126 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) 
(328 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173ba (132 mg, 67%) as a white solid. M.p.: 200–201 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.63 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.39–7.34 (m, 4H), 
7.23 (ddd, J = 5.6, 2.7, 1.4 Hz, 2H), 7.12 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.85 (dd, J = 8.0, 
1.1 Hz, 1H), 6.58 (d, J = 1.9 Hz, 1H), 6.18 (d, J = 1.9 Hz, 1H), 2.03 (s, 6H). 13C-NMR (100 
MHz, CDCl3) δ = 160.6 (Cq), 152.5 (Cq), 151.8 (Cq), 150.6 (Cq), 149.3 (CH), 135.7 (CH), 
135.2 (Cq), 132.4 (Cq), 131.1 (Cq), 129.2 (CH), 129.1 (CH), 128.9 (CH), 125.7 (CH), 122.8 
(CH), 120.5 (CH), 104.0 (CH), 75.3 (Cq), 21.1 (CH3).IR (ATR): 1652, 1583, 1518, 1462, 
887, 790, 702 cm-1. MS (ESI) m/z (relative intensity): 393 (100) [M+H]+. HR-MS (ESI) 
m/z calcd for C21H18N2OBr [M+H]+ 393.0597, found 393.0602. 
 
3,3-Dimethyl-1-phenyl-2-(pyridin-2-yl)pyrrolo[1,2-b]isoquinolin-5(3H)-one (173ca): 
The general procedure A was followed using 2-(pyridin-2-yl)isoquinolin-1(2H)-one 
(172c) (111 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate 
(88a) (328 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173ca (100 mg, 55%) as a white solid. M.p.: 208–209 °C. 





Hz, 1H), 7.65–7.54 (m, 1H), 7.51–7.31 (m, 8H), 7.16 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.94 
(dd, J = 8.0, 1.1 Hz, 1H), 6.43 (s, 1H), 2.15 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 160.6 
(Cq), 144.1 (Cq), 143.0 (Cq), 139.5 (CH), 138.3 (Cq), 136.4 (Cq), 133.1 (Cq), 132.3 (Cq), 
132.0 (CH), 130.7 (CH), 128.3 (CH), 128.1 (CH), 128.0 (CH), 126.4 (CH), 125.8 (CH), 
123.9 (Cq), 120.0 (CH), 111.0 (CH), 99.4 (CH), 38.4 (Cq), 28.8 (CH3). IR (ATR): 1652, 1621, 
1600, 1583, 1563, 1462, 1431, 1353, 1334, 701 cm-1. MS (ESI) m/z (relative intensity): 
751 (15) [2M+Na]+, 365 (100) [M+H]+. HR-MS (ESI) m/z calcd for C25H21N2O [M+H]+ 
365.1648, found 365.1649. The compound 173ca was also unambiguously 
characterized by X-ray crystallographic diffraction analysis (vide infra).  
 
 
7-Chloro-3,3-dimethyl-1-phenyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173da): The 
general procedure A was followed using 4-chloro-2H-[1,2'-bipyridin]-2-one (172d) 
(103 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) 
(328 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173da (95.9 mg, 55%) as a white solid. M.p.: 192–193 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.60 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.93 (d, J = 7.6 Hz, 
1H), 7.46–7.30 (m, 4H), 7.27–7.20 (m, 2H), 7.13 (ddd, J = 7.6, 4.8, 1.0 Hz, 1H), 6.87 (dd, 
J = 7.9, 1.0 Hz, 1H), 5.88 (d, J = 7.6 Hz, 1H), 2.06 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 
158.7 (Cq), 152.2 (Cq), 151.4 (Cq), 150.8 (Cq), 149.4 (CH), 147.9 (CH), 135.7 (CH), 133.0 
(Cq), 131.5 (Cq), 129.3 (CH), 129.1 (CH), 128.8 (CH), 125.8 (CH), 122.7 (CH), 101.3 (CH), 
91.4 (Cq), 76.5 (Cq), 21.1 (CH3).IR (ATR): 1727, 1691, 1610, 1547, 1484, 1399, 1131, 
1037, 881, 726 cm-1. MS (ESI) m/z (relative intensity): 349 (100) [M+H]+. HR-MS (ESI) 






carboxylate (173ea): The general procedure A was followed using methyl 2-oxo-2H-
[1,2'-bipyridine]-4-carboxylate (172e) (115 mg, 0.50 mmol) and methyl (2-methyl-4-
phenylbut-3-yn-2-yl)carbonate (88a) (328 mg, 1.50 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 173ea (96.8 mg, 52%) as 
a white solid. M.p.: 165–166 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.66 (ddd, J = 4.9, 1.9, 
1.0 Hz, 1H), 7.42–7.34 (m, 4H), 7.31–7.23 (m, 2H), 7.14 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 
7.02 (d, J = 1.6 Hz, 1H), 6.87 (dd, J = 8.0, 1.0 Hz, 1H), 6.55 (d, J = 1.6 Hz, 1H), 3.86 (s, 
3H), 2.07 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 165.7 (Cq), 161.7 (Cq), 152.2 (Cq), 151.7 
(Cq), 151.1 (Cq), 149.4 (CH), 140.4 (CH), 135.7 (Cq), 133.2 (Cq), 131.5 (Cq), 129.4 (CH), 
129.1 (CH), 128.8 (CH), 125.8 (CH), 122.8 (CH), 120.6 (CH), 98.6 (CH), 75.5 (Cq), 52.7 
(CH3), 21.0 (CH3). IR (ATR): 1730, 1661, 1593, 1531, 1463, 1442, 1251, 1086, 775, 703 
cm-1. MS (ESI) m/z (relative intensity): 767 (43) [2M+Na]+, 395 (100) [M+Na]+, 373 (78) 




(173fa): The general procedure A was followed using methyl 2-oxo-2H-[1,2'-





phenylbut-3-yn-2-yl)carbonate (88a) (328 mg, 1.50 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 173fa (99.4 mg, 52%) as a 
white solid. M.p.: 151–153 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.66 (ddd, J = 4.8, 1.8, 
0.9 Hz, 1H), 7.43–7.37 (m, 4H), 7.29–7.23 (m, 2H), 7.15 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 
6.87 (dd, J = 8.0, 1.1 Hz, 1H), 6.64 (dd, J = 1.8, 0.9 Hz, 1H), 6.16 (d, J = 1.8 Hz, 1H), 2.07 
(s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 160.8 (Cq), 152.7 (Cq), 152.1 (Cq), 151.9 (Cq), 
149.4 (CH), 141.1 (q, 2JC–F = 33.3 Hz, Cq), 135.8 (CH), 132.8 (Cq), 131.2 (Cq), 129.2 (CH), 
129.1 (CH), 129.0 (CH), 125.8 (CH), 122.9 (CH), 122.6 (q, 1JC–F = 274.1 Hz, Cq), 116.1 (q, 
3JC–F = 4.2 Hz, CH), 95.0 (q, 3JC–F = 3.0 Hz, CH), 75.8 (Cq), 21.0 (CH3). 19F-NMR (376 MHz, 
CDCl3) δ = -66.1 (s). IR (ATR): 2050, 1672, 1603, 1538, 1466, 1281, 1175, 1138, 751, 
702 cm-1. MS (ESI) m/z (relative intensity): 787 (20) [2M+Na]+, 405 (18) [2M+Na]+, 383 




3,3,7-Trimethyl-1-phenyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173ga): The general 
procedure A was followed using 4-methyl-2H-[1,2'-bipyridin]-2-one (172g) (93.1 mg, 
0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (328 mg, 
1.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) 
yielded 173ga (123 mg, 75%) as a white solid. M.p.: 126–127 °C. 1H-NMR (400 MHz, 
CDCl3) δ = 8.63 (dd, J = 4.6, 1.4 Hz, 1H), 7.40–7.31 (m, 4H), 7.24 (dd, J = 6.2, 3.1 Hz, 2H), 
7.10 (dd, J = 7.8, 4.6 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 6.12 (s, 1H), 5.82 (s, 1H), 2.10 (s, 
3H), 2.06 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 160.5 (Cq), 152.5 (Cq), 150.9 (Cq), 150.0 
(Cq), 149.7 (Cq), 149.2 (CH), 135.6 (CH), 135.5 (CH), 133.2 (Cq), 131.9 (Cq), 129.3 (CH), 
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128.9 (CH), 128.5 (CH), 125.6 (CH), 122.4 (CH), 102.7 (CH), 74.5 (Cq), 21.5 (CH3), 21.3 
(CH3). IR (ATR): 1655, 1584, 1531, 1462, 1433, 1349, 1156, 791, 734, 701 cm-1. MS (ESI) 
m/z (relative intensity): 329 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H21N2O [M+H]+ 
329.1648, found 329.1653. The compound 173ga was also unambiguously 
characterized by X-ray crystallographic diffraction analysis (vide infra). 
 
 
2-(5-Fluoropyridin-2-yl)-3,3-dimethyl-1-phenylindolizin-5(3H)-one (173ha): The 
general procedure A was followed using 5'-fluoro-2H-[1,2'-bipyridin]-2-one (172h) 
(95.1 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) 
(328 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173ha (104.7 mg, 63%) as a white solid. M.p.: 177–178 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.49 (dd, J = 3.0, 0.6 Hz, 1H), 7.42–7.33 (m, 3H), 7.30–
7.19 (m, 3H), 7.09 (ddd, J = 8.8, 8.1, 3.0 Hz, 1H), 6.87 (ddd, J = 8.8, 4.4, 0.6 Hz, 1H), 6.36 
(dd, J = 9.1, 1.1 Hz, 1H), 6.04 (dd, J = 6.9, 1.1 Hz, 1H), 2.05 (s, 6H). 13C-NMR (100 MHz, 
CDCl3) δ = 162.1 (Cq), 158.3 (d, 1JC–F = 259.5 Hz, Cq), 150.3 (Cq), 149.5 (Cq), 148.5 (d, 4JC–F 
= 4.5 Hz, Cq), 138.9 (CH), 137.6 (d, 2JC–F = 23.5 Hz, CH), 133.3 (CH), 131.8 (CH), 129.3 
(CH), 129.1 (CH), 128.8 (CH), 126.8 (d, 3JC–F = 4.3 Hz, CH), 122.6 (d, 2JC–F = 18.5 Hz, CH), 
119.1 (CH), 100.1 (CH), 75.1 (Cq), 21.1 (CH3). 19F-NMR (376 MHz, CDCl3) δ = -126.53 
(dd, J = 8.1, 4.5 Hz). IR (ATR): 1654, 1584, 1531, 1473, 1229, 1177, 798, 736, 700, 420 
cm-1. MS (ESI) m/z (relative intensity): 329 (100) [M+H]+. HR-MS (ESI) m/z calcd for 







3,3-Dimethyl-2-(5-methylpyridin-2-yl)-1-phenylindolizin-5(3H)-one (173ia): The 
general procedure A was followed using 5'-methyl-2H-[1,2'-bipyridin]-2-one (172i) 
(93.1 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) 
(328 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173ia (100.2 mg, 61%) as a white solid. M.p.: 190–191 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.46 (d, J = 2.0 Hz, 1H), 7.36–7.31 (m, 4H), 7.29–7.21 (m, 
2H), 7.18 (dd, J = 8.0, 2.0 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.30 (s, 1H), 5.97 (s, 1H), 2.26 
(s, 3H), 2.06 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 162.2 (Cq), 150.8 (Cq), 150.7 (Cq), 
149.7 (CH), 149.5 (Cq), 138.5 (CH), 136.1 (CH), 132.7 (Cq), 132.2 (Cq), 132.1 (Cq), 129.3 
(CH), 128.8 (CH), 128.4 (CH), 125.1 (CH), 104.9 (CH), 100.1 (CH), 74.9 (Cq), 21.2 (CH3), 
18.2 (CH3). IR (ATR): 1652, 1583, 1530, 1475, 1445, 1347, 1176, 797, 734, 700 cm-1. MS 
(ESI) m/z (relative intensity): 329 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H21N2O 
[M+H]+ 329.1648, found 329.1648. 
 
 
2-(5-Chloropyridin-2-yl)-3,3-dimethyl-1-phenylindolizin-5(3H)-one (173ja): The 
general procedure A was followed using 5'-chloro-2H-[1,2'-bipyridin]-2-one (172j) 
(103.3 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) 
(328 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
102 
 
hexane/EtOAc: 1/1) yielded 173ja (126 mg, 72%) as a white solid. M.p.: 163–164 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.59 (d, J = 2.3 Hz, 1H), 7.42–7.36 (m, 3H), 7.34 (dd, J = 
8.5, 2.5 Hz, 1H), 7.31–7.20 (m, 3H), 6.80 (dd, J = 8.5, 0.7 Hz, 1H), 6.36 (s, 1H), 6.02 (d, 
J = 6.7 Hz, 1H), 2.06 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 162.2 (Cq), 150.4 (Cq), 150.3 
(Cq), 149.3 (Cq), 148.2 (CH), 138.7 (CH), 135.4 (CH), 133.9 (Cq), 131.7 (Cq), 131.1 (Cq), 
129.2 (CH), 129.2 (CH), 128.9 (CH), 126.3 (CH), 119.5 (CH), 100.4 (CH), 75.1 (Cq), 21.2 
(CH3). IR (ATR): 1652, 1582, 1528, 1458, 1445, 1155, 1110, 858, 799, 703 cm-1. MS (ESI) 
m/z (relative intensity): 349 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H18N2OCl 




(173ka): The general procedure A was followed using 5'-(trifluoromethyl)-2H-[1,2'-
bipyridin]-2-one (172k) (103.3 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-
yn-2-yl)carbonate (88a) (328 mg, 1.50 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/1) yielded 173ja (114.7 mg, 60%) as a white solid. M.p.: 
155–156 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.91 (dd, J = 2.5, 0.8 Hz, 1H), 7.59 (ddd, J = 
8.3, 2.5, 0.8 Hz, 1H), 7.41 (ddd, J = 5.7, 4.0, 2.1 Hz, 3H), 7.34–7.24 (m, 3H), 6.98 (dd, J 
= 8.4, 0.8 Hz, 1H), 6.39 (s, 1H), 6.05 (d, J = 6.8 Hz, 1H), 2.10 (s, 6H). 13C-NMR (100 MHz, 
CDCl3) δ = 156.0 (Cq), 155.9 (Cq), 150.1 (Cq), 148.9 (Cq), 146.1 (q, 3JC–F = 4.0 Hz, CH), 
138.7 (CH), 135.4 (Cq), 132.7 (q, 3JC–F = 3.5 Hz, CH), 131.5 (Cq), 129.3 (CH), 129.2 (CH), 
129.1 (CH), 125.2 (CH), 124.9 (q, 2JC–F = 33.2 Hz, Cq), 123.3 (q, 1JC–F = 272.4 Hz, Cq), 119.9 
(CH), 100.9 (CH), 75.3 (Cq), 21.2 (CH3). IR (ATR): 1655, 1588, 1531, 1327, 1166, 1131, 
1081, 852, 799, 702 cm-1. MS (ESI) m/z (relative intensity): 383 (100) [M+H]+. HR-MS 








(173la): The general procedure A was followed using 5-(trifluoromethyl)-2H-[1,2'-
bipyridin]-2-one (172l) (120.1 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-
yn-2-yl)carbonate (88a) (328mg, 1.50 mmol). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 1/1) yielded 173la (122.4 mg, 64%) as a white solid. M.p.: 
112–113 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.66 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.69 (dd, 
J = 7.5, 0.9 Hz, 1H), 7.47–7.33 (m, 4H), 7.25 (ddd, J = 5.4, 3.0, 1.1 Hz, 2H), 7.16 (ddd, J 
= 7.5, 4.8, 1.1 Hz, 1H), 6.89 (dd, J = 7.9, 1.1 Hz, 1H), 6.12 (dd, J = 7.5, 0.7 Hz, 1H), 2.09 
(s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 162.0 (Cq), 157.9 (Cq), 154.1 (Cq), 151.8 (Cq), 
149.4 (CH), 138.6 (q, 3JC–F = 5.0 Hz, CH), 135.8 (CH), 132.7 (Cq), 131.1 (Cq), 129.3 (CH), 
129.2 (CH), 129.0 (CH), 125.8 (CH), 123.4 (q, 1JC–F = 271.2 Hz, Cq), 123.0 (CH), 117.6 (q, 
2JC–F = 30.1 Hz, Cq), 98.0 (CH), 76.4 (Cq), 21.2 (CH3). 19F-NMR (376 MHz, CDCl3) δ = -4.46 
(s). IR (ATR): 1666, 1553, 1463, 1314, 1153, 1128, 1062, 787, 732, 702 cm-1. MS (ESI) 
m/z (relative intensity): 383 (15) [M+H]+. HR-MS (ESI) m/z calcd for C22H18N2OF3 








(phenylsulfonyl)benzenesulfonamide (172m) (233.8 mg, 0.50 mmol) and methyl (2-
methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (328mg, 1.50 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 173ma (170.7 mg, 
56%) as a white solid. M.p.: 154–155 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.64 (ddd, J = 
4.8, 1.8, 0.9 Hz, 1H), 8.11–7.89 (m, 4H), 7.67–7.54 (m, 2H), 7.52–7.46 (m, 4H), 7.44–
7.35 (m, 5H), 7.29–7.24 (m, 2H), 7.14 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.86 (dd, J = 8.0, 
1.1 Hz, 1H), 6.05 (d, J = 7.6 Hz, 1H), 1.91 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 158.3 
(Cq), 153.5 (Cq), 153.0 (Cq), 152.0 (Cq), 149.4 (CH), 143.7 (CH), 139.5 (Cq), 135.8 (CH), 
133.7 (CH), 132.8 (Cq), 131.3 (Cq), 129.3 (CH), 129.1 (CH), 129.0 (CH), 128.9 (CH), 128.6 
(CH), 125.7 (CH), 122.9 (CH), 121.8 (Cq), 98.5 (CH), 76.0 (Cq), 20.9 (CH3). IR (ATR): 1661, 
1599, 1537, 1448, 1375, 1354, 1170, 1084, 891, 551 cm-1. MS (ESI) m/z (relative 
intensity): 610 (100) [M+H]+. HR-MS (ESI) m/z calcd for C33H28N3O5S2 [M+H]+ 610.1465, 
found 610.1475.  
 
 
6-Bromo-3,3-dimethyl-1-phenyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173na): The 
general procedure A was followed using 3-bromo-2H-[1,2'-bipyridin]-2-one (172n) 
(125.6 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) 
(328mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173na (129.8 mg, 66%) as a white solid. M.p.: 206–207 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.63 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.69 (d, J = 7.5 Hz, 
1H), 7.46–7.30 (m, 4H), 7.26–7.20 (m, 2H), 7.12 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 6.86 (dd, 
J = 8.0, 1.0 Hz, 1H), 5.97 (d, J = 7.6 Hz, 1H), 2.06 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 
157.8 (Cq), 152.1 (Cq), 150.9 (Cq), 150.2 (Cq), 149.3 (CH), 140.9 (CH), 135.7 (CH), 132.9 





99.9 (CH), 76.3 (Cq), 21.0 (CH3). IR (ATR): 1642, 1586, 1563, 1518, 1337, 1075, 1060, 
796, 739, 698 cm-1. MS (ESI) m/z (relative intensity): 415 (10) [M+Na]+, 393 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C21H18N2OBr [M+H]+ 393.0597, found 393.0604.  
 
 
6-Chloro-3,3-dimethyl-1-phenyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173oa): The 
general procedure A was followed using 3-chloro-2H-[1,2'-bipyridin]-2-one (172o) 
(103.3 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) 
(328mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173oa (121.9 mg, 70%) as a white solid. M.p.: 208–209 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.62 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 7.48 (d, J = 7.6 Hz, 
1H), 7.41–7.32 (m, 4H), 7.26–7.21 (m, 2H), 7.11 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.86 (dt, 
J = 8.0, 1.0 Hz, 1H), 6.02 (d, J = 7.6 Hz, 1H), 2.06 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 
157.7 (Cq), 152.1 (Cq), 150.9 (Cq), 149.3 (CH), 149.2 (Cq), 137.1 (CH), 135.6 (CH), 132.8 
(Cq), 131.4 (Cq), 129.2 (CH), 129.0 (CH), 128.8 (CH), 125.7 (CH), 124.1 (Cq), 122.7 (CH), 
99.0 (CH), 76.1 (Cq), 21.0 (CH3). IR (ATR): 1647, 1588, 1564, 1524, 1339, 1173, 1089, 
789, 764, 699 cm-1. MS (ESI) m/z (relative intensity): 719 (6) [2M+Na]+, 371 (25) 
[M+Na]+, 349 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H18N2OCl [M+H]+ 349.1102, 






(173pa): The general procedure A was followed using 3-chloro-2H-[1,2'-bipyridin]-2-
one (172p) (98.6 mg, 0.50 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-
yl)carbonate (88a) (328mg, 1.50 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 173oa (127.3 mg, 75%) as a white solid. M.p.: 
219–220 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.64 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.14–
7.96 (m, 4H), 7.64–7.56 (m, 2H), 7.53–7.46 (m, 4H), 7.44–7.34 (m, 5H), 7.31–7.24 (m, 
2H), 7.14 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.86 (ddd, J = 8.0, 1.1, 1.1 Hz, 1H), 6.05 (d, J = 
7.6 Hz, 1H), 1.91 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 159.0 (Cq), 155.2 (Cq), 155.2 
(Cq), 151.3 (Cq), 149.5 (CH), 146.4 (CH), 135.9 (CH), 132.8 (Cq), 130.8 (Cq), 129.3 (CH), 
129.2 (CH), 129.1 (CH), 125.8 (CH), 123.3 (CH), 116.5 (Cq), 102.3 (Cq), 99.8 (CH), 76.8 
(Cq), 21.0 (CH3). IR (ATR): 2219, 1650, 1583, 1536, 1460, 1432, 1179, 776, 728, 699 cm-
1. MS (ESI) m/z (relative intensity): 340 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C22H18N3O [M+H]+ 340.1444, found 340.1453.  
 
 
1-(4-Methoxyphenyl)-3,3-dimethyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173ac): The 
general procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 
0.50 mmol) and 4-(4-methoxyphenyl)-2-methylbut-3-yn-2-yl methyl carbonate (88c) 
(373 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173ac (115 mg, 67%) as a white solid. M.p.: 161–162 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.64 (ddd, J = 4.8, 1.8, 0.8 Hz, 1H), 7.40 (dd, J = 7.6, 1.8 
Hz, 1H), 7.31 (d, J = 6.5 Hz, 1H), 7.17 (d, J = 8.7 Hz, 2H), 7.12 (ddd, J = 7.6, 4.8, 1.0 Hz, 
1H), 6.92–6.84 (m, 3H), 6.33 (s, 1H), 6.04 (d, J = 6.8 Hz, 1H), 3.80 (s, 3H), 2.05 (s, 6H). 
13C-NMR (100 MHz, CDCl3) δ = 162.0 (Cq), 159.7 (Cq), 152.8 (Cq), 150.8 (Cq), 150.2 (Cq), 





(CH), 119.2 (CH), 114.3 (CH), 100.2 (CH), 75.0 (Cq), 55.2 (CH3), 21.2 (CH3). IR (ATR): 1654, 
1583, 1532, 1511, 1463, 1251, 1177, 1029, 845, 793 cm-1. MS (ESI) m/z (relative 
intensity): 345 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H21N2O2 [M+H]+ 345.1598, 
found 345.1600.  
 
 
3,3-Dimethyl-1-(naphthalen-2-yl)-2-(pyridin-2-yl)indolizin-5(3H)-one (173ad): The 
general procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 
0.50 mmol) and methyl (2-methyl-4-(naphthalen-2-yl)but-3-yn-2-yl) carbonate (88d) 
(403 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 3ad (106 mg, 58%) as a white solid. M.p.: 185–186 °C. 1H-
NMR (400 MHz, CDCl3) δ = 8.66 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 7.92–7.70 (m, 4H), 7.58–
7.43 (m, 2H), 7.35–7.26 (m, 3H), 7.10 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.89 (ddd, J = 7.9, 
1.1, 1.1 Hz, 1H), 6.40 (dd, J = 9.0, 1.1 Hz, 1H), 6.13 (dd, J = 6.9, 1.1 Hz, 1H), 2.12 (s, 6H). 
13C-NMR (100 MHz, CDCl3) δ = 162.3 (Cq), 152.5 (Cq), 151.1 (Cq), 150.6 (Cq), 149.3 (CH), 
138.9 (CH), 135.7 (CH), 133.3 (Cq), 133.2 (Cq), 133.0 (Cq), 129.4 (Cq), 128.8 (CH), 128.7 
(CH), 128.0 (CH), 127.8 (CH), 126.9 (CH), 126.7 (CH), 126.5 (CH), 125.8 (CH), 122.6 (CH), 
119.0 (CH), 100.2 (CH), 75.3 (Cq), 21.2 (CH3). IR (ATR): 1653, 1582, 1531, 1460, 1433, 
1153, 787, 746, 479 cm-1. MS (ESI) m/z (relative intensity): 365 (100) [M+H]+. HR-MS 






1-(4-Fluorophenyl)-3,3-dimethyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173ae): The 
general procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 
0.50 mmol) and 4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl methyl carbonate (88e) (354 
mg, 1.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
1/1) yielded 3ae (140 mg, 84%) as a white solid. M.p.: 148–149 °C. 1H-NMR (400 MHz, 
CDCl3) δ = 8.63 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.42 (dd, J = 7.6, 1.9 Hz, 1H), 7.28 (dd, J 
= 9.0, 7.0 Hz, 1H), 7.25–7.18 (m, 2H), 7.13 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 7.06–6.97 (m, 
2H), 6.85 (dd, J = 8.0, 1.1 Hz, 1H), 6.36 (dd, J = 9.0, 1.1 Hz, 1H), 6.06 (dd, J = 7.0, 1.1 Hz, 
1H), 2.02 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 162.65 (d, 1JC–F = 249.0 Hz, Cq), 162.3 
(Cq), 152.2 (Cq), 151.2 (Cq), 150.2 (Cq), 149.4 (CH), 139.0 (CH), 135.8 (CH), 132.1 (Cq), 
131.1 (d, 3JC–F = 8.1 Hz, CH), 127.6 (d, 4JC–F = 3.5 Hz, Cq), 125.6 (CH), 122.7 (CH), 118.9 
(CH), 116.0 (d, 2JC–F = 21.6 Hz, CH), 100.1 (CH), 75.2 (Cq), 21.0 (CH3). 19F-NMR (376 MHz, 
CDCl3) δ = -112.01 (s). IR (ATR): 1651, 1581, 1531, 1508, 1462, 1433, 1348, 1224, 1157, 
851, 796 cm-1. MS (ESI) m/z (relative intensity): 687 (32) [2M+Na]+, 355 (10) [M+Na]+, 




3-Ethyl-3-methyl-1-phenyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173af): The general 
procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 0.50 mmol) 





Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 
173af (136 mg, 83%) as a white solid. M.p.: 117–118 °C. 1H-NMR (400 MHz, CDCl3) δ 
= 8.64 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.40–7.33 (m, 4H), 7.30 (dd, J = 9.0, 6.9 Hz, 1H), 
7.27–7.22 (m, 2H), 7.11 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.85 (dt, J = 7.9, 1.1 Hz, 1H), 6.38 
(dd, J = 9.0, 1.1 Hz, 1H), 6.07 (dd, J = 6.9, 1.1 Hz, 1H), 3.18 (dq, J = 14.6, 7.4 Hz, 1H), 
2.34 (dq, J = 13.8, 7.4 Hz, 1H), 2.05 (s, 3H), 0.61 (t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, 
CDCl3) δ = 162.2 (Cq), 152.6 (Cq), 151.4 (Cq), 149.4 (CH), 148.6 (Cq), 139.0 (CH), 135.6 
(CH), 134.9 (Cq), 132.0 (Cq), 129.4 (CH), 128.9 (CH), 128.6 (CH), 125.6 (CH), 122.5 (CH), 
118.8 (CH), 99.8 (CH), 79.0 (Cq), 25.5 (CH2), 21.0 (CH3), 8.0 (CH3). IR (ATR): 1653, 1582, 
1530, 1463, 1445, 1433, 1352, 1155, 795, 701 cm-1. MS (ESI) m/z (relative intensity): 
351 (8) [M+Na]+, 329 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H21N2O [M+H]+ 
329.1648, found 329.1655. 
 
 
3,3-Dimethyl-2-(pyridin-2-yl)-1-(thiophen-3-yl)indolizin-5(3H)-one (173ag): The 
general procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 
0.50 mmol) and methyl (2-methyl-4-(thiophen-2-yl)but-3-yn-2-yl) carbonate (88g) 
(337 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173ag (106 mg, 62%) as a white solid. M.p.: 142–143 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.65 (d, J = 4.3 Hz, 1H), 7.57–7.11 (m, 5H), 6.94 (d, J = 
7.5 Hz, 1H), 6.88 (d, J = 4.3 Hz, 1H), 6.32 (s, 1H), 6.21–6.03 (m, 1H), 2.02 (s, 6H). 
13C-NMR (100 MHz, CDCl3) δ = 162.5 (Cq), 152.5 (Cq), 150.7 (Cq), 150.1 (Cq), 149.3 (CH), 
138.6 (CH), 135.7 (CH), 131.5 (Cq), 128.1 (Cq), 127.9 (CH), 126.3 (CH), 125.3 (CH), 125.1 
(CH), 122.6 (CH), 119.4 (CH), 100.0 (CH), 74.7 (Cq), 21.1 (CH3). IR (ATR): 1650, 1578, 
1461, 1433, 1151, 842, 792, 735, 672 cm-1. MS (ESI) m/z (relative intensity): 663 (10) 
110 
 




3,3-Dimethyl-1-(4-propylphenyl)-2-(pyridin-2-yl)indolizin-5(3H)-one (173ah): The 
general procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 
0.50 mmol) and methyl (2-methyl-4-(4-propylphenyl)but-3-yn-2-yl) carbonate (88h) 
(391 mg, 1.50 mmol). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 1/1) yielded 173ag (102 mg, 57%) as a white solid. M.p.: 137–138 °C. 
1H-NMR (400 MHz, CDCl3) δ = 8.62 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.36 (dd, J = 7.7, 1.9 
Hz, 1H), 7.25 (dd, J = 9.0, 6.9 Hz, 1H), 7.13 (s, 4H), 7.09 (ddd, J = 7.5, 4.8, 1.1 Hz, 1H), 
6.86 (dd, J = 8.0, 1.1 Hz, 1H), 6.34 (dd, J = 9.0, 1.1 Hz, 1H), 6.08 (dd, J = 6.9, 1.1 Hz, 1H), 
2.66–2.41 (m, 2H), 2.04 (s, 6H), 1.70–1.50 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H). 13C-NMR 
(100 MHz, CDCl3) δ = 162.2 (Cq), 152.6 (Cq), 150.6 (Cq), 150.4 (Cq), 149.2 (CH), 143.2 
(Cq), 138.8 (CH), 135.5 (CH), 133.2 (Cq), 129.1 (CH), 129.0 (Cq), 128.9 (CH), 125.7 (CH), 
122.4 (CH), 118.7 (CH), 100.1 (CH), 75.0 (Cq), 37.7 (CH2), 24.2 (CH2), 21.1 (CH3), 13.7 
(CH3). IR (ATR): 1656, 1585, 1531, 1463, 1154, 795, 744, 640 cm-1. MS (ESI) m/z 
(relative intensity): 379 (12) [M+Na]+, 357 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C24H24N2O [M+H]+ 357.1961, found 357.1964. 
 
 





procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 0.50 mmol) 
and 2,2- Dimethyl-4-p-tolylbut-3-yn-2-yl carbonate (88l) (349 mg, 1.50 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) yielded 
173al (100 mg, 61%) as a white solid. M.p.: 156–158 °C. 1H-NMR (400 MHz, CDCl3) δ = 
8.65 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.40 (dd, J = 7.8, 1.8 Hz, 1H), 7.28 (s, 1H), 7.18–7.08 
(m, 5H), 6.89 (dd, J = 8.0, 1.1 Hz, 1H), 6.36 (d, J = 9.0 Hz, 1H), 6.08 (d, J = 6.9 Hz, 1H), 
2.35 (s, 3H), 2.06 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 162.3 (Cq), 152.7 (Cq), 150.7 
(Cq), 150.5 (Cq), 149.3 (CH), 138.9 (CH), 138.5 (Cq), 135.7 (CH), 133.3 (Cq), 129.7 (CH), 
129.2 (CH), 128.9 (Cq), 125.8 (CH), 122.5 (CH), 118.9 (CH), 100.1 (CH), 75.1 (Cq), 21.3 
(CH3), 21.2 (CH3).IR (ATR): 1653, 1584, 1531, 1462, 1348, 840, 1177, 1154, 795, 743 
cm-1. MS (ESI) m/z (relative intensity): 679 (35) [2M+Na]+, 329 (100) [M+H]+. HR-MS 
(ESI) m/z calcd for C22H20N2O [M+H]+ 329.1648, found 329.1652.  
 
 
1-(3-Chlorophenyl)-3,3-dimethyl-2-(pyridin-2-yl)indolizin-5(3H)-one (173aj): The 
general procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) (86.1 mg, 
0.50 mmol) and 4-(3-chlorophenyl)-2-methylbut-3-yn-2-yl methyl carbonate (88j) (379  
mg, 1.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
1/1) yielded 173ag (95.9 mg, 55%) as a white solid. M.p.: 126–127 °C. 1H-NMR (400 
MHz, CDCl3) δ = 8.63 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.41 (dd, J = 7.8, 1.9 Hz, 1H), 7.32–
7.20 (m, 4H), 7.15–7.06 (m, 2H), 6.86 (dd, J = 7.8, 1.1 Hz, 1H), 6.35 (dd, J = 9.0, 1.1 Hz, 
1H), 6.02 (dd, J = 6.9, 1.1 Hz, 1H), 2.02 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 162.1 
(Cq), 152.0 (Cq), 151.6 (Cq), 149.8 (Cq), 149.5 (CH), 138.9 (CH), 135.8 (CH), 134.8 (Cq), 
133.6 (Cq), 131.8 (Cq), 130.2 (CH), 129.2 (CH), 128.8 (CH), 127.6 (CH), 125.6 (CH), 122.8 
(CH), 119.2 (CH), 99.9 (CH), 75.2 (Cq), 21.0 (CH3). IR (ATR): 1711, 1651, 1582, 1529, 
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1461, 1432, 1347, 1178, 1155, 793 cm-1. MS (ESI) m/z (relative intensity): 719 (15) 
[2M+Na]+, 371 (12) [M+Na]+, 349 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H18N2OCl 




(173ak): The general procedure A was followed using 2H-[1,2'-bipyridin]-2-one (172a) 
(86.1 mg, 0.50 mmol) and methyl (2-methyl-4-(4-(trifluoromethyl)phenyl)but-3-yn-2-
yl) carbonate (88k) (430 mg, 1.50 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 1/1) yielded 173ak (105 mg, 55%) as a white solid. M.p.: 
138–139 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.7 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.65–7.59 
(m, 2H), 7.47 (dd, J = 7.8, 1.8 Hz, 1H), 7.41 (dd, J = 7.9, 0.8 Hz, 1H), 7.31 (dd, J = 9.1, 6.9 
Hz, 1H), 7.19 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.86 (dt, J = 7.8, 1.0 Hz, 1H), 6.41 (dd, J = 
9.1, 1.1 Hz, 1H), 6.05 (dd, J = 6.9, 1.1 Hz, 1H), 2.07 (s, 6H). 13C-NMR (100 MHz, CDCl3) 
δ = 162.2 (Cq), 152.2 (Cq), 152.0 (Cq), 149.7 (Cq), 149.6 (CH), 138.9 (CH), 136.0 (CH), 
135.7 (Cq), 131.9 (Cq), 130.7 (q, 2JC–F = 32.7 Hz, Cq), 129.8 (CH), 125.9 (q, 3JC–F = 3.8 Hz, 
CH), 125.5 (CH), 123.8 (q, 1JC–F = 272.2 Hz, Cq), 122.9 (CH), 119.4 (CH), 99.8 (CH), 75.3 
(Cq), 21.1 (CH3). 19F-NMR (376 MHz, CDCl3) δ = -62.74 (s). IR (ATR): 1655, 1584, 1531, 
1463, 1321, 1164, 1123, 1068, 1018 cm-1. MS (ESI) m/z (relative intensity): 787 (45) 
[2M+Na]+, 383 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H17N2OF3 [M+H]+ 383.1366, 
found 383.1367. 
5.3.2 Mechanistic Studies  







4-Methyl-2H-[1,2'-bipyridin]-2-one (172g) (93.1 mg, 0.50 mmol), 4-(trifluoromethyl)-
2H-[1,2'-bipyridin]-2-one (172f) (120 mg, 0.50 mmol), methyl (2-methyl-4-phenylbut-
3-yn-2-yl)carbonate (88a) (328 mg, 1.50 mmol), Cp*Co(CO)I2 (24.0 mg, 10 mol %), 
AgSbF6 (34.4 mg, 20 mol %), HOAc (15.0 mg, 50 mol %), and TFE (2.0 mL) were placed 
in a 25 mL Schlenk pressure tube under N2 atmosphere, and stirred at 90 °C for 10 h. 
After cooling to ambient temperature, the mixture was transferred into a round 
bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 6/1 → 1/1) afforded 173ga (42.7 mg, 
26%) and trace of 173fa. 
 
 
5'-Methyl-2H-[1,2'-bipyridin]-2-one (172i) (93.1 mg, 0.50 mmol), 5'-(trifluoromethyl)-
2H-[1,2'-bipyridin]-2-one (172k) (103 mg, 0.50 mmol), methyl (2-methyl-4-phenylbut-
3-yn-2-yl)carbonate (88a) (328 mg, 1.50 mmol), Cp*Co(CO)I2 (24.0 mg, 10 mol %), 
AgSbF6 (34.4 mg, 20 mol %), HOAc (15.0 mg, 50 mol %), and TFE (2.0 mL) were placed 
in a 25 mL Schlenk pressure tube under N2 atmosphere, and stirred at 90 °C for 10 h. 
After cooling to ambient temperature, the mixture was transferred into a round 
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bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 6/1 → 1/1) afforded 173ia (60.8 mg, 
37%) and 173ka (22.9 mg, 12%). 
 
 
2H-[1,2'-Bipyridin]-2-one (172a) (86.1 mg, 0.50 mmol), methyl (2-methyl-4-(p-
tolyl)but-3-yn-2-yl) carbonate (88i), methyl (2-methyl-4-(4-
(trifluoromethyl)phenyl)but-3-yn-2-yl) carbonate (88k) (430 mg, 1.50 mmol), 
Cp*Co(CO)I2 (24.0 mg, 10 mol %), AgSbF6 (34.4 mg, 20 mol %), HOAc (15.0 mg, 50 
mol %), and TFE (2.0 mL) were placed in a 25 mL Schlenk pressure tube under N2 
atmosphere, and stirred at 90 °C for 10 h. After cooling to ambient temperature, the 
mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and 
concentrated in vacuo. Purification by column chromatography on silica gel (n-
hexane/EtOAc: 6/1 → 1/1) afforded 173ai (49.3 mg, 30%) and 173ak (19.1 mg, 10%). 
H/D Exchange Experiments 
 
 
2H-[1,2'-Bipyridin]-2-one (172a) (86.1 mg, 0.50 mmol), methyl (2-methyl-4-phenylbut-
3-yn-2-yl)carbonate (88a) (328 mg, 1.50 mmol), Cp*Co(CO)I2 (24.0 mg, 10 mol %), 
AgSbF6 (34.4 mg, 20 mol %), CD3CO2D (16.0 mg, 50 mol %), and D3-TFE (2.0 mL) were 
placed in a 25 mL Schlenk pressure tube under N2 atmosphere, and stirred at 90 °C for 





bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3/1 → 1/1) afforded afforded [D]1-172a 




Kinetic Isotope Effect Study 
 
 
Five independent reactions of 172a or [D]1-172a with 88a were performed to 
determine the KIE. 172a (86.2 mg, 0.50 mmol) or [D]1-172a (86.6 mg, 0.50 mmol), 88a 





HOAc (15.0 mg, 50 mol %), and TFE (2.0 mL) were placed in a 25 mL Schlenk pressure 
tube under N2 atmosphere, and stirred at 90 °C. After cooling to ambient temperature, 
the mixture was transferred into a round bottom flask with CH2Cl2 (20 mL) and 
concentrated in vacuo. Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 1/1) yielded 173aa or [D]n-173aa. 
 
t (min) 60  80  100 120  140  
173aa (%) 3 10 15 20 25 







173aa (57.4 mg, 0.2 mmol) and I2 (50.8 mg, 0.2 mmol) were dissolved in THF (1.0 mL). 
y = 0,27x - 12,4
R² = 0,9945
























The resulting solution was stirred for 24 h at 23 °C. The mixture was transferred into a 
round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 1/1) afforded the desired 
product 174 (51.1 mg, 58%). 
 
6-Iodo-3,3-dimethyl-1-phenyl-2-(pyridin-2-yl)indolizin-5(3H)-one (174): White solid. 
M.p.: 212–213 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.64 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 
7.93 (d, J = 7.5 Hz, 1H), 7.43 – 7.33 (m, 4H), 7.27–7.21 (m, 2H), 7.13 (ddd, J = 7.5, 4.8, 
1.0 Hz, 1H), 6.87 (dd, J = 7.9, 1.0 Hz, 1H), 5.88 (d, J = 7.5 Hz, 1H), 2.06 (s, 6H). 13C-NMR 
(100 MHz, CDCl3) δ = 158.7 (Cq), 152.2 (Cq), 151.4 (Cq), 150.8 (Cq), 149.4 (CH), 147.9 
(CH), 135.7 (CH), 133.0 (Cq), 131.5 (Cq), 129.3 (CH), 129.1 (CH), 128.8 (CH), 125.8 (CH), 
122.7 (CH), 101.3 (CH), 91.4 (Cq), 76.5 (Cq), 21.1 (CH3). IR (ATR): 1645, 1591, 1510, 1462, 
1337, 1076, 1053, 791, 701 cm-1. MS (ESI) m/z (relative intensity): 903 (5) [2M+Na]+, 
463 (10) [M+Na]+, 441 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H18N2OI [M+H]+ 
441.0458, found 441.0462. 
 
 
173na (78.7 mg, 0.20 mmol), 2-methylbut-3-yn-2-ol (33.6 mg, 0.40 mmol), [Pd(PPh3) 
Cl2] (14.0 mg, 10 mol %), CuI (3.8 mg, 10 mol %), and Et3N (0.4 mL) DMF (0.8 mL) were 
placed in a 25 mL Schlenk pressure tube under N2 atmosphere, and stirred at 50 °C for 
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24 h. After cooling to ambient temperature, the mixture was transferred into a round 
bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3/1 → 1/1) afforded 175 (71.4 mg, 
90%). as a white solid. M.p.: 162–163 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.63 (ddd, J = 
4.8, 1.9, 1.0 Hz, 1H), 7.48 (d, J = 7.4 Hz, 1H), 7.42–7.32 (m, 4H), 7.27–7.19 (m, 2H), 7.12 
(ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 6.86 (dd, J = 8.0, 1.1 Hz, 1H), 6.07 (d, J = 7.4 Hz, 1H), 2.06 
(s, 6H), 1.61 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 161.2 (Cq), 152.2 (Cq), 151.8 (Cq), 
150.3 (Cq), 149.3 (CH), 142.2 (CH), 135.7 (CH), 133.1 (Cq), 131.5 (Cq), 129.3 (CH), 129.0 
(CH), 128.8 (CH), 125.7 (CH), 122.7 (CH), 113.3 (Cq), 100.1 (CH), 99.8 (Cq), 78.3 (Cq), 
75.9 (Cq), 65.4 (Cq), 31.4 (CH3), 21.2 (CH3). IR (ATR): 2979, 1637, 1583, 1539, 1463, 1339, 
1270, 1166, 780, 702 cm-1. MS (ESI) m/z (relative intensity): 815 (12) [2M+Na]+, 419 
(100) [M+Na]+, 397 (65) [M+H]+. HR-MS (ESI) m/z calcd for C26H25N2O2 [M+H]+ 





5.4 Manganese(I)-Catalyzed C–H Activation Domino Alkyne Annulation 
by Transformable Pyridines 
5.4.1 Characterization Data  
 
1,1-Dimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180aa): The general procedure 
B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 0.25 mmol) and 
methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 0.38 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 
180aa (51.0 mg, 71%) as an orange solid. M.p.: 160–161 °C. 1H-NMR (400 MHz, CDCl3) 
δ = 7.98 (d, J = 6.5 Hz, 1H), 7.52–7.40 (m, 3H), 7.37–7.32 (m, 2H), 7.28 (dd, J = 9.0, 7.1 
Hz, 1H), 6.50–6.40 (m, 1H), 6.28 (dd, J = 9.5, 6.5 Hz, 1H), 5.95–5.72 (m, 2H), 1.21 (s, 
6H). 13C-NMR (100 MHz, CDCl3) δ = 161.5 (Cq), 148.3 (Cq), 142.7 (Cq), 142.5 (CH), 138.0 
(Cq), 137.4 (CH), 132.8 (Cq), 131.8 (Cq), 130.6 (CH), 128.3 (CH), 128.1 (CH), 119.9 (CH), 
115.8 (CH), 115.7 (CH), 99.6 (CH), 38.7 (Cq), 28.3 (CH3). IR (ATR): 3036, 2969, 2161, 
1653, 1585, 1218, 1151, 790, 702 cm-1. MS (ESI) m/z (relative intensity): 597 (25) 
[2M+Na]+, 310 (52) [M+Na]+, 288 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H18NO 
[M+H]+ 288.1383, found 288.1380. The compound 180aa was also unambiguously 
characterized by X-ray crystallographic diffraction analysis (vide infra). 
 
 
1,1,7-Trimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180ba): The general 
procedure B was followed using 3-methyl-2H-[1,2'-bipyridin]-2-one (172b) (46.6 mg, 
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0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180ba (51.2 mg, 68%) as an orange solid. M.p.: 188–189 °C. 1H-NMR 
(400 MHz, CDCl3) δ = 8.00 (d, J = 6.5 Hz, 1H), 7.46–7.34 (m, 3H), 7.35–7.26 (m, 2H), 
7.06 (dd, J = 9.1, 0.5 Hz, 1H), 6.39 (d, J = 9.1 Hz, 1H), 6.23 (dd, J = 9.4, 6.5 Hz, 1H), 5.77 
(d, J = 9.4 Hz, 1H), 1.50 (s, 3H), 1.12 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 161.2 (Cq), 
142.6 (Cq), 142.5 (Cq), 142.4 (CH), 142.2 (CH), 137.7 (Cq), 134.9 (Cq), 132.5 (Cq), 130.9 
(CH), 128.2 (CH), 127.8 (CH), 120.0 (CH), 115.6 (CH), 114.9 (CH), 110.7 (Cq), 38.6 (Cq), 
28.1 (CH3), 16.4 (CH3). IR (ATR): 3032, 2959, 2922, 1652, 1590, 1513, 802, 738 cm-1. 
MS (ESI) m/z (relative intensity): 625 (14) [2M+Na]+, 324 (10) [M+Na]+, 302 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C21H20NO [M+H]+ 302.1539, found 302.1539. 
 
 
1,1,9-Trimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180ca): The general 
procedure B was followed using 5-methyl-2H-[1,2'-bipyridin]-2-one (172c) (46.6 mg, 
0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180ca (40.0 mg, 53%) as an orange solid. M.p.: 225–226 °C. 1H-NMR (400 
MHz, CDCl3) δ = 8.02 (d, J = 6.5 Hz, 1H), 7.42 (dd, J = 4.9, 2.0 Hz, 3H), 7.36–7.30 (m, 2H), 
7.08 (d, J = 9.0 Hz, 1H), 6.40 (d, J = 9.0 Hz, 1H), 6.25 (dd, J = 9.4, 6.5 Hz, 1H), 5.79 (d, J 
= 9.4 Hz, 1H), 1.52 (s, 3H), 1.14 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 161.2 (Cq), 142.5 
(Cq), 142.4 (CH), 142.2 (Cq), 142.1 (CH), 137.7 (Cq), 134.9 (Cq), 132.5 (Cq), 130.9 (CH), 
128.2 (CH), 127.8 (CH), 120.0 (CH), 115.6 (CH), 114.9 (CH), 110.6 (Cq), 38.6 (Cq), 28.1 
(CH3), 16.4 (CH3). IR (ATR): 3031, 2960, 2923, 1652, 1590, 1513, 1020, 801 cm-1. MS 
(ESI) m/z (relative intensity): 625 (22) [2M+Na]+, 324 (52) [M+Na]+, 302 (100) [M+H]+. 






8-Chloro-1,1-dimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180da): The general 
procedure B was followed using 4-chloro-2H-[1,2'-bipyridin]-2-one (172d) (51.7 mg, 
0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180da (44.2 mg, 55%) as an orange solid. M.p.: 190–191 °C. 1H-NMR 
(300 MHz, CDCl3) δ = 7.96 (d, J = 6.6 Hz, 1H), 7.51–7.39 (m, 3H), 7.35–7.25 (m, 2H), 
6.45 (d, J = 1.9 Hz, 1H), 6.27 (dd, J = 9.5, 6.6 Hz, 1H), 5.94–5.78 (m, 2H), 1.19 (s, 6H). 
13C-NMR (125 MHz, CDCl3) δ = 159.9 (Cq), 148.1 (Cq), 145.1 (Cq), 144.5 (Cq), 143.4 (CH), 
137.4 (Cq), 131.9 (Cq), 131.2 (Cq), 130.5 (CH), 128.5 (CH), 128.2 (CH), 119.7 (CH), 116.9 
(CH), 113.9 (CH), 100.9 (CH), 39.0 (Cq), 28.1 (CH3). IR (ATR): 3142, 2963, 2926, 1653, 
1584, 1488, 1082, 753 cm-1. MS (ESI) m/z (relative intensity): 322 (100) [M+H]+ (35Cl). 
HR-MS (ESI) m/z calcd for C20H1735ClNO [M+H]+ 322.0993, found 322.0997. The 
compound 3da was also unambiguously characterized by X-ray crystallographic 
diffraction analysis (vide infra). 
 
 
8-Bromo-1,1-dimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180ea): The general 
procedure B was followed using 4-bromo-2H-[1,2'-bipyridin]-2-one (172e) (62.8 mg, 
0.25 mmol), methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 0.38 
mmol), and MnBr(CO)5 (13.8 mg, 20 mol %). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 10/1) yielded 180ea (58.6 mg, 64%) as an orange solid. 
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M. p. = 200–201 °C. 1H-NMR (300 MHz, CDCl3) δ = 7.96 (d, J = 6.5 Hz, 1H), 7.54–7.36 
(m, 3H), 7.36–7.26 (m, 2H), 6.65 (d, J = 1.8 Hz, 1H), 6.28 (dd, J = 9.5, 6.5 Hz, 1H), 6.04–
5.83 (m, 2H), 1.19 (s, 6H). 13C-NMR (125 MHz, CDCl3) δ = 159.7 (Cq), 147.9 (Cq), 144.4 
(Cq), 143.4 (CH), 137.4 (Cq), 133.8 (Cq), 131.9 (Cq), 131.1 (Cq), 130.5 (CH), 128.5 (CH), 
128.2 (CH), 119.8 (CH), 117.3 (CH), 117.0 (CH), 103.4 (CH), 39.0 (Cq), 28.1 (CH3). IR 
(ATR): 2988, 2927, 1751, 1581, 1488, 1264, 1128, 755 cm-1. MS (ESI) m/z (relative 
intensity): 755 (10) [2M+Na]+ (81Br), 388 (12) [M+Na]+ (79Br), 366 (100) [M+H]+ (79Br). 
HR-MS (ESI) m/z calcd for C20H1779BrNO [M+H]+ 366.0488, found 366.0489; calcd for 
C20H1781BrNO [M+H]+ 368.0468, found 368.0474. The compound 180ea was also 
unambiguously characterized by X-ray crystallographic diffraction analysis (vide infra). 
 
 
1,1,8-Trimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180fa): The general 
procedure B was followed using 4-methyl-2H-[1,2'-bipyridin]-2-one (172f) (46.6 mg, 
0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180fa (56.5 mg, 75%) as an orange solid. M.p.: 225–226 °C. 1H-NMR (400 
MHz, CDCl3) δ = 7.86 (d, J = 6.4 Hz, 1H), 7.51–7.39 (m, 3H), 7.36–7.28 (m, 2H), 6.30–
6.15 (m, 2H), 5.80 (d, J = 9.4 Hz, 1H), 5.65 (d, J = 1.3 Hz, 1H), 2.14 (s, 3H), 1.17 (s, 6H). 
13C-NMR (100 MHz, CDCl3) δ = 161.3 (Cq), 149.3 (Cq), 147.5 (Cq), 143.0 (Cq), 142.0 (CH), 
137.9 (Cq), 132.9 (Cq), 131.6 (Cq), 130.6 (CH), 128.2 (CH), 128.1 (CH), 119.9 (CH), 114.8 
(CH), 114.7 (CH), 101.9 (CH), 38.6 (Cq), 28.3 (CH3), 21.5 (CH3). IR (ATR): 3057, 2972, 
1661, 1592, 1513, 1394, 808 cm-1. MS (ESI) m/z (relative intensity): 625 (20) [2M+Na]+, 
324 (18) [M+Na]+, 302 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H20NO [M+H]+ 






1,1-Dimethyl-12-phenylindolo[1,2-b]isoquinolin-6(1H)-one (180ga): The general 
procedure B was followed using 2-(pyridin-2-yl)isoquinolin-1(2H)-one (172g) (55.6 mg, 
0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180ga (51.5 mg, 61%) as an orange solid. M.p.: 210–211 °C. 1H-NMR 
(400 MHz, CDCl3) δ = 8.51 (ddd, J = 8.1, 1.5, 0.7 Hz, 1H), 7.68 (dd, J = 6.5, 0.7 Hz, 1H), 
7.56 (ddd, J = 7.8, 7.2, 1.5 Hz, 1H), 7.51–7.46 (m, 3H), 7.44–7.37 (m, 4H), 6.24 (dd, J = 
9.5, 6.5 Hz, 1H), 6.07 (s, 1H), 5.76–5.59 (m, 1H), 1.21 (s, 6H). 13C-NMR (100 MHz, CDCl3) 
δ = 160.6 (Cq), 144.1 (Cq), 143.0 (Cq), 139.4 (CH), 138.2 (Cq), 136.3 (Cq), 133.1 (Cq), 132.3 
(Cq), 132.0 (CH), 130.7 (CH), 128.2 (CH), 128.1 (CH), 127.9 (CH), 126.4 (CH), 125.8 (CH), 
123.9 (Cq), 120.0 (CH), 111.0 (CH), 99.4 (CH), 38.4 (Cq), 28.8 (CH3). MS (ESI) m/z 
(relative intensity): 697 (20) [2M+Na]+, 338 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C24H20NO [M+H]+ 338.1539, found 338.1541. The compound 180ga was also 
unambiguously characterized by X-ray crystallographic diffraction analysis (vide infra). 
 
 
1,1,3-Trimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180ha): The general 
procedure B was followed using 4'-methyl-2H-[1,2'-bipyridin]-2-one (172h) (46.5 mg, 
0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180ha (46.7 mg, 63%) as an orange solid. M.p.: 210–211 °C. 1H-NMR 
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(400 MHz, CDCl3) δ = 7.90 (d, J = 1.0 Hz, 1H), 7.51–7.39 (m, 3H), 7.37–7.31 (m, 2H), 
7.28 (dd, J = 9.0, 7.0 Hz, 1H), 6.44 (dd, J = 9.0, 1.0 Hz, 1H), 5.85 (dd, J = 7.0, 1.0 Hz, 1H), 
5.62–5.50 (m, 1H), 2.02 (d, J = 1.6 Hz, 3H), 1.17 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 
161.5 (Cq), 148.6 (Cq), 142.8 (Cq), 138.2 (Cq), 137.7 (CH), 137.4 (CH), 132.8 (Cq), 131.3 
(Cq), 130.6 (CH), 128.2 (CH), 128.1 (CH), 127.6 (Cq), 119.6 (CH), 115.7 (CH), 99.6 (CH), 
38.2 (Cq), 28.5 (CH3), 21.6 (CH3). IR (ATR): 3046, 2973, 2917, 1653, 1584, 1515, 1156, 
701 cm-1. MS (ESI) m/z (relative intensity): 302 (100) [M+H]+. HR-MS (ESI) m/z calcd 
for C21H20NO [M+H]+ 302.1539, found 302.1540. 
 
 
1,1,2-Trimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180ia): The general 
procedure B was followed using 5'-methyl-2H-[1,2'-bipyridin]-2-one (172i) (46.5 mg, 
0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180ia (57.3 mg, 76%) as an orange solid. M. p. = 190–191 °C. 1H-NMR 
(400 MHz, CDCl3) δ = 7.90 (dd, J = 6.8, 1.0 Hz, 1H), 7.42 (dd, J = 5.0, 1.9 Hz, 3H), 7.34–
7.26 (m, 2H), 7.26–7.21 (m, 1H), 6.39 (dd, J = 9.0, 1.0 Hz, 1H), 6.12 (dd, J = 6.8, 1.5 Hz, 
1H), 5.77 (dd, J = 7.1, 1.0 Hz, 1H), 1.92 (s, 3H), 1.24 (s, 6H). 13C-NMR (100 MHz, CDCl3) 
δ = 161.3 (Cq), 149.3 (Cq), 148.4 (Cq), 144.2 (Cq), 137.1 (CH), 136.9 (Cq), 133.1 (Cq), 130.6 
(Cq), 130.5 (CH), 128.1 (CH), 128.0 (CH), 119.5 (CH), 116.8 (CH), 115.0 (CH), 99.1 (CH), 
41.5 (Cq), 27.2 (CH3), 18.7 (CH3). IR (ATR): 3037, 2972, 1651, 1583, 1514, 818, 707 cm-
1. MS (ESI) m/z (relative intensity): 625 (18) [2M+Na]+, 324 (16) [M+Na]+, 302 (100) 







The general procedure B was followed using 5'-(trifluoromethyl)-2H-[1,2'-bipyridin]-2-
one (172j) (60.1 mg, 0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-
yl)carbonate (88a) (83.0 mg, 0.38 mmol). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 10/1) yielded 180ja (49.8 mg, 56%) as an orange solid. M. 
p. = 195–196 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.87 (dd, J = 7.0, 1.4 Hz, 1H), 7.50–7.43 
(m, 3H), 7.36–7.30 (m, 2H), 7.27 (dd, J = 9.2, 2.2 Hz, 1H), 6.93 (dd, J = 7.0, 1.6 Hz, 1H), 
6.47 (dd, J = 9.2, 1.0 Hz, 1H), 5.81 (d, J = 7.0 Hz, 1H), 1.41 (q, J = 1.0 Hz, 6H). 13C-NMR 
(100 MHz, CDCl3) δ = 161.2 (Cq), 148.5 (Cq), 142.4 (Cq), 140.6 (Cq), 137.9 (CH), 135.4 (q, 
2JC-F = 26.5 Hz, Cq), 132.8 (Cq), 132.1 (Cq), 130.3 (CH), 128.6 (CH), 128.3 (CH), 126.2 (q, 
3JC-F = 7.7 Hz, CH), 124.4 (q, 1JC-F = 273.9 Hz, Cq), 117.6 (CH), 111.1 (CH), 101.2 (CH), 
39.8 (Cq), 27.6 (CH3). 19F NMR (375 MHz, CDCl3) δ = -58.89 (s). IR (ATR): 2995, 2940, 
1659, 1596, 1283, 1163, 1107, 998 cm-1. MS (ESI) m/z (relative intensity): 733 (65) 
[2M+Na]+, 378 (50) [M+Na]+, 356 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H17F3NO 
[M+H]+ 356.1257, found 356.1259. 
 
 
2-Chloro-1,1-dimethyl-10-phenylpyrido[1,2-a]indol-6(1H)-one (180ka): The general 
procedure B was followed using 5'-chloro-2H-[1,2'-bipyridin]-2-one (172k) (51.7 mg, 
0.25 mmol) and methyl (2-methyl-4-phenylbut-3-yn-2-yl)carbonate (88a) (83.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
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10/1) yielded 180ka (42.6 mg, 53%) as an orange solid. M. p. = 168–169 °C. 1H-NMR 
(400 MHz, CDCl3) δ = 7.83 (d, J = 7.2 Hz, 1H), 7.56–7.39 (m, 3H), 7.33–7.27 (m, 2H), 
7.25 (dd, J = 9.1, 2.0 Hz, 1H), 6.51–6.25 (m, 2H), 5.81 (dd, J = 7.0, 0.7 Hz, 1H), 1.36 (s, 
6H). 13C-NMR (100 MHz, CDCl3) δ = 161.2 (Cq), 148.3 (Cq), 145.6 (Cq), 142.5 (Cq), 137.5 
(CH), 137.3 (Cq), 132.4 (Cq), 132.3 (Cq), 130.5 (CH), 128.5 (CH), 128.3 (CH), 121.3 (CH), 
116.3 (CH), 114.5 (CH), 100.2 (CH), 43.5 (Cq), 27.5 (CH3). IR (ATR): 2969, 1684, 1584, 
1508, 1487, 1156, 837, 795 cm-1. MS (ESI) m/z (relative intensity): 665 (18) [2M+Na]+ 
(35Cl), 344 (30) [M+Na]+ (35Cl), 322 (100) [M+H]+ (35Cl). HR-MS (ESI) m/z calcd for 
C20H1735ClNO [M+H]+ 322.0993, found 322.0999. 
 
 
1,1-Dimethylpyrido[1,2-a]indol-6(1H)-one (180ab): The general procedure B was 
followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 0.25 mmol) and methyl (2-
methylbut-3-yn-2-yl)carbonate (88b) (54.0 mg, 0.38 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 180ab (31.7 mg, 60%) as 
an orange solid. M. p. = 120–121 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.83 (ddd, J = 6.5, 
1.8, 0.5 Hz, 1H), 7.35 (dd, J = 9.0, 7.0 Hz, 1H), 6.57 (d, J = 1.8 Hz, 1H), 6.43 (dd, J = 9.0, 
0.9 Hz, 1H), 6.37–6.25 (m, 2H), 6.01 (d, J = 9.5 Hz, 1H), 1.33 (s, 6H). 13C-NMR (100 MHz, 
CDCl3) δ = 161.7 (Cq), 149.1 (Cq), 146.5 (Cq), 141.2 (CH), 138.2 (Cq), 137.7 (CH), 120.7 
(CH), 115.9 (CH), 115.8 (CH), 115.5 (CH), 100.1 (CH), 37.4 (Cq), 29.9 (CH3). MS (ESI) m/z 
(relative intensity): 445 (22) [2M+Na]+, 234 (52) [M+Na]+, 212 (100) [M+H]+. HR-MS 







10-Butyl-1,1-dimethylpyrido[1,2-a]indol-6(1H)-one (180ac): The general procedure B 
was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 0.25 mmol) and methyl 
(2-methyloct-3-yn-2-yl)carbonate (88c) (75.4 mg, 0.38 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 180ac (46.8 mg, 70%) as 
an orange solid. M. p. = 142–143 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.83 (d, J = 6.5 Hz, 
1H), 7.36 (dd, J = 9.0, 7.1 Hz, 1H), 6.42 (dd, J = 9.0, 0.9 Hz, 1H), 6.30 (dd, J = 7.1, 0.9 Hz, 
1H), 6.21 (dd, J = 9.5, 6.5 Hz, 1H), 5.83 (dd, J = 9.5, 0.5 Hz, 1H), 2.84–2.64 (m, 2H), 1.64–
1.55 (m, 2H), 1.53–1.43 (m, 2H), 1.40 (s, 6H), 0.98 (t, J = 7.3 Hz, 3H). 13C-NMR (100 
MHz, CDCl3) δ = 161.6 (Cq), 147.3 (Cq), 141.5 (CH), 140.7 (Cq), 138.2 (Cq), 137.2 (CH), 
131.4 (Cq), 119.9 (CH), 115.7 (CH), 114.4 (CH), 98.1 (CH), 37.9 (Cq), 32.9 (CH2), 27.7 
(CH3), 25.6 (CH2), 23.3 (CH2), 13.8 (CH3). IR (ATR): 2959, 2928, 2869, 1750, 1652, 1578, 
1261, 792 cm-1. MS (ESI) m/z (relative intensity): 557 (10) [2M+Na]+, 290 (20) [M+Na]+, 




10-(4-Methoxyphenyl)-1,1-dimethylpyrido[1,2-a]indol-6(1H)-one (180ad): The 
general procedure B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 
0.25 mmol) and 4-(4-methoxyphenyl)-2-methylbut-3-yn-2-yl methyl carbonate (88d) 
(94.4 mg, 0.38 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 10/1) yielded 180ad (57.1 mg, 72%) as an orange solid. M. p. = 192–
193 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.93 (dd, J = 6.5, 0.5 Hz, 1H), 7.36–7.23 (m, 1H), 
7.22 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.41 (dd, J = 9.0, 0.9 Hz, 1H), 6.25 (dd, 
J = 9.5, 6.5 Hz, 1H), 5.91–5.77 (m, 2H), 3.85 (s, 3H), 1.19 (s, 6H). 13C-NMR (100 MHz, 
CDCl3) δ = 161.5 (Cq), 159.5 (Cq), 148.5 (Cq), 142.8 (Cq), 142.4 (CH), 138.0 (Cq), 137.4 
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(CH), 131.7 (CH), 131.6 (Cq), 124.6 (Cq), 119.9 (CH), 115.7 (CH), 115.5 (CH), 113.5 (CH), 
99.5 (CH), 55.3 (CH3), 38.6 (Cq), 28.3 (CH3). IR (ATR): 3034, 2962, 1657, 1547, 1502, 
1284, 1245, 791 cm-1. MS (ESI) m/z (relative intensity): 657 (20) [2M+Na]+, 340 (25) 




1,1-Dimethyl-10-(naphthalen-2-yl)pyrido[1,2-a]indol-6(1H)-one (180ae): The general 
procedure B was followed using 2H-[1,2'-bipyridin]-2-one (148a) (43.1 mg, 0.25 mmol) 
and methyl [2-methyl-4-(naphthalen-2-yl)but-3-yn-2-yl]carbonate (88e) (102.0 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180ae (62.4 mg, 74%) as an orange solid. M. p. = 204–205 °C. 1H-NMR 
(300 MHz, CDCl3) δ = 8.02 (dd, J = 6.5, 0.5 Hz, 1H), 7.97–7.78 (m, 4H), 7.64–7.51 (m, 
2H), 7.44 (dd, J = 8.4, 1.7 Hz, 1H), 7.27 (dd, J = 9.0, 7.0 Hz, 1H), 6.46 (ddd, J = 9.0, 1.0, 
0.5 Hz, 1H), 6.30 (dd, J = 9.5, 6.5 Hz, 1H), 5.92–5.80 (m, 2H), 1.44–0.93 (m, 6H). 13C-
NMR (125 MHz, CDCl3) δ = 161.3 (Cq), 148.2 (Cq), 143.0 (Cq), 142.4 (CH), 138.0 (Cq), 
137.3 (CH), 132.8 (Cq), 132.6 (Cq), 131.6 (Cq), 130.1 (Cq), 129.7 (CH), 128.2 (CH), 127.9 
(CH), 127.7 (CH), 127.6 (CH), 126.6 (CH), 126.5 (CH), 119.9 (CH), 115.8 (CH), 115.7 (CH), 
99.6 (CH), 38.8 (Cq), 28.8 (CH3), 28.1 (CH3). IR (ATR): 3066, 2965, 2925, 1655, 1585, 
1514, 1151, 798, 752 cm-1. MS (ESI) m/z (relative intensity): 697 (12) [2M+Na]+, 360 








10'-Phenyl-6'H-spiro[cyclopentane-1,1'-pyrido[1,2-a]indol]-6'-one (180af): The 
general procedure B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 
0.25 mmol) and methyl [1-(phenylethynyl)cyclopentyl]carbonate (88f) (92.8 mg, 0.38 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) 
yielded 180af (45.4 mg, 58%) as an orange solid. M. p. = 175–176 °C. 1H-NMR (400 
MHz, CDCl3) δ = 7.98 (d, J = 6.5 Hz, 1H), 7.48–7.37 (m, 3H), 7.35–7.28 (m, 2H), 7.28–
7.20 (m, 1H), 6.40 (dd, J = 9.0, 1.0 Hz, 1H), 6.22 (dd, J = 9.5, 6.5 Hz, 1H), 6.06 (dd, J = 
9.5, 0.9 Hz, 1H), 5.80 (dd, J = 7.0, 0.9 Hz, 1H), 2.04–1.90 (m, 2H), 1.85–1.73 (m, 2H), 
1.70–1.58 (m, 2H), 1.42–1.28 (m, 2H). 13C-NMR (100 MHz, CDCl3) δ = 161.4 (Cq), 148.4 
(Cq), 143.2 (Cq), 141.2 (CH), 138.5 (Cq), 137.3 (CH), 132.7 (Cq), 130.9 (Cq), 130.61 (CH), 
128.3 (CH), 128.2 (CH), 118.2 (CH), 115.9 (CH) 115.6 (CH), 99.4 (CH), 48.6 (Cq), 42.0 
(CH2), 26.0 (CH2). IR (ATR): 3037, 2953, 2870, 1655, 1583, 1513, 1282, 791 cm-1. MS 
(ESI) m/z (relative intensity): 649 (15) [2M+Na]+, 336 (11) [M+Na]+, 314 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C22H20NO [M+H]+ 314.1539, found 314.1545. The compound 
180af was also unambiguously characterized by X-ray crystallographic diffraction 
analysis (vide infra). 
 
 
10'-Phenyl-6'H-spiro{cyclohexane-1,1'-pyrido[1,2-a]indol}-6'-one (180ag): The 
general procedure B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 
0.25 mmol) and methyl [1-(phenylethynyl)cyclohexyl]carbonate (88g) (98.2 mg, 0.38 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) 
yielded 180ag (53.2 mg, 65%) as an orange solid. M. p. = 230–231 °C. 1H-NMR (400 
MHz, CDCl3) δ = 7.96 (d, J = 6.4 Hz, 1H), 7.48–7.37 (m, 3H), 7.34–7.27 (m, 2H), 7.27–
7.19 (m, 1H), 6.61 (d, J = 9.7 Hz, 1H), 6.44–6.30 (m, 2H), 5.75 (dd, J = 7.0, 0.9 Hz, 1H), 
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1.76 (td, J = 13.6, 4.7 Hz, 2H), 1.68–1.36 (m, 7H), 0.98–0.75 (m, 1H). 13C-NMR (100 
MHz, CDCl3) δ = 161.4 (Cq), 148.6 (Cq), 143.5 (Cq), 138.6 (Cq), 137.7 (CH), 137.4 (CH), 
133.1 (Cq), 131.5 (Cq), 130.7 (CH), 128.2 (CH), 128.0 (CH), 120.9 (CH), 115.6 (CH), 115.3 
(CH), 99.5 (CH), 42.6 (Cq), 37.0 (CH2), 25.5 (CH2), 21.6 (CH2). IR (ATR): 2935, 2856, 1650, 
1581, 1510, 1140, 792, 699 cm-1. MS (ESI) m/z (relative intensity): 677 (32) [2M+Na]+, 
350 (10) [M+Na]+, 328 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H22NO [M+H]+ 
328.1696, found 328.1690. 
 
 
10'-Phenyl-6'H-spiro{cycloheptane-1,1'-pyrido[1,2-a]indol}-6'-one (180ah): The 
general procedure B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 
0.25 mmol) and methyl [1-(phenylethynyl)cycloheptyl]carbonate (88h) (103.5 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180ah (52.9 mg, 62%) as an orange solid. M. p. = 210–211 °C. 1H-NMR 
(400 MHz, CDCl3) δ = 7.94 (d, J = 6.4 Hz, 1H), 7.51–7.37 (m, 3H), 7.36–7.30 (m, 2H), 
7.29–7.20 (m, 1H), 6.51–6.10 (m, 3H), 5.77 (dd, J = 7.0, 0.9 Hz, 1H), 1.91 (ddd, J = 14.0, 
11.0, 2.5 Hz, 2H), 1.72–1.59 (m, 2H), 1.56–1.43 (m, 4H), 1.41–1.17 (m, 4H). 13C-NMR 
(100 MHz, CDCl3) δ = 161.4 (Cq), 148.6 (Cq), 145.0 (Cq), 140.3 (CH), 138.0 (Cq), 137.4 
(CH), 133.2 (Cq), 131.4 (Cq), 130.8 (CH), 128.2 (CH), 128.1 (CH), 120.4 (CH), 115.7 (CH), 
115.3 (CH), 99.6 (CH), 45.7 (Cq), 40.5 (CH2), 28.6 (CH2), 23.9 (CH2). IR (ATR): 3037, 2916, 
2847, 1658, 1584, 1511, 1159, 701 cm-1. MS (ESI) m/z (relative intensity): 705 (20) 
[2M+Na]+, 364 (13) [M+Na]+, 342 (100) [M+H]+. HR-MS (ESI) m/z calcd for C24H24NO 







10'-Phenyl-6'H-spiro{cyclohexane-1,1'-pyrido[1,2-a]indol}-2-en-6'-one (180ai): The 
general procedure B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 
0.25 mmol) and methyl [1-(phenylethynyl)cyclohex-2-en-1-yl]carbonate (88i) (97.4 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180ai (40.7 mg, 50%) as an orange solid. M. p. = 205–206 °C. 1H-NMR 
(400 MHz, CDCl3) δ = 7.94 (d, J = 6.5 Hz, 1H), 7.36–7.37 (m, 4H), 7.29 (dd, J = 9.0, 7.0 
Hz, 1H), 6.44 (d, J = 9.0 Hz, 1H), 6.26 (dd, J = 9.5, 6.5 Hz, 1H), 6.09 (d, J = 9.5 Hz, 1H), 
5.99 (d, J = 7.0 Hz, 1H), 5.77–5.60 (m, 1H), 5.36–5.33 (m, 1H), 1.97–1.86 (m, 1H), 1.84–
1.73 (m, 1H), 1.72–1.63 (m, 1H), 1.63–1.54 (m, 2H), 1.57–1.47 (m, 2H). 13C-NMR (100 
MHz, CDCl3) δ = 147.9 (Cq), 141.6 (Cq), 138.3 (Cq), 138.2 (CH), 137.4 (CH), 133.0 (Cq), 
132.5 (Cq), 132.3 (Cq), 130.5 (CH), 129.4 (CH), 128.1 (CH), 128.0 (CH), 127.8 (CH), 119.9 
(CH), 115.9 (CH), 115.4 (CH), 99.8 (CH), 42.7 (Cq), 33.4 (CH2), 24.0 (CH2), 18.4 (CH2). IR 
(ATR): 3017, 2928, 1657, 1585, 1515, 1442, 821, 702 cm-1. MS (ESI) m/z (relative 




1,1-Dimethyl-10-(thiophen-2-yl)pyrido[1,2-a]indol-6(1H)-one (180aj): The general 
procedure B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 0.25 mmol) 
and methyl [2-methyl-4-(thiophen-2-yl)but-3-yn-2-yl] carbonate (88j) (85.2 mg, 0.38 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) 
yielded 180aj (44.7 mg, 61%) as an orange solid. M. p. = 174–175 °C. 1H-NMR (400 
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MHz, CDCl3) δ = 7.94 (dd, J = 6.5, 0.5 Hz, 1H), 7.42 (dd, J = 4.9, 2.9 Hz, 1H), 7.32–7.26 
(m, 2H), 7.08 (dd, J = 4.9, 1.3 Hz, 1H), 6.42 (dd, J = 9.0, 1.0 Hz, 1H), 6.26 (dd, J = 9.4, 6.5 
Hz, 1H), 5.94 (ddd, J = 7.1, 1.0, 0.5 Hz, 1H), 5.86 (dd, J = 9.4, 0.5 Hz, 1H), 1.22 (s, 6H). 
13C-NMR (100 MHz, CDCl3) δ = 161.4 (Cq), 148.0 (Cq), 143.7 (Cq), 142.5 (CH), 138.0 (Cq), 
137.5 (CH), 132.2 (Cq), 129.9 (CH), 126.7 (Cq), 125.8 (CH), 125.6 (CH), 119.9 (CH), 115.9 
(CH), 115.8 (CH), 99.4 (CH), 38.6 (Cq), 28.1 (CH3). IR (ATR): 3022,, 1653, 1632, 1541, 
1438, 1309, 1048, 802 cm-1. MS (ESI) m/z (relative intensity): 609 (14) [2M+Na]+, 316 
(27) [M+Na]+, 294 (100) [M+H]+. HR-MS (ESI) m/z calcd for C18H16NOS [M+H]+ 
294.0947, found 294.0955. The compound 180aj was also unambiguously 
characterized by X-ray crystallographic diffraction analysis (vide infra). 
 
1,1-Dimethyl-10-(1-methyl-1H-indol-3-yl)pyrido[1,2-a]indol-6(1H)-one (180ak): The 
general procedure B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 
0.25 mmol) and methyl [2-methyl-4-(1-methyl-1H-indol-3-yl)but-3-yn-2-yl] carbonate 
(88k) (103.1 mg, 0.38 mmol). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 10/1) yielded 180ak (51.1 mg, 60%) as an orange solid. 1H-NMR (300 
MHz, CDCl3) δ = 8.01 (d, J = 6.4 Hz, 1H), 7.51–7.28 (m, 4H), 7.19–7.07 (m, 2H), 6.45 (d, 
J = 9.0 Hz, 1H), 6.33 (dd, J = 9.5, 5.8 Hz, 1H), 5.95–5.82 (m, 2H), 3.93 (s, 3H), 1.43 (s, 
3H), 1.11 (s, 3H). 13C-NMR (125 MHz, CDCl3) δ = 148.4 (Cq), 144.7 (Cq), 142.5 (CH), 138.3 
(Cq), 137.8 (Cq), 137.4 (CH), 136.5 (Cq), 129.2 (CH), 128.9 (Cq), 124.6 (Cq), 122.1 (CH), 
120.1 (CH), 119.8 (CH), 119.7 (CH), 115.7 (CH), 115.4 (CH), 109.3 (CH), 105.9 (Cq), 99.7 
(CH), 38.7 (Cq), 33.1 (CH3), 29.9 (CH3), 26.7 (CH3). IR (ATR): 2963, 2925, 1653, 1584, 
1511, 1243, 1134, 741 cm-1. MS (ESI) m/z (relative intensity): 363 (10) [M+Na]+, 341 






10'-Phenyl-6'H-spiro{cyclopropane-1,1'-pyrido[1,2-a]indol}-6'-one (180al): The 
general procedure B was followed using 2H-[1,2'-bipyridin]-2-one (172a) (43.1 mg, 
0.25 mmol) and 4-cyclopropyl-2-methylbut-3-yn-2-yl methyl carbonate (88l) (69.2 mg, 
0.38 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded 180al (38.3 mg, 61%) as an orange oil. 1H-NMR (400 MHz, CDCl3) δ = 7.85 
(d, J = 6.6 Hz, 1H), 7.32 (dd, J = 9.0, 7.2 Hz, 1H), 6.47 (d, J = 7.2 Hz, 1H), 6.39 (dd, J = 
9.0, 0.9 Hz, 1H), 6.18 (dd, J = 9.5, 6.6 Hz, 1H), 5.85 (d, J = 9.5 Hz, 1H), 1.95–1.83 (m, 
1H), 1.50 (s, 6H), 1.10–1.01 (m, 2H), 0.98–0.89 (m, 2H). 13C-NMR (100 MHz, CDCl3) δ = 
161.7 (Cq), 146.8 (Cq), 144.1 (Cq), 142.4 (CH), 138.0 (Cq), 137.2 (CH), 130.8 (Cq), 119.8 
(CH), 115.6 (CH), 114.4 (CH), 99.5 (CH), 38.5 (Cq), 26.7 (CH3), 7.5 (CH), 7.4 (CH2). IR 
(ATR): 2967, 2928, 1711, 1655, 1516, 1361, 803 cm-1. MS (ESI) m/z (relative intensity): 
525 (30) [2M+Na]+, 274 (20) [M+Na]+, 252 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C17H18NO [M+H]+ 252.1383, found 252.1388. 
 
5.4.2 Mechanistic Studies  
H/D Exchange Experiments 
 
172a (43.1 mg, 0.25 mmol), MnBr(CO)5 (6.9 mg, 10 mol %), NaOAc (10 mg, 50 mol %), 
BPh3 (60 mg, 1.0 equiv), DME (0.9 mL) and CD3OD (0.1 mL) were placed in a 25 mL 
Schlenk pressure tube under N2 atmosphere and stirred at 100 °C for 24 h. After 
cooling to ambient temperature, the mixture was transferred into a round bottom flask 
134 
 
with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) afforded [D]n-172a (40.9 mg, 




172a (43.1 mg, 0.25 mmol), 88a (83.0 mg, 0.38 mmol), MnBr(CO)5 (6.9 mg, 10 mol %), 
NaOAc (10 mg, 50 mol %) and BPh3 (60 mg, 1.0 equiv) in DME (0.9 mL) and CD3OD (0.1 
mL) were placed in a 25 mL Schlenk pressure tube under N2 and stirred at 100 °C for 3 
h. After cooling to ambient temperature, the mixture was transferred into a round 
bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded [D]n-180aa (14.4 mg, 














Kinetic Isotope Effect Study 
 
Five independent reactions of 172a or [D]1-172a with 88a were performed to 
determine the KIE. 172a (43.1 mg, 0.25 mmol) or [D]1-172a (43.3 mg, 0.25 mmol), 88a 
(83.0 mg, 0.38 mmol), MnBr(CO)5 (6.9 mg, 10 mol %), NaOAc (10 mg, 50 mol %), BPh3 
(60 mg, 1.0 equiv), and DME (1.0 mL) were placed in a 25 mL Schlenk pressure tube 
under N2 and stirred at 100 °C. After cooling to ambient temperature, the mixture was 
transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 
180aa or [D]n-180aa. 
t (min) 10  20  40 60  80  
180aa (%) 5 13 27 43 55 




y = 0,7207x - 1,6707
R² = 0,998
























180aa (57.4 mg, 0.2 mmol) or 180ac (53.5 mg, 0.2 mmol), Pd/C (20 mg, 10 mol %, 10 
wt. % of palladium on activated carbon) were dissolved in MeOH (2.0 mL) and refilled 
with H2 (1 atm). The resulting solution was stirred for 4 h at 23 °C. The mixture was 
transferred into a round bottom flask with CH2Cl2 (20 mL) and concentrated in vacuo. 
Purification by column chromatography on silica gel (n-hexane/EtOAc: 1/1) afforded 
the desired products 181a (43.7 mg, 75%) and 181b (36.9 mg, 68%), respectively. 
 
 
1,1-Dimethyl-10-phenyl-2,3,4,4a-tetrahydropyrido[1,2-a]indol-6(1H)-one (181a):  
Colourless oil. 1H-NMR (400 MHz, CDCl3) δ = 7.41–7.34 (m, 3H), 7.31–7.23 (m, 2H), 
7.23–7.17 (m, 1H), 6.30 (dd, J = 9.1, 1.0 Hz, 1H), 5.64 (dd, J = 7.0, 1.0 Hz, 1H), 4.96 (dd, 
J = 11.6, 5.3 Hz, 1H), 3.51–3.46 (m, 1H), 1.88–1.69 (m, 2H), 1.62–1.57 (m, 1H), 1.35 (td, 
J = 13.3, 4.6 Hz, 1H), 1.25 (s, 3H), 1.13–0.96 (m, 1H), 0.83 (s, 3H). 13C-NMR (100 MHz, 
CDCl3) δ = 162.0 (Cq), 154.9 (Cq), 153.9 (Cq), 139.8 (CH), 133.4 (Cq), 130.5 (CH), 129.6 
(CH), 128.6 (Cq), 128.1 (CH), 115.4 (CH), 98.9 (CH), 65.5 (CH), 42.4 (CH2), 37.1 (Cq), 31.4 
(CH2), 30.2 (CH3), 28.3 (CH3), 20.1 (CH2). IR (ATR): 2963, 2932, 2866, 1712, 1650, 1579, 
1358, 792 cm-1. MS (ESI) m/z (relative intensity): 605 (34) [2M+Na]+, 314 (17) [M+Na]+, 







Colourless oil. 1H-NMR (400 MHz, CDCl3) δ = 7.37 (dd, J = 9.0, 7.0 Hz, 1H), 6.29 (dd, J = 
9.0, 1.0 Hz, 1H), 6.13 (dd, J = 7.0, 1.0 Hz, 1H), 4.77 (dd, J = 11.6, 5.2 Hz, 1H), 3.52–3.22 
(m, 1H), 2.65–2.38 (m, 2H), 1.92–1.63 (m, 2H), 1.65–1.55 (m, 2H), 1.52–1.30 (m, 7H), 
1.21 (s, 3H), 0.93 (t, J = 7.0 Hz, 3H), 0.88–0.77 (m, 1H). 13C-NMR (100 MHz, CDCl3) δ = 
162.2 (Cq), 153.6 (Cq), 152.5 (Cq), 139.8 (CH), 126.9 (Cq), 115.0 (CH), 97.1 (CH), 65.3 
(CH), 42.4 (CH2), 37.5 (Cq), 32.7 (CH2), 31.2 (CH2), 29.3 (CH3), 28.2 (CH3), 24.6 (CH2), 
23.0 (CH2), 20.1 (CH2), 13.9 (CH3). IR (ATR): 2955, 2928, 2868, 1652, 1578, 1530, 1456, 
1164 cm-1. MS (ESI) m/z (relative intensity): 565 (48) [2M+Na]+, 294 (32) [M+Na]+, 272 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C18H26NO [M+H]+ 272.2009, found 272.2008. 
 
Catalytic and Stoichiometric Reactions with Cyclometalated Complex 182 
 
MnBr(CO)5 (274 mg, 1.0 mmol), 2H-[1,2'-bipyridin]-2-one 172a (174 mg, 1.0 mmol), 
dicyclohexylamine (362 mg, 2.0 mmol) and 1,4-dioxane (2.0 mL) were placed in a 25 
mL Schlenk tube under N2 and then stirred at 100 ºC for 14 h. At ambient temperature, 
the mixture was diluted with EtOAc (20 mL) and filtered through a short pad of celite. 
The solvent was removed and the residue was purified by column chromatography on 







M. p. = 120─122 °C. 1H-NMR (400 MHz, CDCl3) δ = 9.54 (d, J = 9.0 Hz, 1H), 8.54 (d, J = 
3.9 Hz, 1H), 7.91 (dd, J = 7.2, 7.2 Hz, 1H), 7.19–7.06 (m, 2H), 6.69 (d, J = 6.6 Hz, 1H), 
6.29 (d, J = 9.0 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ = 217.4 (Cq), 212.6 (Cq), 210.2 (Cq), 
183.6 (Cq), 167.6 (Cq), 160.4 (Cq), 152.5 (CH), 140.2 (CH), 138.1 (CH), 122.1 (CH), 120.4 
(CH), 119.7 (CH), 115.9 (CH). MS (ESI) m/z (relative intensity): 361 (76) [M+Na]+, 339 




172a (43.1 mg, 0.25 mmol), 88a (83.0 mg, 0.38 mmol), 182 (8.5 mg, 10 mol %), NaOAc 
(10 mg, 50 mol %), BPh3 (60 mg, 1.0 equiv) and DME (1.0 mL) were placed in a 25 mL 
Schlenk pressure tube under N2 atomosphere and stirred at 100 °C for 24 h. After 
cooling to ambient temperature, the mixture was transferred into a round bottom flask 
with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 180aa (53.8 mg, 75%). 
 
 
182 (84.6 mg, 0.25 mmol), 88a (83.0 mg, 0.38 mmol), NaOAc (10 mg, 50 mol %), BPh3 
140 
 
(60 mg, 1.0 equiv) and DME (1.0 mL) were placed in a 25 mL Schlenk pressure tube 
under N2 atomosphere and stirred at 100 °C for 24 h. After cooling to ambient 
temperature, the mixture was transferred into a round bottom flask with CH2Cl2 (20 
mL) and concentrated in vacuo. Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 10/1) yielded 180aa (46.6 mg, 65%). 
 
Domino C–H activation/Diels-Alder/retro-Diels-Alder with allene 
 
172e (62.8 mg, 0.25 mmol), 88a (83.0 mg, 0.38 mmol), MnBr(CO)5 (6.9 mg, 10 mol %), 
NaOAc (10 mg, 50 mol %), BPh3 (60 mg, 1.0 equiv) and DME (1.0 mL) were placed in a 
25 mL Schlenk pressure tube under N2 atomosphere and stirred at 70 °C for 12 h. After 
cooling to ambient temperature, the mixture was transferred into a round bottom flask 
with CH2Cl2 (20 mL) and concentrated in vacuo. Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 5/1) yielded 183 (19.7 mg, 20%). 
 
4-Bromo-6-(3-methyl-1-phenylbuta-1,2-dien-1-yl)-2H-[1,2'-bipyridin]-2-one (183):  
1H-NMR (400 MHz, CDCl3) δ = 8.40 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.48 (dd, J = 7.7, 1.9 
Hz, 1H), 7.19–7.08 (m, 4H), 6.94 (ddd, J = 6.9, 4.7, 1.3 Hz, 3H), 6.86 (d, J = 2.1 Hz, 1H), 
6.43 (d, J = 2.1 Hz, 1H), 1.67 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 203.6 (Cq), 162.1 
(Cq), 151.1 (Cq), 149.0 (CH), 145.7 (Cq), 137.0 (CH), 136.4 (Cq), 135.7 (Cq), 128.3 (CH), 
127.2 (CH), 126.7 (CH), 124.3 (CH), 123.4 (CH), 122.0 (CH), 112.5 (CH), 101.6 (Cq), 101.2 





calcd for C21H18BrN2O [M+H]+ 393.0597, found 393.0596. 
 
183 (98.0 mg, 0.25 mmol), 88a (83.0 mg, 0.38 mmol), NaOAc (10 mg, 50 mol %), BPh3 
(60 mg, 1.0 equiv) and DME (1.0 mL) were placed in a 25 mL Schlenk pressure tube 
under N2 atomosphere and stirred at 100 °C for 24 h. After cooling to ambient 
temperature, the mixture was transferred into a round bottom flask with CH2Cl2 (20 
mL) and concentrated in vacuo. Purification by column chromatography on silica gel 





5.5 Manganese(II/III/I)-Catalyzed C–H Arylations in Continuous Flow 
5.5.1 Characterization Data  
 
N-n-Butyl-3-(4-methoxyphenyl)picolinamide (188aa). The general procedure C was 
followed using 112a (44.5 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 mmol, 2.5 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188aa (52.6 
mg, 74%) as a white solid. M. p. = 96–97 °C. 1H-NMR (300 MHz, CDCl3) δ = 8.48 (dd, J 
= 4.6, 1.7 Hz, 1H), 7.66–7.62(m, 2H), 7.38 (dd, J = 7.8, 4.6 Hz, 1H), 7.25 (d, J = 8.8 Hz , 
2H), 6.92 (d, J = 8.8 Hz, 2H), 3.81 (s, 3H), 3.34 (td, J = 7.2, 6.0 Hz, 2H), 1.60–1.44 (m, 
2H), 1.42–1.23 (m, 2H), 0.91 (t, J = 7.2 Hz, 3H). 13C-NMR (75 MHz, CDCl3) δ = 165.2 (Cq), 
159.0 (Cq), 148.2 (Cq), 146.4 (CH), 139.9 (CH), 137.7 (Cq), 131.6 (Cq), 129.5 (CH), 124.9 
(CH), 113.4 (CH), 55.2 (CH3), 39.2 (CH2), 31.7 (CH2), 20.2 (CH2), 13.8 (CH3). IR (ATR): 
3330, 2324, 2181, 2032, 514, 478, 455, 432 cm-1. MS (EI) m/z (relative intensity): 284 
(55) [M]+, 242 (20), 227 (70), 213 (50), 185 (100), 169 (32). HR-MS (ESI) m/z calcd for 
C17H21N2O2 [M+H]+ 285.1598, found 285.1597.  
 
N-Benzyl-3-(4-methoxyphenyl)picolinamide (188ba). The general procedure C was 
followed using 112b (53.1 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 mmol, 2.5 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ba (51.7 
mg, 65%) as a white solid. M. p. = 138–140 °C. 1H-NMR (300 MHz, CDCl3) δ = 8.45 (dd, 
J = 4.6, 1.7 Hz, 1H), 7.96 (sbr, 1H), 7.63 (dd, J = 7.8, 1.7 Hz, 1H), 7.36 (dd, J = 7.8, 4.6 Hz, 





NMR (125 MHz, CDCl3) δ = 165.2 (Cq), 159.1 (Cq), 147.9 (Cq), 146.6 (CH), 140.1 (CH), 
138.4 (Cq), 138.0 (Cq), 131.5 (Cq), 129.7 (CH), 128.6 (CH), 127.9 (CH), 127.3 (CH), 125.2 
(CH), 113.5 (CH), 55.2 (CH3), 43.4 (CH2). IR (ATR): 3330, 3066, 2995, 2913, 1655, 1607, 
1250, 600 cm-1. MS (EI) m/z (relative intensity): 318 (40) [M]+, 275 (15), 213 (25), 185 




N-Cyclohexyl-3-(4-methoxyphenyl)picolinamide (188ca). The general procedure C 
was followed using 112c (51.1 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 mmol, 2.5 m in 
THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ca 
(54.3 mg, 70%) as a white solid. M. p. = 95–96 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.48 
(dd, J = 4.7, 1.7 Hz, 1H), 7.63 (dd, J = 7.8, 1.7 Hz, 1H), 7.52 (d, J = 8.6 Hz, 1H), 7.37 (dd, 
J = 7.8, 4.7 Hz, 1H), 7.24 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 3.88–3.78 (m, 4H), 
1.95–1.90 (m, 2H), 1.71–1.66 (m, 2H), 1.61–1.54 (m, 1H), 1.40–1.08 (m, 5H). 13C-NMR 
(100 MHz, CDCl3) δ = 164.4 (Cq), 159.0 (Cq), 148.4 (Cq), 146.5 (CH), 139.9 (CH), 137.7 
(Cq), 131.6 (Cq), 129.5 (CH), 124.8 (CH), 113.4 (CH), 55.1 (CH3), 48.0 (CH), 32.9 (CH2), 
25.5 (CH2), 24.8 (CH2). IR (ATR): 3250, 2929, 2850, 1641, 1511, 1289, 836, 580 cm-1. 
MS (EI) m/z (relative intensity): 310 (65) [M]+, 227 (94), 212 (42), 184 (99), 169 (36), 





N-(4-Methoxybenzyl)-3-(4-methoxyphenyl)picolinamide (188da). The general 
procedure C was followed using 112d (60.6 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 
mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) 
yielded 188da (53.1 mg, 61%) as a white solid. M. p. = 92–93 °C. 1H-NMR (500 MHz, 
CDCl3) δ = 8.49 (dd, J = 4.6, 1.7 Hz, 1H), 7.92 (sbr, 1H), 7.67 (dd, J = 7.8, 1.7 Hz, 1H), 7.41 
(dd, J = 7.8, 4.6 Hz, 1H), 7.28 (d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 8.7 
Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 4.49 (d, J = 5.9 Hz, 2H), 3.85 (s, 3H), 3.79 (s, 3H). 
13C-NMR (125 MHz, CDCl3) δ = 165.1 (Cq), 159.1 (Cq), 158.9 (Cq), 148.0 (Cq), 146.6 (CH), 
140.1 (CH), 137.9 (Cq), 131.5 (Cq), 130.5 (Cq), 129.7 (CH), 129.2 (CH), 125.1 (CH), 114.0 
(CH), 113.4 (CH), 55.3 (CH3), 55.2 (CH3), 42.9 (CH2). IR (ATR): 3330, 3000, 2936, 2835, 
1641, 1242, 1033, 795 cm-1. MS (EI) m/z (relative intensity): 348 (15) [M]+, 185 (15), 
136 (100), 121 (14), 109 (8), 43 (10). HR-MS (EI) m/z calcd for C21H20N2O3 [M]+ 




N-(4-Fluorobenzyl)-3-(4-methoxyphenyl)picolinamide (188ea). The general 
procedure C was followed using 112e (57.6 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 
mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) 





CDCl3)   δ = 8.48 (dd, J = 4.7, 1.7 Hz, 1H), 8.03 (sbr, 1H), 7.67 (dd, J = 7.8, 1.7 Hz, 1H), 
7.41 (dd, J = 7.8, 4.7 Hz, 1H), 7.33–7.19 (m, 4H), 7.06–6.88 (m, 4H), 4.60–4.39 (m, 2H), 
3.84 (s, 3H). 13C-NMR (125 MHz, CDCl3) δ = 165.2 (Cq), 162.0 (d, 1JC–F = 245.4 Hz, Cq), 
159.1 (Cq), 147.8 (Cq), 146.6 (CH), 140.1 (CH), 137.9 (Cq), 134.2 (d, 4JC–F = 3.1 Hz, Cq), 
131.4 (Cq), 129.6 (CH), 129.4 (d, 3JC–F = 8.1 Hz, CH), 125.2 (CH), 115.3 (d, 2JC–F = 21.6 Hz, 
CH), 113.4 (CH), 55.1 (CH3), 42.6 (CH2). 19F-NMR (471 MHz, CDCl3) δ = –115.3. IR (ATR): 
3330, 3064, 2911, 1657, 1508, 1221, 735, 651 cm-1. MS (ESI) m/z (relative intensity): 
695 (100) [2M+Na]+, 359 (26) [M+Na]+, 337 (22) [M+H]+. HR-MS (ESI) m/z calcd for 
C20H18FN2O2 [M+H]+ 337.1347, found 337.1344. 
 
 
N-(2-Fluorobenzyl)-3-(4-methoxyphenyl)picolinamide (188fa). The general 
procedure C was followed using 112f (57.6 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 
mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) 
yielded 188fa (55.4 mg, 66%) as a white solid. M. p. = 115–116 °C. 1H-NMR (500 MHz, 
CDCl3)   δ = 8.51 (dd, J = 4.6, 1.6 Hz, 1H), 8.07 (sbr, 1H), 7.67 (dd, J = 7.8, 1.6 Hz, 1H), 
7.42 (dd, J = 7.8, 4.6 Hz, 1H), 7.36–7.34 (m, 1H), 7.30–7.20 (m, 3H), 7.12–7.00 (m, 2H), 
6.93 (d, J = 8.7 Hz, 2H), 4.75–4.57 (m, 2H), 3.84 (s, 3H). 13C-NMR (126 MHz, CDCl3) δ = 
165.2 (Cq), 160.9 (d, 1JC–F = 246.2 Hz, Cq), 159.1 (Cq), 147.8 (Cq), 146.6 (CH), 140.0 (CH), 
137.9 (Cq), 131.3 (Cq), 130.1 (d, 3JC–F = 4.5 Hz, CH), 129.6 (CH), 129.0 (d, 3JC–F = 8.1 Hz, 
CH), 125.3 (d, 2JC–F = 15.0 Hz, Cq), 125.2 (CH), 124.1 (d, 4JC–F = 3.6 Hz, CH), 115.2 (d, 2JC–F 
= 21.4 Hz, CH), 113.4 (CH), 55.1 (CH3), 37.2 (d, 3JC–F = 4.1 Hz, CH2). 19F-NMR (471 MHz, 
CDCl3) δ = –118.8. IR (ATR): 3300, 3067, 2992, 1656, 1455, 1228, 824, 683 cm-1. MS 
(ESI) m/z (relative intensity): 695 (100) [2M+Na]+, 359 (26) [M+Na]+. HR-MS (ESI) m/z 






The general procedure C was followed using 112g (63.1 mg, 0.25 mmol) and 151a (0.40 
mL, 1.0 mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 
2:1→1:1) yielded 188ga (70.7 mg, 79%) as a white solid. M. p. = 125–126 °C. 1H-NMR 
(400 MHz, CDCl3) δ = 8.49 (dd, J = 4.7, 1.6 Hz, 1H), 7.85 (sbr, 1H), 7.68 (dd, J = 7.8, 1.6 
Hz, 1H), 7.41 (dd, J = 7.8, 4.7 Hz, 1H), 7.34 (d, J = 8.7 Hz, 2H), 7.28–7.24 (m, 1H), 7.21–
7.08 (m, 3H), 6.99 (d, J = 8.7 Hz, 2H), 5.30–5.25 (m, 1H), 3.87 (s, 3H), 2.88–2.74 (m, 2H), 
2.16–2.01 (m, 1H), 1.97–1.75 (m, 3H). 13C-NMR (100 MHz, CDCl3) δ = 164.7 (Cq), 159.2 
(Cq), 148.3 (Cq), 146.7 (CH), 139.9 (CH), 137.7 (Cq), 137.5 (Cq), 136.7 (Cq), 131.5 (Cq), 
129.7 (CH), 129.0 (CH), 128.8 (CH), 127.1 (CH), 126.1 (CH), 125.0 (CH), 113.5 (CH), 55.2 
(CH3), 47.3 (CH), 30.1 (CH2), 29.2 (CH2), 20.0 (CH2). IR (ATR): 2932, 2835, 1668, 1610, 
1499, 1445, 1287, 834 cm-1. MS (EI) m/z (relative intensity): 358 (8) [M]+, 307 (5), 229 




3-(4-Methoxyphenyl)-N-phenethylpicolinamide (188ha). The general procedure C 
was followed using 112h (56.6 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 mmol, 2.5 m in 
THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ha 





(dd, J = 4.6, 1.7 Hz, 1H), 7.79 (sbr, 1H), 7.67 (dd, J = 7.8, 1.7 Hz, 1H), 7.40 (dd, J = 7.8, 
4.6 Hz, 1H), 7.34–7.29 (m, 2H), 7.29–7.20 (m, 5H), 6.97 (d, J = 8.8 Hz, 2H), 3.86 (s, 3H), 
3.65 (td, J = 7.2, 6.2 Hz, 2H), 2.89 (t, J = 7.2 Hz, 2H). 13C-NMR (125 MHz, CDCl3) δ = 
165.3 (Cq), 159.0 (Cq), 148.1 (Cq), 146.5 (CH), 139.9 (CH), 139.0 (Cq), 137.6 (Cq), 131.4 
(Cq), 129.5 (CH), 128.7 (CH), 128.4 (CH), 126.2 (CH), 125.0 (CH), 113.4 (CH), 55.1 (CH3), 
40.5 (CH2), 35.7 (CH2). IR (ATR): 3325, 3026, 2922, 1647, 1514, 1288, 803, 699 cm-1. 
MS (ESI) m/z (relative intensity): 687 (100) [2M+Na]+, 355 (26) [M+Na]+, 333 (10) 
[M+H]+. HR-MS (ESI) m/z calcd for C21H21N2O2 [M+H]+ 333.1598, found 333.1598. 
 
 
(E)-N-n-Butyl-3-(4-methoxyphenyl)-5-styrylpicolinamide (188ia). The general 
procedure C was followed using 112i (70.1 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 
mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) 
yielded 188ia (57.9 mg, 60%) as a white solid. M. p. = 77–78 °C. 1H-NMR (400 MHz, 
CDCl3) δ = 8.60 (d, J = 2.2 Hz, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.75–7.72 (sbr, 1H), 7.55–7.52 
(m, 2H), 7.42–7.36 (m, 2H), 7.35–7.28 (m, 3H), 7.27–7.23 (d, J = 16.4 Hz, 1H), 7.11 (d, 
J = 16.4 Hz, 1H), 6.97 (d, J = 8.8 Hz, 2H), 3.86 (s, 3H), 3.37 (td, J = 7.2, 6.0 Hz, 2H), 1.63–
1.46 (m, 2H), 1.45–1.31 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 
164.9 (Cq), 159.1 (Cq), 146.5 (Cq), 145.1 (CH), 137.9 (Cq), 136.6 (CH), 136.3 (Cq), 134.4 
(Cq), 132.5 (CH), 131.8 (Cq), 129.6 (CH), 128.8 (CH), 128.6 (CH), 126.8 (CH), 123.8 (CH), 
113.4 (CH), 55.2 (CH3), 39.1 (CH2), 31.7 (CH2), 20.2 (CH2), 13.8 (CH3). IR (ATR): 3323, 
2959, 2928, 1646, 1512, 1249, 831, 690 cm-1. MS (ESI) m/z (relative intensity): 795 
(100) [2M+Na]+, 409 (28) [M+Na]+, 387 (14) [M+H]+. HR-MS (ESI) m/z calcd for 
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C25H27N2O2 [M+H]+ 387.2067, found 387.2064. 
 
 
(S)-3-(4-Methoxyphenyl)-N-(1-phenylethyl)picolinamide (188ja). The general 
procedure C was followed using (S)- 112j (56.6 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 
mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) 
yielded (S)- 188ja (56.4 mg, 68%) as a white solid. M. p. = 110–111 °C. 1H-NMR (400 
MHz, CDCl3) δ = 8.50 (dd, J = 4.6, 1.6 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 7.8, 
1.6 Hz, 1H), 7.39 (dd, J = 7.8, 4.6 Hz, 1H), 7.36–7.28 (m, 4H), 7.27–7.20 (m, 3H), 6.91 
(d, J = 8.8 Hz, 2H), 5.22 (dq, J = 8.5, 6.9 Hz, 1H), 3.82 (s, 3H), 1.54 (d, J = 6.9 Hz, 3H). 
13C-NMR (100 MHz, CDCl3) δ = 164.4 (Cq), 159.1 (Cq), 148.1 (Cq), 146.5 (CH), 143.3 (Cq), 
140.0 (CH), 137.8 (Cq), 131.4 (Cq), 129.6 (CH), 128.5 (CH), 127.1 (CH), 126.2 (CH), 125.0 
(CH), 113.4 (CH), 55.1 (CH3), 48.5 (CH), 21.9 (CH3). IR (ATR): 3200, 3026, 1647, 1514, 
1251, 818, 694, 572 cm-1. MS (EI) m/z (relative intensity): 332 (10) [M]+, 227 (6), 212 
(8), 184 (25), 120 (100), 105 (10). HR-MS (EI) m/z calcd for C21H20N2O2 [M]+ 332.1519, 
found 332.1529. HPLC analysis (Chiralcel IA-3, iPrOH/n-hexane 40:60, flow rate = 1.0 











N-n-Butyl-3-(4-methoxyphenyl)-5-phenylpicolinamide (188ka). The general 
procedure C was followed using 112k (63.6 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 
mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) 
yielded 188ka (48.6 mg, 54%) as a white solid. M. p. = 91–92 °C. 1H-NMR (300 MHz, 
CDCl3) δ = 8.74 (d, J = 2.2 Hz, 1H), 7.85 (d, J = 2.2 Hz, 1H), 7.77 (sbr, 1H), 7.68–7.58 (m, 
2H), 7.56–7.39 (m, 3H), 7.33 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 3.86 (s, 3H), 
3.39 (td, J = 7.1, 6.0 Hz, 2H), 1.68–1.50 (m, 2H), 1.45–1.27 (m, 2H), 0.94 (t, J = 7.1 Hz, 
3H). 13C-NMR (100 MHz, CDCl3) δ = 164.9 (Cq), 159.1 (Cq), 146.6 (Cq), 144.8 (CH), 138.2 
(CH), 137.9 (Cq), 137.8 (Cq), 136.6 (Cq), 131.6 (Cq), 129.6 (CH), 129.1 (CH), 128.6 (CH), 
127.1 (CH), 113.4 (CH), 55.2 (CH3), 39.2 (CH2), 31.7 (CH2), 20.2 (CH2), 13.9 (CH3). IR 
(ATR): 3300, 2956, 2931, 1659, 1510, 1244, 832, 762 cm-1. MS (EI) m/z (relative 
intensity): 360 (44) [M]+, 303 (55), 261 (100), 245 (18), 217 (32), 130 (15). HR-MS (ESI) 




N-n-Butyl-4-(4-methoxyphenyl)nicotinamide (188la). The general procedure C was 
followed using 112l (44.6 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 mmol, 2.5 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188la (54.7 
mg, 77%) as a white solid. M. p. = 104–105 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.79 (d, 
J = 0.7 Hz, 1H), 8.60 (d, J = 5.2 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.25 (dd, J = 5.2, 0.7 Hz, 
1H), 6.97 (d, J = 8.8 Hz, 2H), 5.48 (sbr, 1H), 3.85 (s, 3H), 3.23 (td, J = 7.0, 5.8 Hz, 2H), 
1.35–1.21 (m, 2H), 1.13–1.01 (m, 2H), 0.81 (t, J = 7.0 Hz, 3H). 13C-NMR (100 MHz, CDCl3) 
δ = 167.4 (Cq), 160.4 (Cq), 150.7 (CH), 149.6 (CH), 146.5 (Cq), 131.1 (Cq), 129.7 (CH), 
129.5 (Cq), 124.0 (CH), 114.4 (CH), 55.4 (CH3), 39.6 (CH2), 31.1 (CH2), 19.9 (CH2), 13.6 
(CH3). IR (ATR): 3200, 2957, 2870, 1637, 1515, 1247, 828, 577 cm-1. MS (EI) m/z 
(relative intensity): 284 (40) [M]+, 227 (38), 212 (100), 184 (10), 169 (24), 141 (15). HR-
MS (EI) m/z calcd for C17H20N2O2 [M]+ 284.1519, found 284.1533. 
 
 
N-n-Butyl-4-(4-methoxyphenyl)-5-methylnicotinamide (188ma). The general 
procedure C was followed using 112m (48.1 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 
mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) 
yielded 188ma (52.9 mg, 71%) as a white solid. M. p. = 111–112 °C. 1H-NMR (400 MHz, 
CDCl3) δ = 8.70 (s, 1H), 8.48 (s, 1H), 7.15 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 5.39 





(t, J = 7.0 Hz, 3H). 13C-NMR (125 MHz, CDCl3) δ = 166.8 (Cq), 159.6 (Cq), 151.7 (CH), 
147.1 (CH), 146.0 (Cq), 131.6 (Cq), 131.5 (Cq), 129.4 (CH), 128.5 (Cq), 114.3 (CH), 55.3 
(CH3), 39.5 (CH2), 31.2 (CH2), 19.9 (CH2), 17.4 (CH3), 13.7 (CH3). IR (ATR): 3330, 2956, 
2930, 2870, 1638, 1515, 1246, 833 cm-1. MS (ESI) m/z (relative intensity): 619 (85) 
[2M+Na]+, 321 (55) [M+Na]+, 299 (100) [M+H]+. HR-MS (ESI) m/z calcd for C18H23N2O2 
[M+H]+ 299.1754, found 299.1754. 
 
 
N-n-Butyl-3-(4-methoxyphenyl)isonicotinamide (188na). The general procedure C 
was followed using 112n (44.6 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 mmol, 2.5 m in 
THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188na 
(35.5 mg, 50%) as a white solid. M. p. = 121–122 °C. 1H-NMR (400 MHz, CDCl3) δ = 
8.62–8.60 (m, 2H), 7.53 (d, J = 4.9 Hz, 1H), 7.34 (d, J = 8.7 Hz, 2H), 6.98 (d, J = 8.7 Hz, 
2H), 5.42 (sbr, 1H), 3.85 (s, 3H), 3.20 (td, J = 7.0, 5.8 Hz, 2H), 1.30–1.13 (m, 2H), 1.11–
0.94 (m, 2H), 0.80 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 167.2 (Cq), 160.0 
(Cq), 150.9 (CH), 148.7 (CH), 142.2 (Cq), 133.5 (Cq), 130.1 (CH), 128.5 (Cq), 122.2 (CH), 
114.4 (CH), 55.4 (CH3), 39.6 (CH2), 31.0 (CH2), 19.8 (CH2), 13.6 (CH3). IR (ATR): 3200, 
3037, 2931, 1641, 1540, 1247, 831, 670 cm-1. MS (EI) m/z (relative intensity): 284 (62) 
[M]+, 227 (45), 212 (100), 184 (8), 169 (24), 141 (15). HR-MS (EI) m/z calcd for 






N-n-Benzyl-3-(4-methoxyphenyl)isonicotinamide (188oa). The general procedure C 
was followed using 112o (53.1 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 mmol, 2.5 m in 
THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188oa 
(41.3 mg, 52%) as a white solid. M. p. = 150–151 °C. 1H-NMR (400 MHz, CDCl3)   δ = 
8.62–8.48 (m, 2H), 7.53 (d, J = 4.9 Hz, 1H), 7.31–7.25 (m, 2H), 7.22–7.21 (m, 3H), 6.95–
6.92 (m, 2H), 6.89 (d, J = 8.7 Hz, 2H), 5.83 (sbr, 1H), 4.37 (d, J = 5.6 Hz, 2H), 3.83 (s, 3H). 
13C-NMR (100 MHz, CDCl3) δ = 167.1 (Cq), 159.9 (Cq), 150.9 (CH), 148.6 (CH), 142.0 (Cq), 
137.0 (Cq), 133.6 (Cq), 130.1 (CH), 128.6 (CH), 128.3 (Cq), 127.8 (CH), 127.5 (CH), 122.2 
(CH), 114.4 (CH), 55.3 (CH3), 44.0 (CH2). IR (ATR): 3200, 3060, 2962, 1635, 1550, 1248, 
830, 695 cm-1. MS (EI) m/z (relative intensity): 318 (100) [M]+, 212 (40), 185 (35), 170 
(24), 106 (38). HR-MS (EI) m/z calcd for C20H18N2O2 [M]+ 318.1363, found 318.1363. 
 
 
N-n-Butyl-5-(4-methoxyphenyl)pyrimidine-4-carboxamide (188pa). The general 
procedure C was followed using 112p (44.8 mg, 0.25 mmol) and 151a (0.40 mL, 1.0 
mmol, 2.5 m in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) 
yielded 188pa (37.8 mg, 53%) as a white solid. M. p. = 51–52 °C. 1H-NMR (400 MHz, 
CDCl3) δ = 9.15 (d, J = 1.3 Hz, 1H), 8.46 (d, J = 1.3 Hz, 1H), 8.17 (d, J = 8.9 Hz, 2H), 8.05 
(sbr, 1H), 7.03 (d, J = 8.9 Hz, 2H), 3.89 (s, 3H), 3.50 (td, J = 7.1, 6.0 Hz, 2H), 1.68–1.61 
(m, 2H), 1.51–1.34 (m, 2H), 0.97 (t, J = 7.1 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 165.7 





113.1 (CH), 55.5 (CH3), 39.3 (CH2), 31.6 (CH2), 20.1 (CH2), 13.7 (CH3). IR (ATR): 3400, 
3047, 2962, 1672, 1510, 1251, 836, 574 cm-1. MS (ESI) m/z (relative intensity): 593 (25) 
[2M+Na]+, 308 (100) [M+Na]+, 286 (12) [M+H]+. HR-MS (ESI) m/z calcd for C16H20N3O2 




carboxamide (156). The general procedure C was followed using 159a (71.6 mg, 0.25 
mmol) and 151a (0.70 mL, 1.75 mmol, 2.5 m in THF). Isolation by column 
chromatography (n-hexane/EtOAc: 3:1→1:1) yielded 156 (52.0 mg, 53%) as a white 
solid. M. p. = 115–116 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.64–7.61 (m, 1H), 7.44–7.40 
(m, 1H), 7.38–7.28 (m, 5H), 6.91 (d, J = 8.8 Hz, 2H), 5.89 (sbr, 1H), 4.27 (t, J = 7.3 Hz, 
2H), 3.84 (s, 3H), 1.93–1.79 (m, 2H), 1.60 (s, 6H), 1.41–1.28 (m, 2H), 0.95 (t, J = 7.4 Hz, 
3H). 13C-NMR (100 MHz, CDCl3) δ = 168.5 (Cq), 159.3 (Cq), 152.7 (Cq), 139.3 (Cq), 136.2 
(Cq), 132.7 (Cq), 130.2 (CH), 130.1 (CH), 129.9 (CH), 128.6 (CH), 127.1 (CH), 120.4 (CH), 
113.9 (CH), 55.4 (CH3), 51.6 (CH2), 50.0 (CH2), 32.2 (CH2), 27.5 (CH3), 19.8 (CH2), 13.5 
(CH3). IR (ATR): 3292, 2959, 2928, 1632, 1541, 1438, 1309, 1048 cm-1. MS (ESI) m/z 
(relative intensity): 807 (12) [2M+Na]+, 415 (52) [M+Na]+, 393 (34) [M+H]+. HR-MS (ESI) 
m/z calcd for C23H29N4O2 [M+H]+ 393.2285, found 393.2284. 
 
 
N-n-Butyl-3-phenylpicolinamide (188ab). The general procedure C was followed using 
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112a (44.5 mg, 0.25 mmol) and 151b (0.38 mL, 1.0 mmol, 2.6 m in THF). Isolation by 
column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ab (50.8 mg, 80%) as 
a white solid. M. p. = 55–56 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.54 (dd, J = 4.7, 1.7 Hz, 
1H), 7.71 (sbr, 1H), 7.67 (dd, J = 7.8, 1.7 Hz, 1H), 7.48–7.29 (m, 6H), 3.35 (td, J = 7.2, 6.0 
Hz, 2H), 1.62–1.49 (m, 2H), 1.43–1.28 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H). 13C-NMR (100 
MHz, CDCl3) δ = 165.0 (Cq), 148.1 (Cq), 146.8 (CH), 139.9 (CH), 139.5 (Cq), 138.1 (Cq), 
128.3 (CH), 127.8 (CH), 127.4 (CH), 124.9 (CH), 39.1 (CH2), 31.6 (CH2), 20.1 (CH2), 13.7 
(CH3). IR (ATR): 3250, 3060, 2955, 1648, 1541, 1316, 758, 666 cm-1. MS (ESI) m/z 
(relative intensity): 531 (100) [2M+Na]+, 277 (18) [M+Na]+, 255 (12) [M+H]+. HR-MS 
(ESI) m/z calcd for C16H19N2O [M+H]+ 255.1492, found 255.1490. 
 
 
N-n-Butyl-3-(p-tolyl)picolinamide (188ac). The general procedure C was followed 
using 112a (44.5 mg, 0.25 mmol) and 151c (0.42 mL, 1.0 mmol, 2.4 m in THF). Isolation 
by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ac (50.9 mg, 76%) 
as a white solid. M. p. = 110–111 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.52 (dd, J = 4.7, 
1.7 Hz, 1H), 7.68–7.65 (m, 2H), 7.41 (dd, J = 7.8, 4.7 Hz, 1H), 7.22 (m, 4H), 3.36 (td, J = 
7.1, 6.0 Hz, 2H), 2.39 (s, 3H), 1.61–1.48 (m, 2H), 1.44–1.27 (m, 2H), 0.92 (t,  J = 7.1 Hz, 
3H). 13C-NMR (100 MHz, CDCl3) δ = 165.1 (Cq), 148.3 (Cq), 146.6 (CH), 139.9 (CH), 138.1 
(Cq), 137.1 (Cq), 136.5 (Cq), 128.6 (CH), 128.2 (CH), 124.9 (CH), 39.1 (CH2), 31.6 (CH2), 
21.2 (CH3), 20.1 (CH2), 13.7 (CH3). IR (ATR): 3250, 2956, 2922, 1665, 1550, 1306, 801, 
696 cm-1. MS (EI) m/z (relative intensity): 268 (28) [M]+, 211 (42), 168 (70), 154 (13), 







N-n-Butyl-3-[4-(tert-butyl)phenyl]picolinamide (188ad). The general procedure C was 
followed using 112a (44.5 mg, 0.25 mmol) and 151d (0.40 mL, 1.0 mmol, 2.5 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ad (56.6 
mg, 73%) as a white solid. M. p. = 108–109 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.52 (dd, 
J = 4.6, 1.7 Hz, 1H), 7.68–7.65 (m, 2H), 7.48–7.37 (m, 3H), 7.32–7.25 (m, 2H), 3.36 (td, 
J = 7.2, 6.0 Hz, 2H), 1.59–1.48 (m, 2H), 1.41– 1.31 (m, 11H), 0.92 (t, J = 7.2 Hz, 3H). 13C-
NMR (100 MHz, CDCl3) δ = 165.2 (Cq), 150.1 (Cq), 148.2 (Cq), 146.6 (CH), 140.1 (CH), 
137.9 (Cq), 136.3 (Cq), 128.1 (CH), 124.9 (CH), 124.8 (CH), 39.1 (CH2), 34.5 (Cq), 31.5 
(CH2), 31.3 (CH3), 20.1 (CH2), 13.7 (CH3). IR (ATR): 3280, 2957, 2869, 1638, 1547, 1432, 
841, 584 cm-1. MS (EI) m/z (relative intensity): 310 (88) [M]+, 253 (85), 211 (80), 194 
(70), 182 (100). HR-MS (ESI) m/z calcd for C20H27N2O [M+H]+ 311.2118, found 311.2117. 
 
 
3- [(1,1'-Biphenyl)-4-yl]-N-n-butylpicolinamide (188ae). The general procedure C was 
followed using 112a (44.5 mg, 0.25 mmol) and 151e (0.44 mL, 1.0 mmol, 2.3 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ae (41.3 
mg, 50%) as a white solid. M. p. = 118–119 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.56 (dd, 
J = 4.7, 1.7 Hz, 1H), 7.78 (sbr, 1H), 7.72 (dd, J = 7.8, 1.7 Hz, 1H), 7.68–7.60 (m, 4H), 7.49–
7.39 (m, 5H), 7.38–7.31 (m, 1H), 3.39 (td, J = 7.2, 6.0 Hz, 2H), 1.62–1.51 (m, 2H), 1.46–
1.30 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 165.0 (Cq), 148.1 
(Cq), 146.9 (CH), 140.8 (Cq), 140.2 (Cq), 140.1 (CH), 138.5 (Cq), 137.9 (Cq), 128.9 (CH), 
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128.7 (CH), 127.2 (CH), 127.1 (CH), 126.6 (CH), 125.1 (CH), 39.2 (CH2), 31.6 (CH2), 20.2 
(CH2), 13.8 (CH3). IR (ATR): 3220, 2958, 2931, 1643, 1548, 766, 696, 580 cm-1. MS (ESI) 
m/z (relative intensity): 683 (100) [2M+Na]+, 353 (54) [M+Na]+, 331 (17) [M+H]+. HR-
MS (ESI) m/z calcd for C22H23N2O [M+H]+ 331.1805, found 331.1802. 
 
 
N-n-Butyl-3-(4-fluorophenyl)picolinamide (188af). The general procedure C was 
followed using 112a (44.5 mg, 0.25 mmol) and 151f (0.38 mL, 1.0 mmol, 2.6 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188af (44.2 
mg, 65%) as a white solid. M. p. = 81–82 °C. 1H-NMR (300 MHz, CDCl3) δ = 8.52 (dd, J 
= 4.7, 1.7 Hz, 1H), 7.82 (sbr, 1H), 7.62 (dd, J = 7.8, 1.7 Hz, 1H), 7.41 (dd, J = 7.8, 4.7 Hz, 
1H), 7.33–7.19 (m, 2H), 7.15–6.95 (m, 2H), 3.33 (td, J = 7.1, 6.0 Hz, 2H), 1.62–1.46 (m, 
2H), 1.43–1.25 (m, 2H), 0.90 (t, J = 7.1 Hz, 3H). 13C-NMR (125 MHz, CDCl3) δ = 164.7 
(Cq), 162.2 (d, 1JC–F = 246.0 Hz, Cq), 147.8 (Cq), 146.8 (CH), 139.9 (CH), 137.2 (Cq), 135.4 
(d, 4JC–F = 3.4 Hz, Cq), 129.9 (d, 3JC–F = 8.2 Hz, CH), 125.0 (CH), 114.7 (d, 2JC–F = 21.6 Hz, 
CH), 39.1 (CH2), 31.7 (CH2), 20.2 (CH2), 13.8 (CH3). 19F-NMR (282 MHz, CDCl3) δ = –
115.18. IR (ATR): 3330, 2956, 2859, 1648, 1512, 1223, 649, 632 cm-1. MS (EI) m/z 
(relative intensity): 272 (30) [M]+, 215 (50), 172 (100), 145 (32), 72 (28). HR-MS (EI) 
m/z calcd for C16H17FN2O [M]+ 272.1319, found 272.1324. 
 
 





C was followed using 112a (44.5 mg, 0.25 mmol) and 151g (0.36 mL, 1.0 mmol, 2.8 m 
in THF). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 
188ag (40.8 mg, 55%) as a white solid. M. p. = 77–78 °C. 1H-NMR (400 MHz, CDCl3) δ 
= 8.47 (dd, J = 4.6, 1.7 Hz, 1H), 7.68 (dd, J = 7.8, 1.7 Hz, 1H), 7.43 (sbr, 1H), 7.37 (dd,  J 
= 7.8, 4.6 Hz, 1H), 7.24 (d, J = 8.9 Hz, 2H), 6.76 (d, J = 8.9 Hz, 2H), 3.37 (td, J = 7.1, 6.0 
Hz, 2H), 2.98 (s, 6H), 1.61–1.46 (m, 2H), 1.42–1.27 (m, 2H), 0.91 (t, J = 7.1 Hz, 3H). 13C-
NMR (101 MHz, CDCl3) δ = 165.9 (Cq), 150.0 (Cq), 148.7 (Cq), 146.0 (CH), 139.7 (CH), 
138.0 (Cq), 129.3 (CH), 126.7 (Cq), 124.8 (CH), 111.9 (CH), 40.4 (CH3), 39.2 (CH2), 31.6 
(CH2), 20.1 (CH2), 13.8 (CH3). IR (ATR): 3250, 2955, 2929, 2869, 1647, 1523, 821, 633 
cm-1. MS (EI) m/z (relative intensity): 297 (100) [M]+, 240 (30), 198 (65), 182 (18), 154 
(25). HR-MS (EI) m/z calcd for C18H23N3O [M]+ 297.1836, found 297.1830. 
 
 
N-n-Butyl-3-(3-methoxyphenyl)picolinamide (188ah). The general procedure C was 
followed using 112a (44.5 mg, 0.25 mmol) and 151h (0.40 mL, 1.0 mmol, 2.5 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ah (47.6 
mg, 67%) as a white solid. M. p. = 99–100 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.53 (dd, 
J = 4.7, 1.7 Hz, 1H), 7.67 (dd, J = 7.8, 1.7 Hz, 1H), 7.62 (sbr, 1H), 7.41 (dd, J = 7.8, 4.7 Hz, 
1H), 7.33–7.29 (m, 1H), 6.99–6.80 (m, 3H), 3.81 (s, 3H), 3.35 (td, J = 7.2, 6.0 Hz, 2H), 
1.60–1.48 (m, 2H), 1.41–1.30 (m, 2H), 0.91 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, CDCl3) 
δ = 165.0 (Cq), 159.1 (Cq), 148.5 (Cq), 146.9 (CH), 140.8 (Cq), 139.7 (CH), 137.8 (Cq), 
128.8 (CH), 124.8 (CH), 120.9 (CH), 114.1 (CH), 112.8 (CH), 55.1 (CH3), 39.1 (CH2), 31.6 
(CH2), 20.1 (CH2), 13.7 (CH3). IR (ATR): 3300, 2955, 2870, 1656, 1516, 1117, 782, 670 
cm-1. MS (ESI) m/z (relative intensity): 591 (100) [2M+Na]+, 307 (42) [M+Na]+, 285 (21) 




N-n-Butyl-3-(3-fluorophenyl)picolinamide (188ai). The general procedure C was 
followed using 112a (44.5 mg, 0.25 mmol) and 151i (0.44 mL, 1.0 mmol, 2.3 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ai (40.8 
mg, 60%) as a white solid. M. p. = 81–82 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.56 (d, J = 
4.6 Hz, 1H), 7.82 (sbr, 1H), 7.64 (dd, J = 7.7, 1.2 Hz, 1H), 7.44 (dd, J = 7.7, 4.6 Hz, 1H), 
7.35 (m, 1H), 7.14–6.95 (m, 3H), 3.35 (td, J = 7.3, 6.3 Hz, 2H) 1.60–1.53 (m, 2H), 1.44–
1.31 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 164.6 (Cq), 162.2 
(d, 1JC–F = 245.6 Hz, Cq), 147.9 (Cq), 147.2 (CH), 141.8 (d, 3JC–F = 8.1 Hz, Cq), 139.9 (CH), 
137.0 (Cq), 129.3 (d, 3JC–F = 8.4 Hz, CH), 125.1 (CH), 124.2 (d, 4JC–F = 3.0 Hz, CH), 115.5 
(d, 2JC–F = 22.4 Hz, CH), 114.3 (d, 2JC–F = 21.1 Hz, CH), 39.1 (CH2), 31.6 (CH2), 20.1 (CH2), 
13.7 (CH3). 19F-NMR (282 MHz, CDCl3) δ = –115.17. IR (ATR): 3330, 3058, 2958, 2871, 
1656, 1585, 809, 692 cm-1. MS (ESI) m/z (relative intensity): 567 (100) [2M+Na]+, 295 




N-n-Butyl-3-(naphthalen-2-yl)picolinamide (188aj). The general procedure C was 
followed using 112a (44.5 mg, 0.25 mmol) and 151j (0.45 mL, 1.0 mmol, 2.2 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188aj (44.8 
mg, 59%) as a white solid. M. p. = 81–82 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.59 (dd, J 





1.60–1.49 (m, 2H), 1.41–1.28 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, CDCl3) 
δ = 165.0 (Cq), 148.2 (Cq), 147.0 (CH), 140.4 (CH), 138.2 (Cq), 137.4 (Cq), 133.2 (Cq), 
132.7 (Cq), 128.1 (CH), 127.7 (CH), 127.3 (CH), 127.0 (CH), 126.6 (CH), 126.1 (CH), 126.0 
(CH), 125.1 (CH), 39.1 (CH2), 31.6 (CH2), 20.1 (CH2), 13.7 (CH3). IR (ATR): 3300, 3050, 
2927, 1651, 1519, 1302, 809, 481 cm-1. MS (ESI) m/z (relative intensity): 631 (100) 
[2M+Na]+, 327 (38) [M+Na]+, 305 (22) [M+H]+. HR-MS (ESI) m/z calcd for C20H21N2O 
[M+H]+ 305.1648, found 305.1647. 
 
 
N-n-Butyl-3-(thiophen-3-yl)picolinamide (188ak). The general procedure C was 
followed using 112a (44.5 mg, 0.25 mmol) and 151k (0.44 mL, 1.0 mmol, 2.3 m in THF). 
Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188ak (33.2 
mg, 51%) as a white solid. M. p. = 62–63 °C. 1H-NMR (300 MHz, CDCl3) δ = 8.52 (dd, J 
= 4.7, 1.7 Hz, 1H), 7.74 (dd, J = 7.8, 1.7 Hz, 1H), 7.62 (sbr, 1H), 7.41 (dd, J = 7.8, 4.7 Hz, 
1H), 7.34 (dd, J = 4.9, 3.0 Hz, 1H), 7.30 (dd, J = 3.0, 1.4 Hz, 1H), 7.17 (dd, J = 4.9, 1.4 Hz, 
1H), 3.38 (td, J = 7.1, 6.0 Hz, 2H), 1.65–1.47 (m, 2H), 1.44–1.29 (m, 2H), 0.93 (t, J = 7.1 
Hz, 3H). 13C-NMR (126 MHz, CDCl3) δ = 165.1 (Cq), 148.3 (Cq), 146.8 (CH), 139.9 (CH), 
139.3 (Cq), 132.8 (Cq), 128.9 (CH), 125.0 (CH), 124.5 (CH), 122.8 (CH), 39.3 (CH2), 31.7 
(CH2), 20.3 (CH2), 13.9 (CH3). IR (ATR): 3300, 3082, 2956, 2869, 1652, 1517, 859, 706 
cm-1. MS (ESI) m/z (relative intensity): 543 (100) [2M+Na]+, 283 (78) [M+Na]+, 261 (32) 





3-Mesityl-N-(1-phenylethyl)picolinamide (188jl). The general procedure C was 
followed using 112j (56.5 mg, 0.25 mmol) MnCl2 (6.2 mg, 20 mol %), TMEDA (74 μL, 
2.0 equiv) in THF (0.25 mL), 151l (0.70 mL, 1.0 mmol, 1.4 m in THF), nBuBr (81 µL, 3.0 
equiv). Isolation by column chromatography (n-hexane/EtOAc: 2:1→1:1) yielded 188jl 
(46.5 mg, 54%) as a white solid. M. p. = 121–122 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.58 
(dd, J = 4.5, 1.8 Hz, 1H), 8.20 (d, J = 8.7, 1H), 7.53 (dd, J = 7.7, 1.8 Hz, 1H), 7.48 (dd, J = 
7.7, 4.5 Hz, 1H), 7.37–7.29 (m, 4H), 7.28–7.21 (m, 1H), 6.97–6.89 (m, 2H), 5.22 (dq, J = 
8.7, 6.9 Hz, 1H), 2.33 (s, 3H), 1.94 (s, 3H), 1.87 (s, 3H), 1.54 (d, J = 6.9 Hz, 3H). 13C-NMR 
(100 MHz, CDCl3) δ = 163.3 (Cq), 147.8 (Cq), 146.8 (CH), 143.5 (Cq), 140.4 (CH), 137.2 
(Cq), 136.5 (Cq), 136.3 (Cq), 134.4 (Cq), 134.4 (Cq), 128.5 (CH), 128.0 (CH), 127.1 (CH), 
126.2 (CH), 125.7 (CH), 48.2 (CH3), 22.1 (CH), 21.2 (CH3), 20.7 (CH3), 20.7 (CH3). IR (ATR): 
3250, 2972, 1648, 1529, 1212, 1000, 850, 705 cm-1. MS (ESI) m/z (relative intensity): 
711 (100) [2M+Na]+, 367 (33) [M+Na]+, 345 (15) [M+H]+. HR-MS (ESI) m/z calcd for 
C23H25N2O [M+H]+ 345.1961, found 345.1959. 
 
5.5.2 Mechanistic Studies  
Intermolecular competition experiment 
 
To a stirred solution of 112a (44.5 mg, 0.25 mmol), MnCl2 (3.1 mg, 10 mol %), 





(0.40 mL, 1.0 mmol, 2.5 m in THF) and 151f (0.38 mL, 1.0 mmol, 2.6 m in THF) (0.38 
mL, 4.0 equiv) were added dropwise over 30 s. After the mixture was further stirred 
for 1 min at ambient temperature, a solution of 1,2-dichloro-2-methylpropane (DCIB) 
(88 µL, 3.0 equiv) in THF (0.1 mL) was added to the reaction mixture. Then, the mixture 
was placed in a pre-heated oil bath at 60 °C. After stirring for 16 h, a saturated aqueous 
NH4Cl (15 mL) was added and the reaction mixture was extracted with EtOAc (3 × 15 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated 
in vacuo. The crude product was purified by column chromatography (n-hexane/EtOAc: 
2:1→1:1) to yield 188aa (17.8 mg, 25%) and 188af (7.5 mg, 11%). 
 
 
To a stirred solution of 112a (44.5 mg, 0.25 mmol) and 112l (44.5 mg, 0.25 mmol), 
MnCl2 (3.1 mg, 10 mol %), neocuproine (10.4 mg, 20 mol %) and TMEDA (74 μL, 
0.5mmol) in THF (0.40 mL), 151a (0.40 mL, 1.0 mmol, 2.5 m in THF) was added 
dropwise over 30 s. After the mixture was further stirred for 1 min at ambient 
temperature, a solution of 1,2-dichloro-2-methylpropane (DCIB) (88 µL, 0.75 mmol) in 
THF (0.10 mL) was added to the reaction mixture. Then, the mixture was placed in a 
pre-heated oil bath at 60 °C. After stirring for 16 h, a saturated aqueous NH4Cl (15 mL) 
was added and the reaction mixture was extracted with EtOAc (3 × 15 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (n-hexane/EtOAc: 
2:1→1:1) to yield 188aa (23.4 mg, 33%) and 188la (36.9 mg, 52%). 
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Kinetic Isotope Effect Study 
KIE study by independent experiments 
 
Five parallel independent reactions with 112a or [D]1-112a with 151a were performed 
to determine the KIE.  
To a stirred solution of 112a (44.5 mg, 0.25 mmol) or [D]1-112a (44.5 mg, 0.25 mmol), 
MnCl2 (3.1 mg, 10 mol %), neocuproine (10.4 mg, 20 mol %) and TMEDA (74 μL, 0.5 
mmol) in THF (0.40 mL), 151a (0.40 mL, 1.0 mmol, 2.5 m in THF) was added dropwise 
over 30 s. After the mixture was further stirred for 1 min at ambient temperature, a 
solution of 1,2-dichloro-2-methylpropane (DCIB) (88 µL, 0.75 mmol) in THF (0.10 mL) 
was added to the reaction mixture. Afterwards, the mixture was placed in a pre-heated 
oil bath at 60 °C. Then a saturated aqueous NH4Cl (15 mL) was added and the reaction 
mixture was extracted with EtOAc (3 × 15 mL). The combined organic layers were dried 
over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (n-hexane/EtOAc: 2:1→1:1) to yield 188aa and [D]1-188aa. 
 
t 0.5 h 1.5 h 2.5 h 3.5 h 4.5 h 
188aa 7% 20% 32% 43% 56% 








Well-defined Complex 189 as catalyst 
 
To a stirred solution of 112a (44.5 mg, 0.25 mmol), complex 189 (8.3 mg, 10 mol %) 
and TMEDA (74 μL, 0.5 mmol) in THF (0.40 mL), 151a (0.40 mL, 1.0 mmol, 2.5 m in THF) 
was added dropwise over 30 s. After the mixture was further stirred for 1 min at 
ambient temperature, a solution of 1,2-dichloro-2-methylpropane (DCIB) (88 µL, 0.75 
mmol) in THF (0.10 mL) was added to the reaction mixture. Then, the mixture was 
placed in a pre-heated oil bath at 60 °C. After stirring for 16 h, a saturated aqueous 
NH4Cl (15 mL) was added and the reaction mixture was extracted with EtOAc (3 × 15 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated 
in vacuo. The crude product was purified by column chromatography (n-hexane/EtOAc: 
2:1→1:1) to yield 188aa (61.1 mg, 86%). 
 
y = 12,1x + 1,35
R² = 0,9992




















Gram scale C–H arylation in flow 
 
 
A 100 mL oven-dried round-bottom Schlenk flask was charged with amide 112a (1.78 
g, 10 mmol), MnCl2 (0.124 g, 10 mol %), neocuproine (0.416 g, 20 mol %) and TMEDA 
(3.0 mL, 20 mmol) in THF (1.0 mL) and 151a (16 mL, 1.0 mmol, 2.5 m in THF) under N2 
atmosphere and brought to a volume of 20 mL. A solution of 1,2-dichloro-2-
methylpropane (DCIB) (3.52 mL, 30 mmol) in THF was prepared in a vial and brought 
to a volume of 20 mL. The solutions were charged in separate syringes pumps 
(Vapourtec V-3) operating at a flow rate of 100 µL/min. The two solutions were mixed 
with a T-joint connection. Subsequently, the solution was pumped into the 10 mL 
standard heated reactor with 100 min residence time. The back pressure was set to 
4.0 bar and the temperature of the reactor was set to 80 °C. Using the Flow Wizard 
system, the solution was collected automatically. Then, a saturated aqueous NH4Cl (45 
mL) was added and the reaction mixture was extracted with EtOAc (3 × 45 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (n-hexane/EtOAc: 








Reaction a):[137a] To a Schlenk tube charged with 188ja (66.5 mg, 0.20 mmol), 
ZnCl2•TMEDA (152 mg, 0.60 mmol) and THF (1.0 ml), MeMgBr (457 µl, 1.40 mmol, 3 
m) was added dropwise at ambient temperature under N2 atmosphere. After stirring 
for 5 min, dppen (11.9 mg, 0.03 mmol, 15 mol %) and FeCl3 (4.9 mg, 0.03 mmol, 15 
mol %) were added successively. After stirring at ambient temperature for further 5 
min, 2,3-dichlorobutane (70 µl, 0.60 mmol) was added and the reaction mixture stirred 
at 60 °C for 16 h. Then, a saturated aqueous NH4Cl (15 mL) was added and the reaction 
mixture was extracted with EtOAc (3 × 15 mL). The combined organic layers were dried 
over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (n-hexane/EtOAc: 3:1) yielding the desired product 190 (38.9 




1H-NMR (400 MHz, CDCl3) δ = 8.50 (dd, J = 4.7, 1.7 Hz, 1H), 8.26 (sbr, 1H), 7.63 (dd, J = 
166 
 
7.8, 1.7 Hz, 1H), 7.38 (dd, J = 7.8, 4.7 Hz, 1H), 7.22 (d, J = 8.9 Hz, 2H), 7.07–6.93 (m, 
3H), 6.88 (d, J = 8.8 Hz, 2H), 5.63 (dq, J = 8.2, 7.2 Hz, 1H), 3.82 (s, 3H), 2.47 (s, 6H), 1.55 
(d, J = 7.2 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ = 164.2 (Cq), 159.1 (Cq), 148.3 (Cq), 
146.5 (CH), 140.0 (CH), 139.2 (Cq), 137.6 (Cq), 135.6 (Cq), 131.4 (Cq), 129.7 (CH), 129.4 
(CH), 126.7 (CH), 124.9 (CH), 113.4 (CH), 55.1 (CH3), 45.4 (CH3), 21.1 (CH), 19.8 (CH3). 
IR (ATR): 3400, 2957, 2837, 1677, 1447, 1016, 766, 560 cm-1. MS (ESI) m/z (relative 
intensity): 743 (32) [2M+Na]+, 383 (42) [M+Na]+, 360 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C23H25N2O2 [M+H]+ 361.1911, found 361.1907. HPLC analysis (Chiralcel IB-3, 
iPrOH/n-hexane 30:70, flow rate = 1.0 mL/min, λ = 250 nm): tr (minor) = 7.3 min, tr 











was heated with stirring at 150 °C for 45 min in a microwave reactor. After cooling to 
ambient temperature, the mixture was concentrated in vacuo and H2O (10 mL) was 
added to the residue. The pH of the resulting solution was adjusted to 7–8 with 
concentrated NH4OH and the mixture was extracted with EtOAc (3 × 15 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography 
(n-hexane/EtOAc: 6:1) to yield 191 (33.8 mg, 53%) as white solid. 
 
 
3-(2-Fluorophenyl)-8-(4-methoxyphenyl)imidazo[1,5-a]pyridine (191). 1H-NMR (400 
MHz, CDCl3) δ = 7.79–7.73 (m, 2H), 7.72 (d, J = 1.0 Hz, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.48 
(m, 1H), 7.33 (m, 1H), 7.29–7.21 (m, 1H), 7.05 (d, J = 8.8 Hz, 2H), 6.77 (dd, J = 6.7, 0.9 
Hz, 1H), 6.72–6.65 (m, 1H), 3.89 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ = 160.0 (d, 1JC–F 
= 249.5 Hz, Cq), 159.9 (Cq), 134.2 (Cq), 132.5 (Cq), 132.3 (d, 3JC–F = 3.2 Hz, CH), 131.5 (Cq), 
130.9 (d, 3JC–F = 8.2 Hz, CH), 130.1 (Cq), 129.1 (CH), 124.9 (d, 4JC–F = 3.4 Hz, CH), 121.4 
(CH), 120.7 (d, J = 6.6 Hz, CH), 118.4 (d, 2JC–F = 14.4 Hz, Cq), 117.5 (CH), 116.2 (d, 2JC–F = 
21.5 Hz, CH), 114.3 (CH), 113.2 (CH), 55.4 (CH3). 19F-NMR (376 MHz, CDCl3) δ = –111.14. 
IR (ATR): 2933, 2836, 1608, 1507, 1246, 1029, 758, 725 cm-1. MS (ESI) m/z (relative 
intensity): 659 (8) [2M+Na]+, 319 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H16FN2O 




5.6 Metallaelectrocatalyses: Electricity for Resource-Economic Iron- and 
Manganese-Catalyzed C–H Activation 




-carboxamide (192). The general procedure E was followed using 159a (71.6 mg, 0.25 
mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 192 (93.2 mg, 95%) 
as a white solid. M. p. = 112–113 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.63 (dd, J = 7.5, 
1.5 Hz, 1H), 7.42 (ddd, J = 7.5, 7.5, 1.5 Hz, 1H), 7.38–7.28 (m, 5H), 6.91 (d, J = 8.8 Hz, 
2H), 5.89 (sbr, 1H), 4.27 (t, J = 7.3 Hz, 2H), 3.84 (s, 3H), 1.93–1.79 (m, 2H), 1.60 (s, 6H), 
1.41–1.28 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 168.5 (Cq), 
159.3 (Cq), 152.7 (Cq), 139.3 (Cq), 136.2 (Cq), 132.7 (Cq), 130.2 (CH), 130.1 (CH), 129.9 
(CH), 128.6 (CH), 127.1 (CH), 120.4 (CH), 113.9 (CH), 55.4 (CH3), 51.6 (Cq), 50.0 (CH2), 
32.2 (CH2), 27.5 (CH3), 19.8 (CH2), 13.5 (CH3). IR (ATR): 3243, 3142, 2954, 1664, 1515, 
1300, 1242, 831 cm-1. MS (ESI) m/z (relative intensity): 807 (12) [2M+Na]+, 415 (52) 
[M+Na]+, 393 (34) [M+H]+. HR-MS (ESI) m/z calcd for C23H29N4O2 [M+H]+ 393.2285, 









carboxamide (193). The general procedure E was followed using 159b (78.6 mg, 0.25 
mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 193 (103.0 mg, 98%) 
as a white solid. M. p. = 86–87 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.61 (dd, J = 7.5, 1.5 
Hz, 1H), 7.41 (ddd, J = 7.5, 7.5, 1.5 Hz, 1H), 7.36–7.28 (m, 5H), 6.90 (d, J = 8.8 Hz, 2H), 
5.91 (sbr, 1H), 4.28 (t, J = 7.3 Hz, 2H), 3.83 (s, 3H), 1.95–1.80 (m, 2H), 1.59 (s, 6H), 1.37–
1.27 (m, 6H), 0.87 (t, J = 7.0 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 168.5 (Cq), 159.3 
(Cq), 152.7 (Cq), 139.2 (Cq), 136.2 (Cq), 132.6 (Cq), 130.1 (CH), 130.0 (CH), 129.8 (CH), 
128.5 (CH), 127.1 (CH), 120.4 (CH), 113.9 (CH), 55.3 (CH3), 51.6 (Cq), 50.2 (CH2), 31.1 
(CH2), 30.2 (CH2), 27.4 (CH3), 26.1 (CH2), 22.4 (CH2), 13.9 (CH3). IR (ATR): 3293, 2927, 
2858, 1637, 1544, 1514, 1240, 831 cm-1. MS (ESI) m/z (relative intensity): 863 (18) 
[2M+Na]+, 443 (60) [M+Na]+, 421 (100) [M+H]+. HR-MS (ESI) m/z calcd for C25H33N4O2 




carboxamide (194). The general procedure E was followed using 159c (80.1 mg, 0.25 
mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 194 (90.6 mg, 85%) 
as a white solid. M. p. = 136–137 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.60 (dd, J = 7.5, 
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1.5 Hz, 1H), 7.40 (ddd, J = 7.5, 7.5, 1.5 Hz, 1H), 7.39–7.19 (m, 10H), 6.85 (d, J = 8.7 Hz, 
2H), 5.87 (sbr, 1H), 5.45 (s, 2H), 3.79 (s, 3H), 1.56 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ 
= 168.5 (Cq), 159.2 (Cq), 153.2 (Cq), 139.2 (Cq), 136.1 (Cq), 134.8 (Cq), 132.6 (Cq), 130.1 
(CH), 130.0 (CH), 129.8 (CH), 129.0 (CH), 128.5 (CH), 127.9 (CH), 127.1 (CH), 120.5 (CH), 
113.9 (CH), 55.3 (CH3), 53.9 (Cq), 51.6 (CH2), 27.4 (CH3). IR (ATR): 3300, 1639, 1516, 
1251, 1180, 836, 732, 578 cm-1. MS (ESI) m/z (relative intensity): 875 (26) [2M+Na]+, 
449 (65) [M+Na]+, 427 (100) [M+H]+. HR-MS (ESI) m/z calcd for C26H27N4O2 [M+H]+ 




carboxamide (195). The general procedure E was followed using 159d (79.1 mg, 0.25 
mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 195 (101.4 mg, 96%) 
as a white solid. M. p. = 91–92 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.59 (d, J = 8.6 Hz, 
1H), 7.32 (s, 1H), 7.25 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 6.82 (dd, J = 8.6, 2.6 
Hz, 1H), 6.74 (d, J = 2.6 Hz, 1H), 5.79 (sbr, 1H), 4.22 (t, J = 7.3 Hz, 2H), 3.79 (s, 3H), 3.77 
(s, 3H) 1.89–1.74 (m, 2H), 1.52 (s, 6H), 1.34–1.23 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C-
NMR (100 MHz, CDCl3) δ = 167.8 (Cq), 160.4 (Cq), 159.3 (Cq), 152.7 (Cq), 141.1 (Cq), 
132.6 (Cq), 130.6 (CH), 129.9 (CH), 128.5 (Cq), 120.3 (CH), 115.4 (CH), 113.8 (CH), 112.4 
(CH), 55.3 (CH3), 55.2 (CH3), 51.3 (Cq), 49.8 (CH2), 32.1 (CH2), 27.4 (CH3), 19.6 (CH2), 
13.3 (CH3). IR (ATR): 3301, 2961, 1627, 1600, 1317, 1031, 838 cm-1. MS (ESI) m/z 
(relative intensity): 867 (13) [2M+Na]+, 445 (52) [M+Na]+, 423 (100) [M+H]+. HR-MS 








biphenyl]-2-carboxamide (196). The general procedure E was followed using 159e 
(85.6 mg, 0.25 mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 196 (109.9 
mg, 98%) as a white solid. M. p. = 100–101 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.58 (d, 
J = 8.2 Hz, 1H), 7.37 (dd, J = 8.2, 2.0 Hz, 1H), 7.34–7.27 (m, 4H), 6.92 (d, J = 8.8 Hz, 2H), 
5.86 (sbr, 1H), 4.26 (t, J = 7.3 Hz, 2H), 3.83 (s, 3H), 1.89–1.77 (m, 2H), 1.58 (s, 6H), 1.32 
(s, 11H), 0.94 (t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 168.4 (Cq), 159.2 (Cq), 
153.1 (Cq), 152.7 (Cq), 138.9 (Cq), 133.3 (Cq), 133.2 (Cq), 130.1 (CH), 128.4 (CH), 127.2 
(CH), 124.2 (CH), 120.4 (CH), 113.8 (CH), 55.3 (CH3), 51.5 (Cq), 49.8 (CH2), 34.7 (Cq), 
32.1 (CH2), 31.1 (CH3), 27.4 (CH3), 19.7 (CH2), 13.4 (CH3). IR (ATR): 3281, 2961, 1634, 
1514, 1240, 1044, 834 cm-1. MS (ESI) m/z (relative intensity): 919 (10) [2M+Na]+, 471 
(30) [M+Na]+, 449 (100) [M+H]+. HR-MS (ESI) m/z calcd for C27H37N4O2 [M+H]+ 




biphenyl]-2-carboxamide (197). The general procedure E was followed using 159f 
(83.1 mg, 0.25 mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 197 (102.0 
mg, 93%) as a white solid. M. p. = 94–95 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.55 (d, J = 
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8.1 Hz, 1H), 7.31 (s, 1H), 7.25 (d, J = 8.7 Hz, 2H), 7.16 (dd, J = 8.2, 2.0 Hz, 1H), 7.08 (d, J 
= 1.9 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 5.85 (sbr, 1H), 4.23 (t, J = 7.3 Hz, 2H), 3.80 (s, 3H), 
2.45 (s, 3H), 1.90–1.75 (m, 2H), 1.54 (s, 6H), 1.35–1.26 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C-NMR (100 MHz, CDCl3) δ = 167.8 (Cq), 159.4 (Cq), 152.6 (Cq), 141.2 (Cq), 139.8 (Cq), 
132.5 (Cq), 132.2 (Cq), 130.0 (CH), 129.2 (CH), 127.2 (CH), 124.3 (CH), 120.4 (CH), 113.9 
(CH), 55.3 (CH3), 51.5 (Cq), 49.9 (CH2), 32.1 (CH2), 27.4 (CH3), 19.7 (CH2), 15.2 (CH3), 
13.4 (CH3). IR (ATR): 3274, 2869, 1633, 1513, 1239, 1025, 831 cm-1. MS (ESI) m/z 
(relative intensity): 899 (10) [2M+Na]+, 461 (35) [M+Na]+, 439 (100) [M+H]+. HR-MS 




phenyl]-2-carboxamide (198). The general procedure E was followed using 159g (76.1 
mg, 0.25 mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 198 (95.4 mg, 93%) 
as a white solid. M. p. = 109–110 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.58 (dd, J = 8.5, 
6.1 Hz, 1H), 7.32 (s, 1H), 7.25 (d, J = 8.8 Hz, 2H), 7.04–6.92 (m, 2H), 6.87 (d, J = 8.8 Hz, 
2H), 5.92 (sbr, 1H), 4.24 (t, J = 7.4 Hz, 2H), 3.79 (s, 3H), 1.91–1.73 (m, 2H), 1.55 (s, 6H), 
1.41–1.21 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 167.5 (Cq), 
163.0 (d, 1JC–F = 250.3 Hz, Cq), 159. 6 (Cq), 152.6 (Cq), 141.8 (d, 3JC–F = 8.3 Hz, Cq), 132.3 
(d, 4JC–F = 3.4 Hz, Cq), 131.4 (d, 4JC–F = 1.8 Hz, Cq), 130.8 (d, 3JC–F = 9.0 Hz, CH), 129.9 (CH), 
120.3 (CH), 116.9 (d, 2JC–F = 21.9 Hz, CH), 114.0 (CH), 113.9 (d, 2JC–F = 21.3 Hz, CH), 55.3 
(CH3), 51.6 (Cq), 49.9 (CH2), 32.1 (CH2), 27.3 (CH3), 19.7 (CH2), 13.4 (CH3). 19F-NMR (376 
MHz, CDCl3) δ = –110.69 (ddd, J = 8.7, 8.7, 5.8 Hz). IR (ATR): 3274, 2963, 2873, 1630, 





(75) [M+Na]+, 411 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H28FN4O2 [M+H]+ 




biphenyl]-2-carboxamide (199). The general procedure E was followed using 159h 
(80.2 mg, 0.25 mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 199 (55.5 mg, 
52%) as a white solid. M. p. = 106–107 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.53 (d, J = 
8.8 Hz, 1H), 7.32 (s, 1H), 7.29–7.23 (m, 4H), 6.88 (d, J = 8.8 Hz, 2H), 5.94 (sbr, 1H), 4.24 
(t, J = 7.3 Hz, 2H), 3.80 (s, 3H), 1.87–1.78 (m, 2H), 1.55 (s, 6H), 1.37–1.22 (m, 2H), 0.92 
(t, J = 7.4 Hz, 3H).  13C-NMR (100 MHz, CDCl3) δ = 167.4 (Cq), 159.6 (Cq), 152.5 (Cq), 
141.0 (Cq), 135.6 (Cq), 134.5 (Cq), 131.2 (Cq), 130.1 (CH), 130.0 (CH), 129.9 (CH), 127.1 
(CH), 120.3 (CH), 114.0 (CH), 55.3 (CH3), 51.6 (Cq), 49.9 (CH2), 32.1 (CH2), 27.4 (CH3), 
19.7 (CH2), 13.4 (CH3). IR (ATR): 3272, 2958, 2089, 1631, 1549, 1257, 1023, 837 cm-1. 
MS (ESI) m/z (relative intensity): 875 (10) [2M+Na]+ (35Cl), 449 (90) [M+Na]+ (35Cl), 427 





biphenyl]-2-carboxamide (200). The general procedure E was followed using 159i 
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(83.6 mg, 0.25 mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 200 (87.0 mg, 
79%) as a white solid. M. p. = 89–90 °C. 1H-NMR (300 MHz, CDCl3) δ = 7.51 (d, J = 7.8 
Hz, 1H), 7.39–7.28 (m, 4H), 7.26–7.19 (m, 4H), 7.13 (dd, J = 7.8, 1.8 Hz, 1H), 7.07 (d, J 
= 1.8 Hz, 1H), 6.83 (d, J = 8.7 Hz, 2H), 5.79 (sbr, 1H), 5.43 (s, 2H), 3.78 (s, 3H), 2.35 (s, 
3H), 1.53 (s, 6H). 13C-NMR (125 MHz, CDCl3) δ = 168.2 (Cq), 159.1 (Cq), 153.1 (Cq), 139.9 
(Cq), 139.1 (Cq), 134.7 (Cq), 133.2 (Cq), 132.7 (Cq), 130.7 (CH), 129.9 (CH), 128.9 (CH), 
128.7 (CH), 128.4 (CH), 127.8 (CH), 127.7 (CH), 120.5 (CH), 113.8 (CH), 55.3 (CH3), 53.9 
(CH2), 51.5 (Cq), 27.5 (CH3), 21.3 (CH3). IR (ATR): 3272, 2954, 1628, 1514, 1244, 1030, 
582 cm-1. MS (ESI) m/z (relative intensity): 903 (10) [2M+Na]+, 463 (45) [M+Na]+, 441 




[1,1'-biphenyl]-2-carboxamide (201). The general procedure E was followed using 
159j (97.1 mg, 0.25 mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 201 (66.8 
mg, 54%) as a white solid. M. p. = 100–101 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.68 (dd, 
J = 7.9, 0.8 Hz, 1H), 7.59–7.52 (m, 2H), 7.39–7.30 (m, 3H), 7.31–7.26 (m, 3H), 7.24–
7.19 (m, 2H), 6.86 (d, J = 8.7 Hz, 2H), 6.00 (sbr, 1H), 5.44 (s, 2H), 3.79 (s, 3H), 1.56 (s, 
6H). 13C-NMR (125 MHz, CDCl3) δ = 167.3 (Cq), 159.7 (Cq), 153.0 (Cq), 140.0 (Cq), 139.3 
(Cq), 134.7 (Cq), 131.8 (q,    2JC–F = 32.6 Hz, Cq), 131.0 (Cq), 130.0 (CH), 129.1 (CH), 
129.0 (CH), 128.7 (CH), 128.0 (CH), 127.0 (q, 3JC–F = 3.8 Hz, CH), 123.8 (q, 3JC–F = 3.7 Hz, 
CH), 123.7 (q,  1JC–F = 272.5 Hz, Cq), 120.4 (CH), 114.1 (CH), 55.4 (CH3), 54.0 (CH2), 51.8 





1518, 1257, 1116, 837 cm-1. MS (ESI) m/z (relative intensity): 1011 (10) [2M+Na]+, 517 
(60) [M+Na]+, 495 (100) [M+H]+. HR-MS (ESI) m/z calcd for C27H26F3N4O2 [M+H]+ 




biphenyl]-2-carboxamide (202). The general procedure E was followed using 159k 
(76.1 mg, 0.25 mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 202 (54.4 mg, 
53%) as a white solid. M. p. = 116–117 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.41 (dd, J = 
7.6, 1.3 Hz, 1H), 7.32–7.20 (m, 4H), 7.15 (ddd, J = 9.4, 8.2, 1.3 Hz, 1H), 6.91 (d, J = 8.8 
Hz, 2H), 5.90 (sbr, 1H), 4.24 (t, J = 7.3 Hz, 2H), 3.81 (s, 3H), 1.91–1.73 (m, 2H), 1.52 (s, 
6H), 1.37–1.27 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 166.9 (d, 
4JC–F = 3.2 Hz, Cq), 159.7 (d, 1JC–F = 246.5 Hz, Cq), 159.6 (Cq), 152.6 (Cq), 138.8 (d, 3JC–F = 
1.8 Hz, Cq), 131.0 (d, 4JC–F = 1.5 Hz, CH), 128.8 (d, 3JC–F = 8.6 Hz, CH), 126.9 (d, 2JC–F = 
17.1 Hz, Cq), 125.3 (Cq), 124.1 (d, 4JC–F = 3.6 Hz, CH), 120.3 (CH), 117.2 (d, 2JC–F = 23.5 
Hz, CH), 113.9 (CH), 55.3 (CH3), 51.7 (Cq), 49.9 (CH2), 32.2 (CH2), 27.4 (CH3), 19.7 (CH2), 
13.4 (CH3). 19F-NMR (376 MHz, CDCl3) δ = –115.10 (dd, J = 9.4, 5.1 Hz). IR (ATR): 3285, 
2954, 1638, 1454, 1240, 838, 568 cm-1. MS (ESI) m/z (relative intensity): 843 (12) 
[2M+Na]+, 433 (96) [M+Na]+, 411 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H28FN4O2 






carboxamide (203). The general procedure E was followed using 159l (87.6 mg, 0.25 
mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 203 (77.6 mg, 68%) 
as a white solid. M. p. = 120–121 °C. 1H-NMR (300 MHz, CDCl3) δ = 7.42–7.30 (m, 3H), 
7.30 (s, 1H), 7.30–7.13 (m, 6H), 6.97 (dd, J = 8.5, 2.8 Hz, 1H), 6.84 (d, J = 8.7 Hz, 2H), 
5.81 (sbr, 1H), 5.46 (s, 2H), 3.84 (s, 3H), 3.80 (s, 3H), 1.54 (s, 6H). 13C-NMR (100 MHz, 
CDCl3) δ = 167.9 (Cq), 158.9 (Cq), 158.6 (Cq), 153.1 (Cq), 136.8 (Cq), 134.7 (Cq), 132.3 (Cq), 
131.7 (Cq), 131.4 (CH), 130.1 (CH), 129.0 (CH), 128.5 (CH), 127.9 (CH), 120.5 (CH), 116.5 
(CH), 113.9 (CH), 113.0 (CH), 55.5 (CH3), 55.4 (CH3), 54.0 (CH2), 51.6 (Cq), 27.4 (CH3). IR 
(ATR): 3290, 1634, 1548, 1465, 1271, 1045 cm-1. MS (ESI) m/z (relative intensity): 935 
(10) [2M+Na]+, 479 (100) [M+Na]+, 457 (100) [M+H]+. HR-MS (ESI) m/z calcd for 




naphthamide (204). The general procedure E was followed using 159m (92.6 mg, 0.25 
mmol) and 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 204 (85.8 mg, 72%) 
as a white solid. M. p. = 161–162 °C. 1H-NMR (400 MHz, CDCl3) δ = 8.12 (s, 1H), 7.86–





(m, 2H), 7.38–7.31 (m, 6H), 7.26–7.21 (m, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.07 (sbr, 1H), 
5.45 (s, 2H), 3.80 (s, 3H), 1.61 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 168.3 (Cq), 159.2 
(Cq), 153.2 (Cq), 136.6 (Cq), 134.8 (Cq), 134.5 (Cq), 133.7 (Cq), 132.7 (Cq), 131.7 (Cq), 
130.2 (CH), 129.1 (CH), 129.0 (CH), 128.7 (CH), 128.6 (CH), 128.2 (CH), 128.0 (CH), 
127.6 (CH), 127.4 (CH), 126.4 (CH), 120.6 (CH), 113.9 (CH), 55.3 (CH3), 54.0 (CH2), 51.6 
(Cq), 27.5 (CH3). IR (ATR): 3269, 2024, 1966, 1634, 1543, 1455, 1241, 720 cm-1. MS (ESI) 
m/z (relative intensity): 975 (12) [2M+Na]+, 499 (70) [M+Na]+, 477 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C30H29N4O2 [M+H]+ 477.2285, found 477.2285. The analytical 




3-carboxamide (205). The general procedure E was followed using 159n (73.1 mg, 0.25 
mmol) 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 205 (77.7 mg, 78%) 
as a white solid. M. p. = 98–99 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.43–7.35 (m, 3H), 
7.32 (d, J = 5.3 Hz, 1H), 7.14 (d, J = 5.3 Hz, 1H), 6.91 (d, J = 8.8 Hz, 2H), 6.00 (sbr, 1H), 
4.24 (t, J = 7.3 Hz, 2H), 3.81 (s, 3H), 1.83 (m, 2H), 1.59 (s, 6H), 1.39–1.17 (m, 2H), 0.91 
(t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 163.2 (Cq), 160.2 (Cq), 152.6 (Cq), 143.7 
(Cq), 133.8 (Cq), 131.0 (CH), 129.2 (CH), 124.8 (Cq), 123.7 (CH), 120.5 (CH), 114.2 (CH), 
55.3 (CH3), 51.3 (Cq), 49.9 (CH2), 32.1 (CH2), 27.6 (CH3), 19.7 (CH2), 13.4 (CH3). IR (ATR): 
3278, 2957, 2142, 1656, 1634, 1291, 1178, 829 cm-1. MS (ESI) m/z (relative intensity): 
819 (12) [2M+Na]+, 421 (60) [M+Na]+, 399 (100) [M+H]+. HR-MS (ESI) m/z calcd for 





ferrocenoylamide (206). The general procedure E was followed using 159o (107.1 mg, 
0.25 mmol) 151a (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 206 (93.5 mg, 70%) 
as a white solid. M. p. = 137–138 °C. 1H-NMR (300 MHz, CDCl3) δ = 7.49 (d, J = 8.7 Hz, 
2H), 7.41 (s, 1H), 7.33 (m, 3H), 7.25 (dd, J = 5.6, 2.2 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 
6.15 (sbr, 1H), 5.47 (s, 2H), 4.79 (dd, J = 2.5, 1.6 Hz, 1H), 4.36 (dd, J = 2.5, 1.6 Hz, 1H), 
4.31 (dd, J = 2.5, 2.5 Hz, 1H), 4.15 (s, 5H), 3.81 (s, 3H), 1.63 (s, 3H), 1.57 (s, 3H). 13C-
NMR (125 MHz, CDCl3) δ = 168.9 (Cq), 158.9 (Cq), 153.2 (Cq), 134.8 (Cq), 131.6 (CH), 
128.9 (CH), 128.5 (CH), 128.2 (Cq), 127.9 (CH), 120.6 (CH), 113.5 (CH), 88.3 (Cq), 76.3 
(Cq), 72.6 (CH), 70.8 (CH), 70.2 (CH), 68.4 (CH), 55.4 (CH3), 54.0 (Cq), 51.1 (CH2), 28.2 
(CH3), 27.7 (CH3). IR (ATR): 3337, 2956, 1638, 1517, 1294, 1048, 822 cm-1. MS (ESI) m/z 
(relative intensity): 1091 (5) [2M+Na]+, 557 (75) [M+Na]+, 535 (100) [M+H]+. HR-MS 
(ESI) m/z calcd for C30H31FeN4O2 [M+H]+ 535.1791, found 535.1794. The analytical data 




The general procedure E was followed using 159p (67.6 mg, 0.25 mmol) 151a (0.88 mL, 





(n-hexane/EtOAc: 3:1→1:1) yielded 207 (61.2 mg, 65%) as a white solid. M. p. = 88–
89 °C. 1H-NMR (300 MHz, CDCl3) δ = 8.30 (dd, J = 4.9, 1.8 Hz, 1H), 7.70 (d, J = 8.5, 1H), 
7.60 (ddd, J = 8.1, 7.5, 1.8 Hz, 1H), 7.36 (d, J = 8.8 Hz, 2H), 7.29–7.18 (m, 2H), 7.07 (dd, 
J = 7.5, 4.9 Hz, 1H), 6.95–6.82 (m, 3H), 6.81 (d, J = 2.6 Hz, 1H), 3.83 (s, 3H), 3.74 (s, 3H), 
1.59 (s, 6H). 13C-NMR (100 MHz, CDCl3) δ = 167.8 (Cq), 164.2 (Cq), 160.3 (Cq), 159.2 (Cq), 
147.3 (CH), 141.2 (Cq), 136.7 (CH), 132.9 (Cq), 130.7 (CH), 130.1 (CH), 129.3 (Cq), 121.4 
(CH), 119.1 (CH), 115.4 (CH), 113.7 (CH), 112.4 (CH), 56.9 (Cq), 55.4 (CH3), 55.3 (CH3), 
27.1 (CH3). IR (ATR): 3290, 2959, 2956, 2108, 1990, 1637, 1540, 831 cm-1. MS (ESI) m/z 
(relative intensity): 775 (10) [2M+Na]+, 399 (14) [M+Na]+, 377 (100) [M+H]+. HR-MS 
(ESI) m/z calcd for C23H25N2O3 [M+H]+ 377.1860, found 377.1861. The analytical data 




The general procedure E was followed using 159q (60.1 mg, 0.25 mmol) 151a (0.88 mL, 
1.75 mmol, 2.0 m in THF). Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 3:1→1:1) yielded 208 (50.2 mg, 58%) as a white solid. M. p. = 106–
107 °C. 1H-NMR (300 MHz, CDCl3) δ = 8.31 (dd, J = 4.9, 1.8 Hz, 1H), 7.69 (dd, J = 7.4, 
1.8 Hz, 1H), 7.61 (ddd, J = 8.1, 7.4, 1.8 Hz, 1H), 7.49–7.30 (m, 6H), 7.27–7.21 (m, 1H), 
7.09 (ddd, J = 7.4, 4.9 Hz, 1H), 6.86 (d, J = 8.6 Hz, 2H), 3.75 (s, 3H), 1.62 (s, 6H). 13C-
NMR (125 MHz, CDCl3) δ = 168.3 (Cq), 164.1 (Cq), 159.0 (Cq), 147.3 (CH), 139.3 (Cq), 
137.0 (Cq), 136.7 (CH), 132.9 (Cq), 130.2 (CH), 130.1 (CH), 129.5 (CH), 128.6 (CH), 127.0 
(CH), 121.5 (CH), 119.1 (CH), 113.7 (CH), 57.0 (Cq), 55.3 (CH3), 27.1 (CH3). IR (ATR): 3293, 
2988, 1640, 1542, 1474, 1240, 835 cm-1. MS (ESI) m/z (relative intensity): 715 (5) 
[2M+Na]+, 369 (4) [M+Na]+, 347 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H23N2O2 
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[M+H]+ 347.1754, found 347.1756. The analytical data are in accordance to those 




carboxamide (209). The general procedure E was followed using 159a (76.1 mg, 0.25 
mmol) and 151c (0.83 mL, 1.75 mmol, 2.1 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 209 (102.0 mg, 77%) 
as a white solid. M. p. = 106–107 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.61 (dd, J = 7.5, 
1.5 Hz, 1H), 7.40 (ddd, J = 7.5, 7.5, 1.5 Hz, 1H), 7.35–7.22 (m, 5H), 7.16 (d, J = 7.6 Hz, 
2H), 5.86 (sbr, 1H), 4.24 (t, J = 7.3 Hz, 2H), 2.36 (s, 3H), 1.92–1.76 (m, 2H), 1.55 (s, 6H), 
1.87–1.79 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 168.4 (Cq), 
152.7 (Cq), 139.6 (Cq), 137.4 (Cq), 137.3 (Cq), 136.2 (Cq), 130.1 (CH), 129.8 (CH), 129.1 
(CH), 128.8 (CH), 128.5 (CH), 127.2 (CH), 120.4 (CH), 51.6 (Cq), 49.9 (CH2), 32.2 (CH2), 
27.3 (CH3), 21.1 (CH3), 19.7 (CH2), 13.4 (CH3). IR (ATR): 3262, 3146, 2959, 1668, 1532, 
1469, 1306, 756 cm-1. MS (ESI) m/z (relative intensity): 775 (16) [2M+Na]+, 399 (60) 










mmol) and 151d (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 210 (102.0 mg, 76%) 
as a white solid. M. p. = 136–137 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.66 (dd, J = 7.6, 
1.5 Hz, 1H), 7.46–7.38 (m, 4H), 7.38–7.29 (m, 4H), 5.76 (sbr, 1H), 4.26 (t, J = 7.3 Hz, 2H), 
1.93–1.73 (m, 2H), 1.49 (s, 6H), 1.38–1.28 (m, 11H), 0.94 (t, J = 7.4 Hz, 3H). 13C-NMR 
(100 MHz, CDCl3) δ = 168.2 (Cq), 152.6 (Cq), 150.7 (Cq), 139.5 (Cq), 137.3 (Cq), 136.1 (Cq), 
130.0 (CH), 129.9 (CH), 128.7 (CH), 128.6 (CH), 127.3 (CH), 125.4 (CH), 120.4 (CH), 51.4 
(Cq), 49.9 (CH2), 34.5 (Cq), 32.2 (CH2), 31.3 (CH3), 27.2 (CH3), 19.7 (CH2), 13.4 (CH3). IR 
(ATR): 3314, 2963, 2867, 1635, 1541, 1318, 1046, 581 cm-1. MS (ESI) m/z (relative 
intensity): 859 (20) [2M+Na]+, 441 (52) [M+Na]+, 419 (100) [M+H]+. HR-MS (ESI) m/z 




carboxamide (211). The general procedure E was followed using 159a (76.1 mg, 0.25 
mmol) and 151h (0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 211 (102.0 mg, 98%) 
as a white solid. M. p. = 111–112 °C. 1H-NMR (300 MHz, CDCl3) δ = 7.62 (dd, J = 7.3, 
1.7 Hz, 1H), 7.46–7.33 (m, 2H), 7.33–7.23 (m, 3H), 6.99–6.81 (m, 3H), 5.85 (sbr, 1H), 
4.24 (t, J = 7.3 Hz, 2H), 3.77 (s, 3H), 1.91–1.71 (m, 2H), 1.54 (s, 6H), 1.39–1.14 (m, 2H), 
0.93 (t, J = 7.4 Hz, 3H). 13C-NMR (100 Hz, CDCl3) δ = 168.0 (Cq), 159.4 (Cq), 152.6 (Cq), 
141.7 (Cq), 139.4 (Cq), 136.2 (Cq), 129.8 (CH), 129.7 (CH), 129.4 (CH), 128.5 (CH), 127.5 
(CH), 121.1 (CH), 120.2 (CH), 114.1 (CH), 113.5 (CH), 55.3 (CH3), 51.6 (Cq), 49.9 (CH2), 
32.2 (CH2), 27.4 (CH3), 19.8 (CH2), 13.5 (CH3). IR (ATR): 2960, 2873, 1653, 1511, 1467, 
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1210, 759 cm-1. MS (ESI) m/z (relative intensity): 807 (20) [2M+Na]+, 415 (50) [M+Na]+, 





carboxamide (212). The general procedure E was followed using 159a (76.1 mg, 0.25 
mmol) and 151m (0.76 mL, 1.75 mmol, 2.3 m in THF). Purification by column 
chromatography on silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 212 (102.0 mg, 84%) 
as a white solid. M. p. = 112–113 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.65 (dd, J = 7.4, 
1.5 Hz, 1H), 7.41 (ddd, J = 7.4, 7.4, 1.5 Hz, 1H), 7.37–7.28 (m, 3H), 7.01 (d, J = 0.7 Hz, 
2H), 7.00 (s, 1H), 5.86 (sbr, 1H), 4.26 (t, J = 7.3 Hz, 2H), 2.32 (s, 6H), 1.99–1.75 (m, 2H), 
1.53 (s, 6H), 1.40–1.21 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ = 
168.2 (Cq), 152.7 (Cq), 140.3 (Cq), 139.9 (Cq), 138.0 (Cq), 136.0 (Cq), 130.0 (CH), 129.8 
(CH), 129.1 (CH), 128.6 (CH), 127.3 (CH), 126.7 (CH), 120.3 (CH), 51.5 (Cq), 49.9 (CH2), 
32.2 (CH2), 27.3 (CH3), 21.2 (CH3), 19.7 (CH2), 13.4 (CH3). IR (ATR): 3243, 2951, 2975, 
1659, 1525, 1300, 1194, 1056 cm-1. MS (ESI) m/z (relative intensity): 803 (15) [2M+Na]+, 
413 (28) [M+Na]+, 391 (100) [M+H]+. HR-MS (ESI) m/z calcd for C24H31N4O [M+H]+ 








(213). The general procedure E was followed using 159a (76.1 mg, 0.25 mmol) and 
151j (0.80 mL, 1.75 mmol, 2.2 m in THF). Purification by column chromatography on 
silica gel (n-hexane/EtOAc: 3:1→1:1) yielded 213 (102.0 mg, 88%) as a white solid. M. 
p. = 140–141 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.89–7.77 (m, 4H), 7.65 (dd, J = 7.6, 1.5 
Hz, 1H), 7.51–7.43 (m, 4H), 7.4–7.35 (m, 2H), 6.97 (s, 1H), 5.94 (sbr, 1H), 4.0 (t, J = 7.3 
Hz, 2H), 1.71–1.60 (m, 2H), 1.50 (s, 6H), 1.33–1.14 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H). 13C-
NMR (100 MHz, CDCl3) δ = 168.3 (Cq), 152.6 (Cq), 139.5 (Cq), 137.9 (Cq), 136.5 (Cq), 
133.1 (Cq), 132.4 (Cq), 130.4 (CH), 129.9 (CH), 128.5 (CH), 128.0 (CH), 127.9 (CH), 127.5 
(CH), 127.5 (CH), 127.5 (CH), 126.3 (CH), 126.1 (CH), 120.0 (CH), 51.7 (Cq), 49.7 (CH2), 
32.0 (CH2), 27.1 (CH3), 19.6 (CH2), 13.4 (CH3). IR (ATR): 3247, 3055, 2966, 1634, 1558, 
1322, 1051, 754 cm-1. MS (ESI) m/z (relative intensity): 847 (15) [2M+Na]+, 435 (52) 





The general procedure E was followed using 159a (76.1 mg, 0.25 mmol) and 151k 
(0.88 mL, 1.75 mmol, 2.0 m in THF). Purification by column chromatography on silica 
gel (n-hexane/EtOAc: 3:1→1:1) yielded 214 (102.0 mg, 63%) as a white solid. M. p. = 
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116–117 °C. 1H-NMR (400 MHz, CDCl3) δ = 7.63 (dd, J = 6.6, 1.6 Hz, 1H), 7.51–7.31 (m, 
6H), 7.16 (dd, J = 4.6, 1.6 Hz, 1H), 6.06 (sbr, 1H), 4.32 (t, J = 7.3 Hz, 2H), 2.01–1.80 (m, 
2H), 1.68 (s, 6H), 1.36 (dt, J = 14.7, 7.4 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C-NMR (100 
MHz, CDCl3) δ = 168.4 (Cq), 152.6 (Cq), 140.5 (Cq), 136.3 (Cq), 134.0 (Cq), 129.8 (CH), 
129.7 (CH), 128.7 (CH), 128.3 (CH), 127.5 (CH), 125.6 (CH), 123.0 (CH), 120.4 (CH), 51.6 
(Cq), 49.9 (CH2), 32.1 (CH2), 27.4 (CH3), 19.7 (CH2), 13.4 (CH3). IR (ATR): 3297, 3149, 
2929, 2874, 1633, 1543, 1195, 751, 627 cm-1. MS (ESI) m/z (relative intensity): 759 (22) 
[2M+Na]+, 391 (52) [M+Na]+, 369 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H25N4OS 
[M+H]+ 369.1744, found 369.1742. 
 
5.6.2 Mechanistic Studies  
Comparision of Electrochemical Oxidation versus Chemical Oxidation 
General procedure for chemical oxidation C–H arylation: A solution of ArMgBr 
(2.10 mL, 7.0 equiv, 1.0 m in THF) was slowly added to a mixture of amide 159 
(0.3 mmol) and ZnBr2•TMEDA (308 mg, 3.00 equiv) under N2. The resulting mixture 
was stirred at ambient temperature for 10 min, then a solution of FeCl3 (4.9 mg, 
10 mol %) and dppe (11.9 mg, 10 mol %) in THF (1.5 mL) was added. The reaction 
mixture was stirred at ambient temperature for 10 min and then DCIB (76.2 mg, 
2.0 equiv) was added. The mixture was stirred at 55 °C (t = 0 min). At ambient 
temperature, saturated aqueous NH4Cl solution (10 mL) was added, the reaction 
mixture was extracted with EtOAc (3 × 10 mL) and dried over Na2SO4. Evaporation of 
the solvents and purification by column chromatography on silica gel (n-Hexane/EtOAc 
3:1→1:1) the desired product 192, 194, 196. 
 
Kinetic Studies by 19F-NMR 
 
General procedure for chemical oxidation C–H arylation: A solution of ArMgBr 





(0.3 mmol) and ZnBr2•TMEDA (308 mg, 3.00 equiv) under N2. The resulting mixture 
was stirred at ambient temperature for 10 min, then a solution of FeCl3 (4.9 mg, 
10 mol %) and dppe (11.9 mg, 10 mol %) in THF (1.5 mL) was added. The reaction 
mixture was stirred at ambient temperature for 10 min and then DCIB (76.2 mg, 
2.0 equiv) was added. The mixture was stirred at 55 °C (t = 0 min). Aliquots (100 µL) 
were removed via a syringe periodically every 5 and 10 min. The conversion was 
determined by 19F-NMR using n-nonyl fluoride (54 µL, 0.3 mmol) as the internal 
standard. 
General procedure for electrochemical oxidation C–H arylation: The electrocatalysis 
was carried out in an undivided cell with a RVC anode (10 mm × 15 mm × 6 mm) and 
a platinum cathode (10 mm × 15 mm × 0.25 mm). A solution of ArMgBr (0.88 mL, 7.0 
equiv, 2.0 m in THF) was slowly added to a mixture of amide 159 (0.25 mmol, 
1.00 equiv), Fe(acac)3 (8.8 mg, 10 mol %), dppe (10.0 mg, 10 mol %) and ZnCl2·TMEDA 
(189 mg, 3.00 equiv) were placed in a 10 mL cell and dissolved in THF (5 mL). 
Electrolysis was performed at 40 °C with a constant current of 5 mA (t = 0 min). 
Aliquots (300 µL) were removed periodically every 5 and 10 min. The conversion was 
determined by 19F-NMR using n-nonyl fluoride (45 µL, 0.25 mmol) as the internal 
standard. 
Each reaction was performed three times, the measured conversions were averaged 






















Figure 5.2. Comparision of electrochemical versus chemical oxidation reaction rate of 
201.  
Intermolecular Competition Experiment 
 
A solution of ArMgBr (0.88 mL, 7.0 equiv, 2.0 m in THF) was slowly added to a mixture 
of amide 159d (79.1 mg, 0.25 mmol) and 159j (88.6 mg, 0.25 mmol), Fe(acac)3 (8.8 mg, 
10 mol %), dppe (10.0 mg, 10 mol %) and ZnCl2·TMEDA (189 mg, 3.00 equiv) were 
placed in a 10 mL cell and dissolved in THF (5 mL). Electrolysis was performed at 40 °C 
with a constant current of 5 mA maintained for 2 h. At ambient temperature, a 
saturated aqueous NH4Cl solution (10 mL) was added and the RVC anode was washed 





EtOAc (3 × 10 mL) and then dried over Na2SO4. Evaporation of the solvents and 
purification by column chromatography on silica gel (n-hexane/EtOAc 3:1→1:1) 
yielded 195 (80.3 mg, 76%) and 201 (17.3 mg, 15%). 
 
Kinetic Isotope Effect Studies 
 
Five parallel independent reactions of 159a or [D5] -159a with 151a were performed 
to determine the KIE. A solution of ArMgBr (0.88 mL, 7.0 equiv, 2.0 m in THF) was 
slowly added to a mixture of amide 159a (76.1 mg, 0.25 mmol) and [D5]-159a (72.9 
mg, 0.25 mmol), Fe(acac)3 (8.8 mg, 10 mol %), dppe (10.0 mg, 10 mol %) and 
ZnCl2·TMEDA (189 mg, 3.00 equiv) were placed in a 10 mL cell and dissolved in THF 
(5 mL). Electrolysis was performed at 40 °C with a constant current of 5 mA. At 
ambient temperature, a saturated aqueous NH4Cl solution (10 mL) was added and the 
RVC anode was washed with EtOAc (3 × 2 mL) in an ultrasonic bath. The combined 
phases were extracted with EtOAc (3 × 10 mL) and then dried over Na2SO4. Evaporation 
of the solvents and purification by column chromatography on silica gel 
(n-hexane/EtOAc 3:1→1:1), Then 1H-NMR conversions were obtained by the use of 
CH2Br2 (17 µL, 0.25 mmol) as the standard. 
t (min) 15  30  45 60  75  90  
192 (%) 9 19 25 32 38 45 




Figure 5.3. Kinetic profile with substrates 192a or [D5]-192a. 
 Gram-Scale Synthesis of 192 
 
 
Benzamide 159a (1.15 g, 4.00 mmol, 1.00 equiv), Fe(acac)3 (141 mg, 10 mol %), dppe 
(160 mg, 10 mol %), ZnCl2·TMEDA (3.02 g, 3.00 equiv) and 151a (14.0 mL, 7.0 equiv, 
2.0 m in THF) were placed in an undivided cell (100 mL) with a RVC anode (25 mm × 
50 mm × 6 mm) and a platinum cathode (25 mm × 50 mm × 0.25 mm) and dissolved 
in THF (50 mL). Electrocatalysis was performed at 40 °C with a constant current of 
41.7 mA maintained for 11.6 h (4.51 F/mol). At ambient temperature, saturated 
aqueous NH4Cl (10 mL) was added, and the RVC anode was washed with EtOAc (3 × 10 
mL) in an ultrasonic bath. The combined phases were extracted with EtOAc (3 × 30 mL) 
and then dried over Na2SO4. Evaporation of the solvents and purification by column 
chromatography (n-hexane/EtOAc = 3:1→1:1) yielded 192 (1.40 g, 89%) as a white 
solid. 
y = 0,4648x + 3,6
R² = 0,9936



























Figure 5.4. Electrolysis setup for gram-scale.  
192 
 
5.7 Crystallographic Data 
The crystal structures of 173, 180 and 188aa were measured and solved by Dr. 
Christopher Golz (Alcarazo research group). 
The crystal was kept at 99.93 K during data collection. Using Olex2,[148] the structure 
was solved with the XT[149] structure solution program using Intrinsic Phasing and 
refined with the XL[150] refinement package using Least Squares minimisation. 
Table 5.1. Crystal data and structure refinement 173aa. 
Compound 173aa 
Empirical formula C21H18N2O 
Formula weight 314.37 
Temperature/K 99.93 
Crystal system monoclinic 












F(000)  664.0 
 
Crystal size/mm3 0.475 × 0.36 × 0.242 
Radiation MoKα (λ = 0.71073) 





Index ranges -14 ≤ h ≤ 14, 0 ≤ k ≤ 27, 0 ≤ l ≤ 11 
Reflections collected 4532 
Independent reflections 4532 [Rint = ?, Rsigma = 0.0160] 
Data/restraints/parameters 4532/0/220 
Goodness-of-fit on F2 1.071 
Final R indexes [I>=2σ (I)] R1 = 0.0364, wR2 = 0.0939 
Final R indexes [all data] R1 = 0.0380, wR2 = 0.0953 
Largest diff. peak/hole / e Å-3 0.35/-0.21 
 
 
Figure 5.5. Molecular structure of 173aa with thermal ellipoids at 50% probablitiy level. 
The hydrogen atoms are omitted for clarity. 
Crystal Data for C21H18N2O (M =314.37 g/mol): monoclinic, space group P21/c (no. 14), 
a = 10.2077(4) Å, b = 19.7705(7) Å, c = 8.1575(3) Å, β = 97.3950(10)°, V = 
1632.58(11) Å3, Z = 4, T = 99.93 K, μ(MoKα) = 0.079 mm-1, Dcalc = 1.279 g/cm3, 4532 
reflections measured (5.76° ≤ 2Θ ≤ 59.326°), 4532 unique (Rint = ?, Rsigma = 0.0160) 
which were used in all calculations. The final R1 was 0.0364 (I > 2σ(I)) and wR2 was 




Table 5.2. Bond Lengths [Å] for 173aa. 
Atom Atom Length/Å 
O1 C1 1.2373(12) 
N1 C1 1.3934(11) 
N1 C5 1.3734(11) 
N1 C14 1.4892(11) 
N2 C17 1.3504(12) 
N2 C21 1.3377(12) 
C1 C2 1.4426(14) 
C2 C3 1.3595(15) 
C3 C4 1.4182(14) 
C4 C5 1.3674(13) 
C5 C6 1.4609(12) 
C6 C7 1.4775(12) 
C6 C13 1.3554(12) 
C7 C8 1.3980(12) 
C7 C12 1.3969(13) 
C8 C9 1.3903(13) 
C9 C10 1.3889(15) 
C10 C11 1.3891(15) 
C11 C12 1.3922(13) 
C13 C14 1.5253(12) 
C13 C17 1.4775(12) 
C14 C15 1.5377(12) 
C14 C16 1.5318(12) 
C17 C18 1.3995(12) 





C19 C20 1.3857(15) 
C20 C21 1.3881(14) 
Table 5.3. Bond angles [°] for 173aa 
Atom Atom Atom Angle/ ̊
C1 N1 C14 124.13(8) 
C5 N1 C1 124.01(8) 
C5 N1 C14 111.80(7) 
C21 N2 C17 117.57(9) 
O1 C1 N1 121.11(9) 
O1 C1 C2 125.04(9) 
N1 C1 C2 113.84(8) 
C3 C2 C1 122.27(9) 
C2 C3 C4 121.15(9) 
C5 C4 C3 117.38(9) 
N1 C5 C6 107.74(7) 
C4 C5 N1 121.30(8) 
C4 C5 C6 130.93(8) 
C5 C6 C5 122.42(8) 
C13 C6 C5 108.82(8) 
C13 C6 C7 128.75(8) 
C8 C7 C6 120.16(8) 
C12 C7 C6 120.72(8) 
C12 C7 C8 119.12(8) 
C9 C8 C7 120.43(9) 
C10 C9 C8 120.16(9) 
C9 C10 C11 119.77(9) 
C10 C11 C12 120.34(9) 
196 
 
C11 C12 C7 120.17(9) 
C6 C13 C14 110.84(8) 
C6 C13 C17 127.92(8) 
C17 C13 C14 120.76(8) 
N1 C14 C13 100.45(7) 
N1 C14 C15 109.05(7) 
N1 C14 C16 110.85(7) 
C13 C14 C15 112.40(7) 
C13 C14 C16 111.10(7) 
C16 C14 C15 112.37(7) 
N2 C17 C13 116.92(8) 
N2 C17 C18 121.84(8) 
C18 C17 C13 120.98(8) 
C19 C18 C17 119.38(9) 
C20 C19 C18 118.93(9) 
C19 C20 C21 117.92(9) 
N1 C21 C20 124.36(9) 
 
Table 5.4. Crystal data and structure refinement 173ca. 
Compound 173ca 
Empirical formula C25H20N2O 
Formula weight 364.43 
Temperature/K 100.01 
Crystal system triclinic 




















Crystal size/mm3 0.348 × 0.281 × 0.191 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.904 to 59.224 
Index ranges -12 ≤ h ≤ 11, -14 ≤ k ≤ 14, -15 ≤ l ≤ 15 
Reflections collected 17309 
Independent reflections 5094 [Rint = 0.0229, Rsigma = 0.0231] 
Data/restraints/parameters 5094/0/255 
Goodness-of-fit on F2 1.048 
Final R indexes [I>=2σ (I)] R1 = 0.0410, wR2 = 0.1026 
Final R indexes [all data] R1 = 0.0469, wR2 = 0.1081 





Figure 5.6. Molecular structure of 173ca with thermal ellipoids at 50% probablitiy level. 
The hydrogen atoms are omitted for clarity. 
Crystal Data for C25H20N2O (M =364.43 g/mol): triclinic, space group P-1 (no. 2), a = 
8.7963(9) Å, b = 10.3540(12) Å, c = 11.5419(14) Å, α = 110.430(3)°, β = 100.373(3)°, γ = 
101.270(4)°, V = 930.16(18) Å3, Z = 2, T = 100.01 K, μ(MoKα) = 0.080 mm-1, Dcalc = 
1.301 g/cm3, 17309 reflections measured (4.904° ≤ 2Θ ≤ 59.224°), 5094 unique (Rint = 
0.0229, Rsigma = 0.0231) which were used in all calculations. The final R1 was 0.0410 (I > 
2σ(I)) and wR2 was 0.1081 (all data). 
Table 5.5. Bond Lengths [Å] for 173ca. 
Atom Atom Length/Å 
O1 C1 1.2327(13) 
N1 C1 1.3789(13) 
N1 C9 1.3903(13) 
N1 C17 1.4948(12) 
N2 C12 1.3460(13) 
N2 C16 1.3422(14) 
C1 C2 1.4741(14) 





C2 C7 1.4116(14) 
C3 C4 1.3780(15) 
C4 C5 1.4032(16) 
C5 C6 1.3816(15) 
C6 C7 1.4129(14) 
C7 C8 1.4351(14) 
C8 C9 1.3572(14) 
C9 C10 1.4625(14) 
C10 C11 1.3541(14) 
C10 C20 1.4775(14) 
C11 C12 1.4793(14) 
C11 C17 1.5207(14) 
C12 C13 1.4000(15) 
C13 C14 1.3855(15) 
C14 C15 1.3883(18) 
C15 C16 1.3849(18) 
C17 C18 1.5314(15) 
C17 C19 1.5339(14) 
C20 C21 1.3983(14) 
C20 C25 1.3986(14) 
C21 C22 1.3909(15) 
C22 C23 1.3912(17) 
C23 C24 1.3882(18) 






Table 5.6. Bond angles [°] for 173ca 
Atom Atom Atom Angle/ ̊
C1 N1 C9 124.06(9) 
C1 N1 C17 124.06(8) 
C9 N1 C17 111.77(8) 
C16 N2 C12 117.36(10) 
O1 C1 N1 122.02(9) 
O1 C1 C2 123.40(9) 
N1 C1 C2 114.58(9) 
C3 C2 C1 117.99(9) 
C2 C3 C4 120.53(9) 
C3 C2 C7 121.46(9) 
C7 C2 C1 120.15(10) 
C4 C3 C2 119.85(10) 
C3 C4 C5 120.76(10) 
C6 C5 C4 120.38(10) 
C5 C6 C7 118.32(9) 
C2 C7 C6 119.16(9) 
C6 C7 C8 122.50(9) 
C9 C8 C7 118.80(9) 
N1 C9 C10 107.24(8) 
C8 C9 N1 121.92(9) 
C8 C9 C10 130.82(9) 
C9 C10 C20 122.63(9) 
C11 C10 C9 108.94(9) 
C11 C10 C20 128.43(9) 





C10 C11 C17 111.62(9) 
C12 C11 C17 122.34(9) 
N2 C12 C11 117.10(9) 
N2 C12 C13 122.52(9) 
C13 C12 C11 120.38(9) 
C14 C13 C12 118.93(10) 
C13 C14 C15 118.85(11) 
C16 C15 C14 118.41(10) 
N2 C16 C15 123.86(11) 
N1 C17 C11 100.31(8) 
N1 C17 C18 110.87(8) 
N1 C17 C19 109.89(8) 
C11 C17 C18 110.49(9) 
C11 C17 C19 113.37(8) 
C18 C17 C19 111.42(9) 
C21 C20 C10 121.26(9) 
C21 C20 C25 118.79(9) 
C25 C20 C10 119.95(9) 
C22 C21 C20 120.51(10) 
C21 C22 C23 120.28(10) 
C24 C23 C22 119.43(10) 
C25 C24 C23 120.58(10) 
C24 C25 C20 120.40(10) 
 
Table 5.7. Crystal data and structure refinement 173ga. 
Compound 173ga 
Empirical formula C22H20N2O 
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Formula weight 328.40 
Temperature/K 100.0 
Crystal system triclinic 
















Crystal size/mm3 0.346 × 0.235 × 0.178 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/°   4.592 to 57.512   
Index ranges -12 ≤ h ≤ 12, -13 ≤ k ≤ 13, -13 ≤ l ≤ 13 
Reflections collected 24237 
Independent reflections 4505 [Rint = 0.0217, Rsigma = 0.0172] 
Data/restraints/parameters 4505/0/229 
Goodness-of-fit on F2 1.036 
Final R indexes [I>=2σ (I)] R1 = 0.0409, wR2 = 0.1051 
Final R indexes [all data] R1 = 0.0437, wR2 = 0.1077 







Figure 5.7. Molecular structure of 173ga with thermal ellipoids at 50% probablitiy level. 
The hydrogen atoms are omitted for clarity. 
Crystal Data for C22H20N2O (M =328.40 g/mol): triclinic, space group P-1 (no. 2), a = 
9.0581(12) Å, b = 9.9273(12) Å, c = 10.2645(12) Å, α = 105.947(4)°, β = 96.819(4)°, γ = 
97.151(4)°, V = 869.20(19) Å3, Z = 2, T = 100.0 K, μ(MoKα) = 0.078 mm-1, Dcalc = 
1.255 g/cm3, 24237 reflections measured (4.592° ≤ 2Θ ≤ 57.512°), 4505 unique (Rint = 
0.0217, Rsigma = 0.0172) which were used in all calculations. The final R1 was 0.0409 (I > 
2σ(I)) and wR2 was 0.1077 (all data). 
Table 5.8. Bond Lengths [Å] for 173ga. 
Atom Atom Length/Å 
O1 C1 1.2364(12) 
N1 C1 1.3934(13) 
N1 C5 1.3747(12) 
N1 C13 1.4938(12) 
N2 C8 1.3432(13) 
N2 C12 1.3407(13) 
C1 C2 1.4437(14) 
C2 C3 1.3664(14) 
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C3 C4 1.4228(14) 
C3 C22 1.5027(14) 
C4 C5 1.3620(14) 
C5 C6 1.4607(13) 
C6 C7 1.3470(14) 
C6 C16 1.4776(13) 
C7 C8 1.4773(13) 
C7 C13 1.5227(14) 
C8 C9 1.3990(14) 
C9 C10 1.3833(15) 
C10 C11 1.3886(15) 
C11 C12 1.3839(15) 
C13 C14 1.5329(14) 
C13 C15 1.5330(14) 
C16 C17 1.3959(14) 
C16 C21 1.3951(14) 
C17 C18 1.3890(14) 
C18 C19 1.3874(15) 
C19 C20 1.3913(16) 
C20 C21 1.3895(14) 
 
Table 5.9. Bond angles [°] for 173ca 
Atom Atom Atom Angle/ ̊
C1 N1 C9 125.09(8) 
C5 N1 C17 123.29(9) 
C5 N1 C17 111.60(8) 





O1 C1 N1 121.33(9) 
O1 C1 C2 124.71(9) 
N1 C1 C2 113.95(9) 
C3 C2 C1 123.28(9) 
C2 C3 C4 119.32(9) 
C2 C3 C7 121.47(9) 
C4 C3 C1 119.20(9) 
C5 C4 C2 118.40(9) 
N1 C5 C5 107.79(8) 
C4 C5 C4 121.72(9) 
C4 C5 C7 130.49(9) 
C5 C6 C6 122.11(9) 
C7 C6 C8 108.88(9) 
C7 C6 C7 129.01(9) 
C6 C7 C10 126.08(9) 
C6 C7 N1 111.32(9) 
C8 C7 C10 122.38(8) 
N2 C8 C20 116.91(9) 
N2 C8 C9 122.27(9) 
C9 C8 C20 120.81(9) 
C10 C9 C12 119.18(9) 
C9 C10 C17 118.74(10) 
C12 C11 C17 118.41(10) 
N2 C12 C11 123.75(10) 
N1 C13 C13 100.37(7) 
N1 C13 C11 109.92(8) 
N1 C13 C12 110.88(8) 
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C7 C13 C15 113.59(8) 
C7 C13 C14 110.30(8) 
C14 C13 C15 111.31(8) 
C17 C16 C11 120.90(9) 
C21 C16 C18 119.84(9) 
C21 C16 C19 119.25(9) 
C18 C17 C18 120.13(9) 
C19 C18 C19 120.30(10) 
C18 C19 C19 119.98(10) 
C21 C20 C19 119.79(10) 
C20 C21 C16 120.55(10) 
 
Table 5.10. Crystal data and structure refinement 180aa. 
Compound 180aa 
Empirical formula C20H17NO 
Formula weight 287.35 
Temperature/K 99.99 
Crystal system triclinic 
















Crystal size/mm3 0.306 × 0.259 × 0.24 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.464 to 63.028 
Index ranges -11 ≤ h ≤ 12, -14 ≤ k ≤ 11, -14 ≤ l ≤ 15 
Reflections collected 10987 
Independent reflections 4872 [Rint = 0.0224, Rsigma = 0.0309] 
Data/restraints/parameters 4872/0/201 
Goodness-of-fit on F2 1.021 
Final R indexes [I>=2σ (I)] R1 = 0.0452, wR2 = 0.1216 
Final R indexes [all data] R1 = 0.0517, wR2 = 0.1276 
Largest diff. peak/hole / e Å-3 0.48/-0.27 
 
 
Figure 5.8. Molecular structure of 180aa with thermal ellipoids at 50% probablitiy level. 
The hydrogen atoms are omitted for clarity. 
Crystal Data for C20H17NO (M =287.35 g/mol): triclinic, space group P-1 (no. 2), a = 
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8.3674(7) Å, b = 9.9101(8) Å, c = 10.4597(7) Å, α = 104.876(3)°, β = 113.305(3)°, γ = 
99.676(3)°, V = 733.49(10) Å3, Z = 2, T = 99.99 K, μ(MoKα) = 0.080 mm-1, Dcalc = 
1.301 g/cm3, 10987 reflections measured (4.464° ≤ 2Θ ≤ 63.028°), 4872 unique (Rint = 
0.0224, Rsigma = 0.0309) which were used in all calculations. The final R1 was 0.0452 (I > 
2σ(I)) and wR2 was 0.1276 (all data). 
 
Table 5.11. Bond Lengths [Å] for 180aa. 
Atom Atom Length/Å 
O1 C1 1.2359(12) 
N1 C1 1.4049(12) 
N1 C5 1.3897(11) 
N1 C12 1.4114(12) 
C1 C2 1.4409(15) 
C2 C3 1.3656(15) 
C3 C4 1.4150(14) 
C4 C5 1.3669(13) 
C5 C6 1.4521(13) 
C6 C7 1.3711(12) 
C6 C13 1.4831(12) 
C7 C8 1.5098(13) 
C7 C12 1.4537(13) 
C8 C9 1.5100(13) 
C8 C19 1.5533(14) 
C8 C20 1.5404(14) 
C9 C10 1.3409(14) 
C10 C11 1.4495(14) 
C11 C12 1.3555(12) 





C13 C18 1.3987(13) 
C14 C15 1.3917(13) 
C15 C16 1.3923(14) 
C16 C17 1.3899(13) 
C17 C18 1.3939(13) 
 
Table 5.12. Bond angles [°] for 180aa 
Atom Atom Atom Angle/ ̊
C1 N1 C12 127.38(8) 
C5 N1 C1 124.07(8) 
C5 N1 C12 108.52(7) 
O1 C1 N1 120.43(9) 
O1 C1 C2 125.91(9) 
N1 C1 C2 113.65(8) 
C3 C2 C1 122.27(9) 
C2 C3 C4 121.52(9) 
C5 C4 C3 117.80(9) 
N1 C5 C6 108.17(8) 
C4 C5 N1 120.70(9) 
C4 C5 C6 131.10(9) 
C5 C6 C13 119.92(8) 
C7 C6 C5 107.80(8) 
C7 C6 C13 132.27(9) 
C6 C7 C8 131.32(8) 
C6 C7 C12 108.39(8) 
C12 C7 C8 119.95(8) 
C7 C8 C9 110.97(8) 
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C7 C8 C19 107.64(8) 
C7 C8 C20 112.69(8) 
C9 C8 C19 107.68(8) 
C9 C8 C20 108.33(8) 
C20 C8 C19 109.40(8) 
C10 C9 C8 124.66(9) 
C9 C10 C11 122.16(9) 
C12 C11 C10 117.56(9) 
N1 C12 C7 107.10(7) 
C11 C12 N1 129.13(9) 
C11 C12 C7 123.76(9) 
C14 C13 C6 119.73(8) 
C18 C13 C6 121.49(8) 
C18 C13 C14 118.58(8) 
C15 C14 C13 120.71(9) 
C14 C15 C16 120.11(9) 
C17 C16 C15 119.76(8) 
C16 C17 C18 120.15(9) 
C17 C18 C13 120.68(8) 
 
Table 5.13. Crystal data and structure refinement 180da. 
Compound 180da 
Empirical formula C20H16ClNO 
Formula weight 321.79 
Temperature/K 214.99 
Crystal system monoclinic 
















Crystal size/mm3 0.342 × 0.142 × 0.074 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.786 to 57.464 
Index ranges -12 ≤ h ≤ 12, -13 ≤ k ≤ 13, -23 ≤ l ≤ 23 
Reflections collected 23026 
Independent reflections 4004 [Rint = 0.0273, Rsigma = 0.0184] 
Data/restraints/parameters 4004/0/210 
Goodness-of-fit on F2 1.058 
Final R indexes [I>=2σ (I)] R1 = 0.0376, wR2 = 0.0948 
Final R indexes [all data] R1 = 0.0440, wR2 = 0.0998 





Figure 5.9. Molecular structure of 180da with thermal ellipoids at 50% probablitiy level. 
The hydrogen atoms are omitted for clarity. 
Crystal Data for C20H16ClNO (M =321.79 g/mol): monoclinic, space group P21/n (no. 
14), a = 9.1784(8) Å, b = 9.7854(7) Å, c = 17.6525(16) Å, β = 102.112(3)°, V = 
1550.2(2) Å3, Z = 4, T = 214.99 K, μ(MoKα) = 0.250 mm-1, Dcalc = 1.379 g/cm3, 23026 
reflections measured (4.786° ≤ 2Θ ≤ 57.464°), 4004 unique (Rint = 0.0273, Rsigma = 
0.0184) which were used in all calculations. The final R1 was 0.0376 (I > 2σ(I)) 
and wR2 was 0.0998 (all data). 
Table 5.14. Bond Lengths [Å] for 180da. 
Atom Atom Length/Å 
Cl1 C3 1.7336(14) 
O1 C1 1.2305(16) 
N1 C1 1.4057(16) 
N1 C5 1.3886(14) 
N1 C8 1.4081(16) 
C1 C2 1.429(2) 
C2 C3 1.359(2) 





C4 C5 1.3620(17) 
C5 C6 1.4513(16) 
C6 C7 1.3639(16) 
C6 C15 1.4888(15) 
C7 C8 1.4473(16) 
C7 C12 1.5100(17) 
C8 C9 1.3506(17) 
C9 C10 1.444(2) 
C10 C11 1.330(2) 
C11 C12 1.5099(19) 
C12 C13 1.544(2) 
C12 C14 1.5337(19) 
C15 C16 1.3903(17) 
C15 C20 1.3889(16) 
C16 C17 1.3911(18) 
C17 C18 1.3789(19) 
C18 C19 1.3807(19) 
C19 C20 1.3871(18) 
 
Table 5.15. Bond angles [°] for 180da 
Atom Atom Atom Angle/ ̊
C1 N1 C8 127.17(10) 
C5 N1 C1 124.09(11) 
C5 N1 C8 108.71(10) 
O1 C1 N1 120.28(13) 
O1 C1 C2 125.93(13) 
N1 C1 C2 113.78(11) 
214 
 
C3 C2 C1 121.55(12) 
C2 C3 Cl1 119.41(10) 
C2 C3 C4 122.92(12) 
C4 C3 Cl1 117.66(11) 
C5 C4 C3 116.90(12) 
N1 C5 C6 107.83(10) 
C4 C5 N1 120.73(11) 
C4 C5 C6 131.40(11) 
C5 C6 C15 121.63(10) 
C7 C6 C5 107.81(10) 
C7 C6 C15 130.55(11) 
C6 C7 C8 108.72(11) 
C6 C7 C12 131.50(11) 
C8 C7 C12 119.73(11) 
N1 C8 C7 106.88(10) 
C9 C8 N1 129.06(12) 
C9 C8 C7 124.01(12) 
C8 C9 C10 117.58(13) 
C11 C10 C9 122.36(13) 
C10 C11 C12 124.66(13) 
C7 C12 C13 108.99(11) 
C7 C12 C14 111.29(11) 
C11 C12 C7 111.09(11) 
C11 C12 C13 107.23(12) 
C11 C12 C14 108.45(12) 
C14 C12 C13 109.70(13) 





C20 C15 C6 120.87(11) 
C20 C15 C16 118.43(11) 
C15 C16 C17 120.74(12) 
C18 C17 C16 120.14(12) 
C17 C18 C19 119.60(12) 
C18 C19 C20 120.36(12) 
C19 C20 C15 120.70(12) 
 
 
Table 5.16. Crystal data and structure refinement 180ea. 
Compound 180ea 
Empirical formula C20H16BrNO 
Formula weight 366.25 
Temperature/K 99.99 
Crystal system monoclinic 












Crystal size/mm3 0.398 × 0.328 × 0.128 
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Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.738 to 63.28 
Index ranges -13 ≤ h ≤ 13, -14 ≤ k ≤ 14, -25 ≤ l ≤ 25 
Reflections collected 54741 
Independent reflections 5186 [Rint = 0.0212, Rsigma = 0.0128] 
Data/restraints/parameters 5186/0/210 
Goodness-of-fit on F2 1.043 
Final R indexes [I>=2σ (I)] R1 = 0.0236, wR2 = 0.0736 
Final R indexes [all data] R1 = 0.0244, wR2 = 0.0741 
Largest diff. peak/hole / e Å-3 0.59/-0.43 
 
 
Figure 5.10. Molecular structure of 180ea with thermal ellipoids at 50% probablitiy 
level. The hydrogen atoms are omitted for clarity. 
Crystal Data for C20H16BrNO (M =366.25 g/mol): monoclinic, space group P21/n (no. 
14), a = 9.2403(5) Å, b = 9.7366(6) Å, c = 17.5839(12) Å, β = 102.074(2)°, V = 
1547.01(17) Å3, Z = 4, T = 99.99 K, μ(MoKα) = 2.661 mm-1, Dcalc = 1.572 g/cm3, 54741 
reflections measured (4.738° ≤ 2Θ ≤ 63.28°), 5186 unique (Rint = 0.0212, Rsigma = 0.0128) 
which were used in all calculations. The final R1 was 0.0236 (I > 2σ(I)) and wR2 was 






Table 5.17. Bond Lengths [Å] for 180ea. 
Atom Atom Length/Å 
Br1 C3 1.8858(11) 
O1 C1 1.2315(14) 
N1 C1 1.4035(13) 
N1 C5 1.3897(12) 
N1 C14 1.4094(14) 
C1 C2 1.4382(16) 
C2 C3 1.3673(16) 
C3 C4 1.4110(15) 
C4 C5 1.3673(14) 
C5 C6 1.4527(14) 
C6 C7 1.4837(14) 
C6 C13 1.3695(14) 
C7 C8 1.3967(14) 
C7 C12 1.3953(14) 
C8 C9 1.3917(15) 
C9 C10 1.3897(15) 
C10 C11 1.3887(15) 
C11 C12 1.3961(15) 
C13 C14 1.4490(14) 
C13 C18 1.5106(15) 
C14 C15 1.3551(14) 
C15 C16 1.4503(17) 
C16 C17 1.3401(17) 
C17 C18 1.5096(16) 
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C18 C19 1.5498(16) 
C18 C20 1.5392(16) 
 
Table 5.18. Bond angles [°] for 180ea 
Atom Atom Atom Angle/ ̊
C1 N1 C14 127.07(9) 
C5 N1 C1 124.37(9) 
C5 N1 C14 108.51(8) 
O1 C1 N1 120.75(11) 
O1 C1 C2 125.36(10) 
N1 C1 C2 113.88(9) 
C3 C2 C1 121.10(10) 
C2 C3 Br1 119.47(8) 
C2 C3 C4 123.08(10) 
C4 C3 Br1 117.44(8) 
C5 C4 C3 116.81(9) 
N1 C5 C6 108.16(9) 
C4 C5 N1 120.73(9) 
C4 C5 C6 131.06(9) 
C5 C6 C7 121.76(9) 
C13 C6 C5 107.54(9) 
C13 C6 C7 130.67(9) 
C8 C7 C6 120.55(9) 
C12 C7 C6 120.74(9) 
C12 C7 C8 118.70(9) 
C9 C8 C7 120.58(10) 





C11 C10 C9 119.66(10) 
C10 C11 C12 120.03(10) 
C7 C12 C11 120.70(10) 
C6 C13 C14 108.68(9) 
C6 C13 C18 131.31(9) 
C14 C13 C18 119.96(9) 
N1 C14 C13 107.06(8) 
C15 C14 N1 128.91(10) 
C15 C14 C13 123.99(10) 
C14 C15 C16 117.44(10) 
C17 C16 C15 122.24(10) 
C16 C17 C18 124.56(10) 
C13 C18 C19 108.95(9) 
C13 C18 C20 111.27(9) 
C17 C18 C13 111.18(9) 
C17 C18 C19 107.34(9) 
C17 C18 C20 108.51(9) 
C20 C18 C19 109.50(10) 
 
Table 5.19. Crystal data and structure refinement 180ga. 
Compound 180ga 
Empirical formula C24H19NO 
Formula weight 337.40 
Temperature/K 149.98 
Crystal system triclinic 














Crystal size/mm3 0.407 × 0.288 × 0.178 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.158 to 61.104 
Index ranges -12 ≤ h ≤ 12, -14 ≤ k ≤ 14, -16 ≤ l ≤ 16 
Reflections collected 32730 
Independent reflections 5231 [Rint = 0.0229, Rsigma = 0.0176] 
Data/restraints/parameters 5231/0/237 
Goodness-of-fit on F2 1.027 
Final R indexes [I>=2σ (I)] R1 = 0.0411, wR2 = 0.1168 
Final R indexes [all data] R1 = 0.0425, wR2 = 0.1183 







Figure 5.11. Molecular structure of 180ga with thermal ellipoids at 50% probablitiy 
level. The hydrogen atoms are omitted for clarity. 
Crystal Data for C24H19NO (M =337.40 g/mol): triclinic, space group P-1 (no. 2), a = 
8.6794(10) Å, b = 10.1657(11) Å, c = 11.5718(12) Å, α = 107.780(4)°, β = 
108.770(4)°, γ = 103.334(5)°, V = 857.10(17) Å3, Z = 2, T = 149.98 K, μ(MoKα) = 0.079 
mm-1, Dcalc = 1.307 g/cm3, 32730 reflections measured (5.158° ≤ 2Θ ≤ 61.104°), 5231 
unique (Rint = 0.0229, Rsigma = 0.0176) which were used in all calculations. The 
final R1 was 0.0411 (I > 2σ(I)) and wR2 was 0.1183 (all data). 
 
Table 5.20. Bond Lengths [Å] for 180ga. 
Atom Atom Length/Å 
O1 C1 1.2313(10) 
N1 C1 1.3888(10) 
N1 C5 1.3995(9) 
N1 C14 1.4101(10) 
C1 C2 1.4648(12) 
C2 C3 1.4127(11) 
C2 C24 1.4038(11) 
C3 C4 1.4340(11) 
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C3 C21 1.4093(11) 
C4 C5 1.3554(10) 
C5 C6 1.4535(10) 
C6 C7 1.4830(10) 
C6 C13 1.3660(10) 
C7 C8 1.3943(11) 
C7 C12 1.3939(12) 
C8 C9 1.3936(11) 
C9 C10 1.3885(14) 
C10 C11 1.3842(16) 
C11 C12 1.3924(13) 
C13 C14 1.4540(11) 
C13 C18 1.5109(11) 
C14 C15 1.3531(11) 
C15 C16 1.4506(13) 
C16 C17 1.3393(14) 
C17 C18 1.5127(12) 
C18 C19 1.5327(13) 
C18 C20 1.5528(12) 
C21 C22 1.3790(13) 
C22 C23 1.4013(15) 
C23 C24 1.3802(14) 
 
Table 5.21. Bond angles [°] for 180ga 
Atom Atom Atom Angle/ ̊
C1 N1 C5 124.20(7) 





C5 N1 C14 108.67(6) 
O1 C1 N1 120.71(8) 
O1 C1 C2 124.68(8) 
N1 C1 C2 114.60(7) 
C3 C2 C1 121.12(7) 
C24 C2 C1 118.88(8) 
C24 C2 C3 120.00(8) 
C2 C3 C4 119.79(7) 
C21 C3 C2 118.65(8) 
C21 C3 C4 121.55(8) 
C5 C4 C3 118.93(7) 
N1 C5 C6 107.55(6) 
C4 C5 N1 121.23(7) 
C4 C5 C6 131.21(7) 
C5 C6 C7 119.83(7) 
C13 C6 C5 108.15(7) 
C13 C6 C7 132.02(7) 
C8 C7 C6 120.68(7) 
C12 C7 C6 120.31(7) 
C12 C7 C8 118.88(8) 
C9 C8 C7 120.67(8) 
C10 C9 C8 120.09(9) 
C11 C10 C9 119.42(8) 
C10 C11 C12 120.76(9) 
C11 C12 C7 120.17(9) 
C6 C13 C14 108.58(7) 
C6 C13 C18 131.96(7) 
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C14 C13 C18 119.19(7) 
N1 C14 C13 106.93(6) 
C15 C14 N1 129.14(8) 
C15 C14 C13 123.72(8) 
C14 C15 C16 117.33(8) 
C17 C16 C15 122.42(8) 
C16 C17 C18 123.91(8) 
C13 C18 C17 110.58(7) 
C13 C18 C19 113.37(7) 
C13 C18 C20 107.24(7) 
C17 C18 C19 110.00(7) 
C17 C18 C20 106.63(7) 
C19 C18 C20 108.74(8) 
C22 C21 C3 120.56(9) 
C21 C22 C23 120.46(9) 
C24 C23 C22 120.02(8) 
C23 C24 C2 120.26(9) 
 
Table 5.22. Crystal data and structure refinement 180af. 
Compound 180af 
Empirical formula C22H19NO 
Formula weight 313.38 
Temperature/K 215.12 
Crystal system triclinic 
















Crystal size/mm3 0.324 × 0.125 × 0.11 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.428 to 59.342 
Index ranges -13 ≤ h ≤ 13, -13 ≤ k ≤ 13, -13 ≤ l ≤ 13 
Reflections collected 16703 
Independent reflections 4492 [Rint = 0.0209, Rsigma = 0.0190] 
Data/restraints/parameters 4492/0/217 
Goodness-of-fit on F2 1.076 
Final R indexes [I>=2σ (I)] R1 = 0.0464, wR2 = 0.1306 
Final R indexes [all data] R1 = 0.0505, wR2 = 0.1340 






Figure 5.12. Molecular structure of 180af with thermal ellipoids at 50% probablitiy 
level. The hydrogen atoms are omitted for clarity. 
Crystal Data for C22H19NO (M =313.38 g/mol): triclinic, space group P-1 (no. 2), a = 
9.875(2) Å, b = 10.011(2) Å, c = 10.0121(19) Å, α = 67.728(6)°, β = 77.189(8)°, γ = 
61.053(9)°, V = 800.7(3) Å3, Z = 2, T = 215.12 K, μ(MoKα) = 0.079 mm-1, Dcalc = 
1.300 g/cm3, 16703 reflections measured (5.428° ≤ 2Θ ≤ 59.342°), 4492 unique (Rint = 
0.0209, Rsigma = 0.0190) which were used in all calculations. The final R1 was 0.0464 (I > 
2σ(I)) and wR2 was 0.1340 (all data). 
 
Table 5.23. Bond Lengths [Å] for 180af. 
Atom Atom Length/Å 
O1 C1 1.2324(17) 
N1 C1 1.4053(15) 
N1 C5 1.3844(14) 
N1 C14 1.4067(16) 
C1 C2 1.434(2) 
C2 C3 1.355(2) 
C3 C4 1.4126(17) 





C5 C6 1.4521(15) 
C6 C7 1.4828(14) 
C6 C13 1.3639(15) 
C7 C8 1.3870(16) 
C7 C12 1.3895(16) 
C8 C9 1.3911(17) 
C9 C10 1.375(2) 
C10 C11 1.374(2) 
C11 C12 1.3895(17) 
C13 C14 1.4542(15) 
C13 C18 1.5032(16) 
C14 C15 1.3514(17) 
C15 C16 1.441(2) 
C16 C17 1.334(2) 
C17 C18 1.5099(18) 
C18 C19 1.5440(18) 
C18 C22 1.5584(18) 
C19 C20 1.5361(19) 
C20 C21 1.538(2) 
C21 C22 1.532(2) 
 
Table 5.24. Bond angles [°] for 180af 
Atom Atom Atom Angle/ ̊
C1 N1 C14 127.56(11) 
C5 N1 C1 123.83(11) 
C5 N1 C14 108.60(9) 
O1 C1 N1 119.99(14) 
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O1 C1 C2 126.21(13) 
N1 C1 C2 113.79(12) 
C3 C2 C1 122.14(12) 
C2 C3 C4 121.81(13) 
C5 C4 C3 117.69(12) 
N1 C5 C6 107.90(9) 
C4 C5 N1 120.68(10) 
C4 C5 C6 131.42(10) 
C5 C6 C7 119.20(9) 
C13 C6 C5 108.18(9) 
C13 C6 C7 132.61(10) 
C8 C7 C6 120.41(10) 
C8 C7 C12 118.63(10) 
C12 C7 C6 120.72(10) 
C7 C8 C9 120.45(11) 
C10 C9 C8 120.26(12) 
C11 C10 C9 119.90(11) 
C10 C11 C12 120.17(12) 
C7 C12 C11 120.58(12) 
C6 C13 C14 108.02(10) 
C6 C13 C18 131.94(10) 
C14 C13 C18 119.81(10) 
N1 C14 C13 107.23(9) 
C15 C14 N1 129.24(12) 
C15 C14 C13 123.44(12) 
C14 C15 C16 117.51(12) 





C16 C17 C18 124.25(13) 
C13 C18 C17 110.59(11) 
C13 C18 C19 116.33(10) 
C13 C18 C22 110.17(10) 
C17 C18 C19 110.64(11) 
C17 C18 C22 108.27(10) 
C19 C18 C22 100.16(10) 
C20 C19 C18 105.27(11) 
C19 C20 C21 105.73(12) 
C22 C21 C20 106.13(11) 
C21 C22 C18 104.78(11) 
 
Table 5.25. Crystal data and structure refinement 180aj. 
Compound 180aj 
Empirical formula C18H15NOS 
Formula weight 293.37 
Temperature/K 150.0 
Crystal system orthorhombic 














Crystal size/mm3 0.429 × 0.429 × 0.34 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.06 to 59.188 
Index ranges -16 ≤ h ≤ 15, -21 ≤ k ≤ 21, -21 ≤ l ≤ 21 
Reflections collected 26519 
Independent reflections 4013 [Rint = 0.0236, Rsigma = 0.0158] 
Data/restraints/parameters 4013/51/199 
Goodness-of-fit on F2 1.058 
Final R indexes [I>=2σ (I)] R1 = 0.0365, wR2 = 0.0969 
Final R indexes [all data] R1 = 0.0397, wR2 = 0.0996 
Largest diff. peak/hole / e Å-3 0.37/-0.29 
 
 
Figure 5.13. Molecular structure of 180aj with thermal ellipoids at 50% probablitiy 
level. The hydrogen atoms are omitted for clarity. 
Crystal Data for C18H15NOS (M =293.37 g/mol): orthorhombic, space group Pbca (no. 





150.0 K, μ(MoKα) = 0.224 mm-1, Dcalc = 1.362 g/cm3, 26519 reflections measured 
(5.06° ≤ 2Θ ≤ 59.188°), 4013 unique (Rint = 0.0236, Rsigma = 0.0158) which were used in 
all calculations. The final R1 was 0.0365 (I > 2σ(I)) and wR2 was 0.0996 (all data). 
Table 5.26. Bond Lengths [Å] for 180aj. 
Atom Atom Length/Å 
S1 C8 1.622(6) 
S1 C11 1.781(17) 
S2 C9 1.702(13) 
S2 C10 1.6952(12) 
O1 C1 1.2363(13) 
N1 C1 1.3996(12) 
N1 C5 1.3902(12) 
N1 C13 1.4094(13) 
C1 C2 1.4376(15) 
C2 C3 1.3657(16) 
C3 C4 1.4138(14) 
C4 C5 1.3658(14) 
C5 C6 1.4556(13) 
C6 C7 1.4734(13) 
C6 C12 1.3673(13) 
C7 C8 1.4260(14) 
C7 C10 1.3813(14) 
C8 C9 1.389(8) 
C10 C11 1.417(10) 
C12 C13 1.4497(13) 
C12 C17 1.5109(14) 
C13 C14 1.3536(14) 
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C14 C15 1.4486(16) 
C15 C16 1.3413(15) 
C16 C17 1.5127(14) 
C17 C18 1.5355(15) 
C17 C19 1.5499(15) 
 
Table 5.27. Bond angles [°] for 180aj 
Atom Atom Atom Angle/ ̊
C8 S1 C11 92.8(5) 
C10 S2 C9 92.4(3) 
C1 N1 C13 126.75(8) 
C5 N1 C1 124.38(9) 
C5 N1 C13 108.85(8) 
O1 C1 N1 120.34(10) 
O1 C1 C2 125.93(9) 
N1 C1 C2 113.73(9) 
C3 C2 C1 122.01(9) 
C2 C3 C4 121.75(10) 
C5 C4 C3 117.73(9) 
N1 C5 C6 107.53(8) 
C4 C5 N1 120.38(9) 
C4 C5 C6 132.09(9) 
C5 C6 C7 121.64(9) 
C12 C6 C5 108.08(8) 
C12 C6 C7 130.26(9) 
C8 C7 C6 125.03(9) 
C10 C7 C6 122.96(9) 





C10 C7 C8 112.00(9) 
C7 C8 S1 113.7(4) 
C9 C8 C7 111.5(5) 
C8 C9 S2 111.9(7) 
C7 C10 S2 112.16(8) 
C7 C10 C11 112.8(5) 
C10 C11 S1 108.5(8) 
C6 C12 C13 108.42(8) 
C6 C12 C17 131.80(9) 
C13 C12 C17 119.78(8) 
N1 C13 C12 107.03(8) 
C14 C13 N1 128.92(9) 
C14 C13 C12 123.67(9) 
C13 C14 C15 117.77(9) 
C16 C15 C14 121.97(10) 
C15 C16 C17 124.24(10) 
C12 C17 C16 110.63(8) 
C12 C17 C18 111.39(9) 
C12 C17 C19 109.15(9) 
C16 C17 C18 109.71(9) 
C16 C17 C19 106.09(9) 




Table 5.28. Crystal data and structure refinement 188aa. 
Compound 188aa 
Empirical formula C17H20N2O2 
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Formula weight 284.35 
Temperature/K 100.01 
Crystal system orthorhombic 












Crystal size/mm3 0.458 × 0.402 × 0.146 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/°  4.642 to 59.22 
Index ranges  -14 ≤ h ≤ 14, -11 ≤ k ≤ 13, -43 ≤ l ≤ 42 
Reflections collected 22335 
Independent reflections 4350 [Rint = 0.0257, Rsigma = 0.0200] 
Data/restraints/parameters 4350/0/192 
Goodness-of-fit on F2 1.084 
Final R indexes [I>=2σ (I)] R1 = 0.0467, wR2 = 0.1142 
Final R indexes [all data] R1 = 0.0498, wR2 = 0.1161 








Figure 5.14. Molecular structure of 188aa with thermal ellipoids at 50% probablitiy 
level. The hydrogen atoms are omitted for clarity. 
 
Crystal Data for C17H20N2O2 (M =284.35 g/mol): orthorhombic, space group Pbca  
(no. 61), a = 10.6389(4) Å, b = 9.3991(3) Å, c = 31.0555(13) Å, V = 3105.4(2) Å3, Z =  
8, T = 100.01 K, μ(MoKα) = 0.080 mm-1, Dcalc = 1.216 g/cm3, 22335 reflections 
measured (4.642° ≤ 2Θ ≤ 59.22°), 4350 unique (Rint = 0.0257, Rsigma = 0.0200) which 
were used in all calculations. The final R1 was 0.0467 (I > 2σ(I)) and wR2 was 0.1161 (all 
data). 
Table 5.29. Bond Lengths [Å] for 188aa. 
Atom Atom Length/Å 
O1 C1 1.2345(14) 
O2 C10 1.3661(14) 
O2 C13 1.4256(16) 
N1 C1 1.3311(14) 
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N1 C14 1.4584(14) 
N2 C2 1.3413(14) 
N2 C6 1.3392(15) 
C1 C2 1.5099(15) 
C2 C3 1.4068(15) 
C3 C4 1.3963(15) 
C3 C7 1.4812(15) 
C4 C5 1.3834(17) 
C5 C6 1.3870(17) 
C7 C8 1.4033(15) 
C7 C12 1.3918(15) 
C8 C9 1.3791(16) 
C9 C10 1.3988(16) 
C10 C11 1.3913(16) 
C11 C12 1.3913(16) 
C14 C15 1.5229(17) 
C15 C16 1.5248(18) 
C16 C17 1.521(2) 
 
Table 5.30. Bond angles [°] for 188aa 
Atom Atom Atom Angle/ ̊
C10 O2 C13 116.83(10) 
C1 N1 C14 123.64(10) 
C6 N2 C2 118.15(10) 
O1 C1 N1 124.98(10) 





N1 C1 C2 115.10(9) 
N2 C2 C1 114.19(10) 
N2 C2 C3 123.46(10) 
C3 C2 C1 122.14(10) 
C2 C3 C7 123.25(10) 
C4 C3 C2 116.51(10) 
C4 C3 C7 120.23(10) 
C5 C4 C3 120.55(11) 
C4 C5 C6 118.22(11) 
N2 C6 C5 123.05(11) 
C8 C7 C3 121.65(10) 
C12 C7 C3 120.48(10) 
C12 C7 C8 117.85(10) 
C9 C8 C7 121.21(10) 
C8 C9 C10 119.94(11) 
O2 C10 C9 115.43(10) 
O2 C10 C11 124.62(11) 
C11 C10 C9 119.95(11) 
C12 C11 C10 119.22(11) 
C11 C12 C7 121.82(10) 
N1 C14 C15 111.72(10) 
C14 C15 C16 114.58(10) 
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